<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>JP5866328B2 - 
  MN / CA9 splice variant
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/JP5866328B2/en">
    
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  MN / CA9 splice variant
 
     ">
    <meta name="DC.date" content="2013-11-19" scheme="dateSubmitted">
    <meta name="DC.description" content="">
    <meta name="citation_patent_application_number" content="JP:2013238749A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/9a/6c/41/ed356cbdb22021/JP5866328B2.pdf">
    <meta name="citation_patent_number" content="JP:5866328:B2">
    <meta name="DC.date" content="2016-02-17" scheme="issue">
    <meta name="DC.contributor" content="パストレク ジャロミール" scheme="inventor">
    <meta name="DC.contributor" content="パストレク ジャロミール" scheme="inventor">
    <meta name="DC.contributor" content="バラトーヴァ モニカ" scheme="inventor">
    <meta name="DC.contributor" content="バラトーヴァ モニカ" scheme="inventor">
    <meta name="DC.contributor" content="インスティトゥート オブ ヴァイロロジー" scheme="assignee">
    <meta name="DC.contributor" content="インスティトゥート  オブ  ヴァイロロジー" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  MN / CA9 splice variant
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result" hidden="">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"></section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">33</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/70/a3/ee/92a32e52b6d9a0/0005866328-12.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/46/0f/dc/118dce14f4c798/0005866328-13.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/41/6c/a8/6548a905dda3a2/0005866328-14.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/50/2b/3c/6515cbf3a7af0f/0005866328-15.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d4/16/c7/cdbd9c45800aba/0005866328-16.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/bd/a2/b7/92ff383d64a1b3/0005866328-17.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/7f/25/bb/0ba0ab6eab258b/0005866328-18.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/40/96/3a/5dd7134583c97c/0005866328-19.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/8f/6b/e2/cd22a348cb547a/0005866328-20.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/5e/67/37/de199fae893f03/0005866328-21.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/c7/a3/02/40406de9be7895/0005866328-22.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/92/06/59/1814b822c9d06f/0005866328-23.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a0/e4/0e/3aa7ded51acc1a/0005866328-24.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/ac/9a/0f/54b4dce91a7ba8/0005866328-25.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a9/e0/34/ad9133cd0ac365/0005866328-26.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a8/87/52/553c6d30bb8dca/0005866328-27.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0f/9c/d0/bdc3ba9124837b/0005866328-28.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d1/e2/b9/27cbb09c033e4e/0005866328-29.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f5/54/f0/7f997e84c80ac9/0005866328-30.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/c9/19/4c/501dbc5dd9a855/0005866328-31.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/75/87/8f/ee48aed3a6ee9d/0005866328-32.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/92/18/a2/4d0c307b524c21/0005866328-33.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d5/4d/81/d427e4fcd0c5ab/0005866328-34.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/71/23/af/9ff8b8ae839938/0005866328-35.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0d/da/be/62f355e3796690/0005866328-36.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/e8/68/fe/aba2fcd1bae605/0005866328-37.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f4/8a/57/5464de308a560b/0005866328-38.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d5/bd/9d/5abd95f9ef3ace/0005866328-39.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/4f/9d/d2/8e9e7dadd78137/0005866328-40.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/32/1f/cd/8364ecf854fc7c/0005866328-41.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/79/7d/86/bbd44737cca110/0005866328-42.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d1/19/bc/8edf10ceef6d20/0005866328-43.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/e3/ca/db/b7fd5ca5278bec/0005866328-44.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N"><a id="link" href="#" class="style-scope state-modifier">C12N</a></state-modifier>
                  <span class="description style-scope classification-tree">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N9/00"><a id="link" href="#" class="style-scope state-modifier">C12N9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C12N9/88"><a id="link" href="#" class="style-scope state-modifier">C12N9/88</a></state-modifier>
                  <span class="description style-scope classification-tree">Lyases (4.)</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/02"><a id="link" href="#" class="style-scope state-modifier">A61P35/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents specific for leukemia</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/00"><a id="link" href="#" class="style-scope state-modifier">C12Q1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/68"><a id="link" href="#" class="style-scope state-modifier">C12Q1/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6876"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6876</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6883"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6883</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6886"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6886</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q2600/00"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Oligonucleotides characterized by their use</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12Q2600/106"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/106</a></state-modifier>
                  <span class="description style-scope classification-tree">Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q2600/00"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Oligonucleotides characterized by their use</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12Q2600/136"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/136</a></state-modifier>
                  <span class="description style-scope classification-tree">Screening for pharmacological compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 5 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">JP5866328B2</h2>
                  <p class="tagline style-scope patent-result">Japan</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Published granted patent (Second level)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/9a/6c/41/ed356cbdb22021/JP5866328B2.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;mrna&quot;,&quot;seq&quot;,&quot;human&quot;,&quot;nucleic acid&quot;,&quot;sequence&quot;]" data-before="20061012"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/JP5866328B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5866328B2/ja"><a id="link" href="#" class="style-scope state-modifier">Japanese</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="パストレク ジャロミール"><a id="link" href="#" class="style-scope state-modifier">パストレク ジャロミール</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="パストレク ジャロミール"><a id="link" href="#" class="style-scope state-modifier">パストレク ジャロミール</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="バラトーヴァ モニカ"><a id="link" href="#" class="style-scope state-modifier">バラトーヴァ モニカ</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="バラトーヴァ モニカ"><a id="link" href="#" class="style-scope state-modifier">バラトーヴァ モニカ</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2007</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20100056611A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US12/444,888</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN101641450A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN200780045271A</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2076611A4/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP07870784A</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5479099B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2009532452A</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2008069864A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US2007/021905</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2665371A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002665371A</div>
                <div class="style-scope application-timeline">Filing date: 2007-10-12</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2013</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5866328B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2013238749A</div>
                <div class="style-scope application-timeline">Filing date: 2013-11-19</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application JP2013238749A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2013-11-19</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="インスティトゥート オブ ヴァイロロジー"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by インスティトゥート オブ ヴァイロロジー, インスティトゥート  オブ  ヴァイロロジー</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2014-04-03</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2014057596A/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of JP2014057596A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2016-02-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2016-02-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP5866328B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of JP5866328B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Expired - Fee Related</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2027-10-12</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (16)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (3)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=JP&amp;NR=5866328B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/JP/5866328/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/JP5866328B2">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Japanese</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES101034798" lang="EN" load-source="google" class="style-scope patent-text">
  <technical-field class="style-scope patent-text">
    <p num="0001" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明は、遺伝医学の一般領域におけるものであり、生化学的工学、免疫化学および腫瘍学の分野におけるものである。さらに詳細には、本発明は、ＭＮ遺伝子すなわち、ＭＮ／ＣＡ９、ＣＡ９、または炭酸脱水酵素９としても知られる発癌遺伝子と考えられている細胞遺伝子に関するものであり、その遺伝子は、現在、ＭＮタンパク質、ＭＮ／ＣＡ ＩＸイソ酵素、ＭＮ／ＣＡ ＩＸ、炭酸脱水酵素ＩＸ、ＣＡ ＩＸまたはＭＮ／Ｇ２５０タンパク質としても知られている腫瘍性タンパク質をコードしている。
</span>
&nbsp;&nbsp;The present invention is in the general field of genetic medicine, in the fields of biochemical engineering, immunochemistry and oncology. More particularly, the present invention relates to a cellular gene that is considered an MN gene, an oncogene also known as MN / CA9, CA9, or <figure-callout id="9" label="carbonic anhydrase" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">carbonic anhydrase</a></figure-callout> 9, which gene is currently represented by the MN protein. Encodes an oncoprotein, also known as MN / CA IX isoenzyme, MN / CA IX, carbonic anhydrase IX, CA IX or MN / G250 protein.
</span>
    </p>
    <p num="0002" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに詳細には、本発明は、選択的にスプライスされた［ＡＳ］型のＭＮ／ＣＡ９ ｍＲＮＡ、およびそれを検出するためのプローブ／プライマーに関する。ＡＳのＭＮ／ＣＡ９ ｍＲＮＡは、主として正常細胞および酸素正常状態下で発現し、完全長［ＦＬ］のＭＮ／ＣＡ９ ｍＲＮＡの発現を測定するアッセイ、特にＲＴ−ＰＣＲアッセイを阻害する可能性がある。本発明はまた、ＡＳ型のＭＮ／ＣＡ ＩＸ、および、それを単独で、またはＦＬ型のＭＮ／ＣＡ９ ｍＲＮＡと組み合わせて、検出、あるいは検出および定量化するためのアッセイを用いる診断／予後診断法に関する。さらに本発明は、ＦＬのＭＮ／ＣＡ ＩＸタンパク質を標的とする手段として、ＭＮ／ＣＡ９の選択的スプライシングを活用する治療方法に関する。本発明の焦点であるＡＳ型のＭＮ／ＣＡ９／ＣＡ ＩＸの種類は、脊椎動物であって差し支えなく、哺乳動物であることが好ましく、ヒトであることがさらに好ましい。
</span>
&nbsp;&nbsp;More particularly, the present invention relates to selectively spliced [AS] type MN / CA9 mRNA and probes / primers for detecting it. AS's MN / CA9 mRNA is expressed primarily under normal cells and normoxia, and may inhibit assays that measure the expression of full-length [FL] MN / CA9 mRNA, particularly RT-PCR assays. The present invention also provides a diagnostic / prognostic method using an AS-type MN / CA IX and an assay for detecting or detecting and quantifying it alone or in combination with FL-type MN / CA9 mRNA. About. Furthermore, the present invention relates to a therapeutic method utilizing alternative splicing of MN / CA9 as a means of targeting the MN / CA IX protein of FL. The type of AS type MN / CA9 / CA IX that is the focus of the present invention may be a vertebrate, preferably a mammal, and more preferably a human.
</span>
    </p>
  </technical-field>
  <background-art class="style-scope patent-text">
    <p num="0003" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  上述の通り、ＭＮ遺伝子およびタンパク質は、多くの別名が知られており、それらの名称は、本明細書において同義的に使用される。ＭＮタンパク質は、亜鉛に結合することが判明しており、炭酸脱水酵素（ＣＡ）活性を有し、現在、９番目の炭酸脱水酵素イソ酵素−ＭＮ／ＣＡ ＩＸまたはＣＡ ＩＸであると考えられている［非特許文献１］。炭酸脱水酵素の命名法に従って、ヒトＣＡイソ酵素は、大文字のローマ字と数字で記され、一方、それらの遺伝子は、イタリック文字とアラビア数字で記される。あるいは、本明細書では、「ＭＮ」は、文脈に示されるように、炭酸脱水酵素イソ酵素ＩＸ（ＣＡ ＩＸ）タンパク質／ポリペプチド、または炭酸脱水酵素イソ酵素９（ＣＡ９）の遺伝子、核酸、ｃＤＮＡ、ｍＲＮＡなどを称するのに使用される。
</span>
&nbsp;&nbsp;As mentioned above, the MN gene and protein are known by many aliases, and their names are used interchangeably herein. The MN protein has been found to bind to zinc, has carbonic anhydrase (CA) activity and is now considered to be the ninth carbonic anhydrase isoenzyme -MN / CA IX or CA IX [Non-Patent Document 1]. In accordance with the carbonic anhydrase nomenclature, human CA isoenzymes are written in capital roman letters and numbers, while their genes are written in italic letters and Arabic numerals. Alternatively, as used herein, “MN” refers to carbonic anhydrase isoenzyme IX (CA IX) protein / polypeptide, or carbonic anhydrase isoenzyme 9 (CA9) gene, nucleic acid, cDNA, as indicated in the context. Used to refer to mRNA and the like.
</span>
    </p>
    <p num="0004" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質はまた、Ｇ２５０抗原であることが確認されている。非特許文献２には、「配列分析およびデータベース検索により、Ｇ２５０抗原は、ＭＮ、すなわち、子宮頚部癌に確認されたヒト腫瘍関連抗原と同一であることが明らかとなった（パストレク（Ｐａｓｔｏｒｅｋ）ら、１９９４年）」ことが記載されている。
</span>
&nbsp;&nbsp;The MN protein has also been identified as a G250 antigen. Non-Patent <figure-callout id="2" label="Document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Document</a></figure-callout> 2 states that “sequence analysis and database search revealed that the G250 antigen is identical to the human tumor-associated antigen identified in MN, ie, cervical cancer (Pastrek et al. 1994) ”.
</span>
    </p>
    <p num="0005" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡ ＩＸは、非特許文献３により最初に記載されたＭ７５モノクローナル抗体を用いてザバダ，Ｊ（Ｚａｖａｄａ，Ｊ．）、パストレコバ，Ｓ．（Ｐａｓｔｏｒｅｋｏｖａ，Ｓ．）およびパストレク，Ｊ．（Ｐａｓｔｏｒｅｋ，Ｊ．）［「ザバダ（Ｚａｖａｄａ）ら」、例えば、特許文献１を参照］により同定された癌関連炭酸脱水酵素である。その抗体は、ＣＡ ＩＸをコードするｃＤＮＡのクローニング［非特許文献４］、腫瘍および正常組織におけるＣＡ ＩＸ発現の評価［非特許文献５、および他の多くの引用文献］、細胞密度によるＣＡ ＩＸ調節試験［非特許文献６、非特許文献７］、ならびに低酸素症によるＣＡ ＩＸ誘導の実証［非特許文献８、および他の多くの引用文献］に使用された。このような試験の全ては、ＭＮ／ＣＡ ＩＸ／ＣＡ９が、前新生物／新生物腫瘍マーカーとして診断および／または予後診断に、および標的として治療に使用できるというザバダ（Ｚａｖａｄａ）らの独創的な着想および研究［例えば、ザバダ（Ｚａｖａｄａ）ら、特許文献１］を裏付けるものであり、Ｍ７５モノクローナル抗体は、種々の免疫検出法および免疫標的アプローチに有用な、価値のあるＣＡ ＩＸ特異的試薬であることを示している。
</span>
&nbsp;&nbsp;CA IX was obtained from Zabada, J (Zavada, J.), Pastorekova, S., using the M75 monoclonal antibody first described by <figure-callout id="3" label="NPL" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">NPL</a></figure-callout> 3. (Pasterekova, S.) and Pastorek, J .; (Pastorek, J.) [Zavada et al., See, for example, US Pat. Its antibodies include cloning of cDNA encoding CA IX [Non-Patent Document 4], assessment of CA IX expression in tumors and normal tissues [<figure-callout id="5" label="Non-Patent Document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-Patent Document</a></figure-callout> 5, and many other cited references], CA IX regulation by cell density. Used in trials [6, 7], and demonstration of CA IX induction by hypoxia [8, and many other cited references]. All such studies are the original of Zavada et al. That MN / CA IX / CA9 can be used in diagnosis and / or prognosis as a pre-neoplastic / neoplastic tumor marker and in therapy as a target. In support of ideas and research [eg, Zavada et al., US Pat. No. 6,057,049], the M75 monoclonal antibody is a valuable CA IX-specific reagent useful for various immunodetection methods and immunotargeting approaches. It is shown that.
</span>
    </p>
    <p num="0006" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの特許文献２（１９９３年９月１６日公開）および特許文献１（１９９５年２月７日発行）は、ＭＮ遺伝子およびＭＮタンパク質の発見および生物学的性質ならびに分子的性質について記載している。ＭＮ遺伝子は、全ての被験脊椎動物の染色体ＤＮＡに存在し、その発現は、腫瘍形成能と強く関連することが判明した。
</span>
&nbsp;&nbsp;Zavada et al., Patent Document 2 (published on September 16, 1993) and Patent Document 1 (issued on February 7, 1995) describe the discovery and biological and molecular properties of the MN gene and MN protein. It is described. The MN gene was present in the chromosomal DNA of all test vertebrates, and its expression was found to be strongly associated with tumorigenic potential.
</span>
    </p>
    <p num="0007" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質は、ヒト子宮頚部癌に由来するＨｅＬａ細胞において最初に確認された。ＭＮタンパク質は、多くのタイプのヒト癌（中でもとりわけ子宮頚部、卵巣、子宮内膜、腎臓、膀胱、乳房、大腸、肺、食道、および前立腺）において見られる。ＭＮタンパク質を有意に発現する正常組織は極めて少ないことが判明している。これらのＭＮ発現正常組織としては、ヒト胃粘膜および胆嚢上皮、ならびに消化管の他の幾つかの正常組織が挙げられる。逆説的に言えば、通常ＭＮを発現する幾つかの組織、例えば胃粘膜における癌および他の前新生物疾患／新生物疾患においては、ＭＮ遺伝子発現が消滅するか、または減少することが判明している。
</span>
&nbsp;&nbsp;MN protein was first identified in HeLa cells derived from human cervical cancer. MN protein is found in many types of human cancers (among others, cervix, ovary, endometrium, kidney, bladder, breast, large intestine, lung, esophagus, and prostate). It has been found that very few normal tissues significantly express MN protein. These MN-expressing normal tissues include human gastric mucosa and gallbladder epithelium, and some other normal tissues of the gastrointestinal tract. Paradoxically, it has been found that in some tissues that normally express MN, such as cancer in the gastric mucosa and other preneoplastic / neoplastic diseases, MN gene expression disappears or decreases. ing.
</span>
    </p>
    <p num="0008" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  一般に、発癌は、ＭＮタンパク質の異常発現が前兆となり得る。例えば、発癌は：（１）通常ＭＮタンパク質を有意に発現しない組織において、ＭＮタンパク質が存在する場合；（２）通常ＭＮタンパク質を発現する組織にＭＮタンパク質が存在しない場合；（３）組織において通常に発現されるレベルからＭＮ遺伝子発現が、有意に増加レベルまたは有意に減少レベルにある場合；または（４）ＭＮタンパク質が、細胞内の異常位置に発現する場合、が前兆となり得る。
</span>
&nbsp;&nbsp;In general, carcinogenesis can be preceded by abnormal expression of MN protein. For example, carcinogenesis is: (1) when MN protein is present in a tissue that does not significantly express MN protein; (2) when MN protein is not present in a tissue that normally express MN protein; (3) usually in tissue Can be a precursor when MN gene expression is significantly increased or significantly decreased from the level expressed in the cell; or (4) the MN protein is expressed at an abnormal location in the cell.
</span>
    </p>
    <p num="0009" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの特許文献２および特許文献３（１９９５年１２月２１日公開）には、ＭＮ遺伝子およびＭＮタンパク質の発見、ならびにＭＮ遺伝子発現と腫瘍形成能との強い関連付けが、いかにして癌および前癌病態の診断／予後診断法および治療方法を生み出したかについて開示している。その明細書には、脊椎動物における異常ＭＮ遺伝子発現を検出、または検出および定量化することによって、新生物疾患の発症および存在を確認するための方法および組成物が提供されている。例えば、ＭＮ抗原を検出、または検出および定量化するためにＭＮ特異的抗体を用いる免疫アッセイ、ハイブリダイゼーションアッセイ、あるいは、ＭＮ ｍＲＮＡなどのＭＮ核酸を検出、または検出および定量化するために、ＭＮ ｃＤＮＡなどのＭＮ核酸を用いてＲＴ−ＰＣＲなどのＰＣＲアッセイなど、脊椎動物のサンプルの種々の従来のアッセイにより、異常ＭＮ遺伝子発現を検出、または検出および定量化することができる。
</span>
&nbsp;&nbsp;<figure-callout id="2" label="Patent document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Patent document</a></figure-callout> 2 and patent document 3 (published December 21, 1995) of Zavada et al. Show how the discovery of MN gene and MN protein and the strong association between MN gene expression and tumorigenic potential. Disclosed is the creation of diagnostic / prognostic and therapeutic methods for cancer and precancerous conditions. The specification provides methods and compositions for confirming the onset and presence of neoplastic disease by detecting or detecting and quantifying abnormal MN gene expression in vertebrates. For example, to detect, or detect and quantify MN nucleic acids, such as immunoassays, hybridization assays, or MN mRNA, which use MN-specific antibodies to detect or detect and quantify MN antigens Abnormal MN gene expression can be detected or detected and quantified by various conventional assays of vertebrate samples, such as PCR assays such as RT-PCR using MN nucleic acids such as.
</span>
    </p>
    <p num="0010" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮ／ＣＡ ＩＸは、ウェスタンブロッティングによる推定で５８および５４ｋＤａの見かけの分子量を有する原形質膜および核タンパク質として、ＨｅＬａ細胞において最初に確認された。ＭＮ／ＣＡ ＩＸは、３ｋＤａの単一炭水化物鎖によりＮ−グリコシル化され、非還元条件下でＳ−Ｓ結合オリゴマーを形成する［非特許文献３；非特許文献４］。ＭＮ／ＣＡ ＩＸは、細胞表面に位置する膜間タンパク質であるが、一部の事例では、ＭＮ／ＣＡ ＩＸは、核内に検出されている［非特許文献５；非特許文献３］。
</span>
&nbsp;&nbsp;MN / CA IX was first identified in HeLa cells as a plasma membrane and nucleoprotein with an apparent molecular weight of 58 and 54 kDa as estimated by Western blotting. MN / CA IX is N-glycosylated with a 3 kDa single carbohydrate chain to form an SS bond oligomer under non-reducing conditions [Non-Patent <figure-callout id="3" label="Document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Document</a></figure-callout> 3; Non-Patent Document 4]. MN / CA IX is an intermembrane protein located on the cell surface, but in some cases, MN / CA IX has been detected in the nucleus [Non-patent <figure-callout id="5" label="document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">document</a></figure-callout> 5; Non-patent document 3].
</span>
    </p>
    <p num="0011" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮは、双子タンパク質（twin protein）であるｐ５４／５８ＮによりＨｅＬａ細胞中に見られる。ｐ５４／５８Ｎ（ＭＡｂ Ｍ７５）と反応するモノクローナル抗体を用いた免疫ブロット法により、５４ｋｄと５８ｋｄに２本のバンドが現われた。これらの２本のバンドは、恐らくは翻訳後プロセシングにより異なるであろうタンパク質の１種に相当すると考えられる。
</span>
&nbsp;&nbsp;MN is found in HeLa cells by p54 / 58N, a twin protein. By immunoblotting using a monoclonal antibody that reacts with p54 / 58N (MAb M75), two bands appeared at 54 kd and 58 kd. These two bands are likely to represent one of the proteins that may differ due to post-translational processing.
</span>
    </p>
    <p num="0012" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの特許文献２および特許文献３には、本明細書の図８Ａ〜８Ｃに示されているＭＮ ｃＤＮＡ配列（配列番号１）、図８Ａ〜８Ｃにも示されているＭＮアミノ酸配列（配列番号２）、および本明細書の図９Ａ〜９Ｆに示されているＭＮゲノム配列（配列番号３）が開示されている。ＭＮ遺伝子は、１１のエクソンおよび１０のイントロンで構成される。配列番号１のヒトＭＮ ｃＤＮＡ配列は、１５２２の塩基対（ｂｐ）を含む。配列番号７０のＭＮ ｃＤＮＡ配列は、１５５２のｂｐを含む（ＥＭＢＬ登録番号Ｘ６６８３９；パストレク（Ｐａｓｔｏｒｅｋ）ら（１９９４年））。
</span>
&nbsp;&nbsp;<figure-callout id="2" label="Patent Documents" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="3" label="Patent Documents" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Patent Documents</a></figure-callout></a></figure-callout> 2 and 3 of Zavada et al. Describe the MN cDNA sequence (SEQ ID NO: 1) shown in FIGS. 8A to 8C of this specification, and the MN amino acid also shown in FIGS. 8A to 8C. The sequence (SEQ ID NO: 2) and the MN genomic sequence shown in FIGS. 9A-9F herein (SEQ ID NO: 3) are disclosed. The MN gene is composed of 11 exons and 10 introns. The human MN cDNA sequence of SEQ ID NO: 1 contains 1522 base pairs (bp). The MN cDNA sequence of SEQ ID NO: 70 contains 1552 bp (EMBL accession number X66839; Pastorek et al. (1994)).
</span>
    </p>
    <p num="0013" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図８Ａ〜８Ｃに示されているＭＮタンパク質の最初の３７のアミノ酸（配列番号２）は、推定上のＭＮシグナルペプチド［配列番号４］を構成する。ＭＮタンパク質は、細胞外（ＥＣ）ドメイン［図８Ａ〜８Ｃのアミノ酸（ａａ）の３８〜４１４（配列番号５）］、膜貫通（ＴＭ）ドメイン［ａａの４１５〜４３４（配列番号６）］、および細胞内（ＩＣ）ドメイン［ａａ４３５〜４５９（配列番号７）］を有する。細胞外ドメインは、アミノ酸（ａａ）の約５３〜１１１（配列番号８）または好ましくはａａの約５２〜１２５（配列番号８１）にプロテオグリカン様（ＰＧ）ドメイン、およびａａの約１３５〜３９１（配列番号９）または好ましくはａａの約１２１〜３９７（配列番号８２）に炭酸脱水酵素（ＣＡ）ドメインを含む。
</span>
&nbsp;&nbsp;The first 37 amino acids (SEQ ID NO: 2) of the MN protein shown in FIGS. 8A-8C constitute the putative MN signal peptide [SEQ ID NO: 4]. The MN protein consists of an extracellular (EC) domain [amino acids (aa) 38-414 (SEQ ID NO: 5) in FIGS. 8A-8C], a transmembrane (TM) domain [aa 415-434 (SEQ ID NO: 6)], And an intracellular (IC) domain [aa435 to 459 (SEQ ID NO: 7)]. The extracellular domain is a proteoglycan-like (PG) domain at about 53-111 of amino acid (aa) (SEQ ID NO: 8) or preferably about 52-125 of aa (SEQ ID NO: 81), and about 135-391 of aa (sequence No. 9) or preferably about 121 to 397 (SEQ ID NO: 82) of aa contains a carbonic anhydrase (CA) domain.
</span>
    </p>
    <p num="0014" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの特許文献２および特許文献３には、ＭＮ特異的抗体の製造について記載されている。代表的で好ましいＭＮ特異的な抗体であるモノクローナル抗体Ｍ７５（ＭＡｂ Ｍ７５）、そのハイブリドーマ（ＶＵ−Ｍ７５）は、ＡＴＣＣ指定番号ＨＢ１１１２８として、米国バージニア州マナサス所在のアメリカン・タイプ・カルチャー・コレクション（ＡＴＣＣ）に寄託された。Ｍ７５抗体は、ＭＮタンパク質を発見し、同定するために用いられ、例えば、新鮮、凍結、またはホルマリン−、アルコール−、アセトン−あるいは他の様式で固定、および／または、パラフィン埋め込みおよび脱パラフィン化された組織サンプルにおいて、ラジオイムノアッセイおよび免疫組織化学的にウェスタンブロットでＭＮ抗原を容易に同定するためにＭ７５抗体を使用することができる。別の代表的で好ましいＭＮ特異的抗体であるＭａｂ ＭＮ１２は、指定ＨＢ１１６４７としてＡＴＣＣに寄託されたハイブリドーマＭＮ１２．２．２により分泌される。ザバダ（Ｚａｖａｄａ）らの特許文献３の実施例１では、ＭＡｂ Ｍ７５を用いて組織の免疫組織化学的染色からＭＮ遺伝子の発癌性を立証する代表的な結果を提供している。
</span>
&nbsp;&nbsp;Zavada et al., US Pat. Nos. 5,099,086 and 5,099, describe the production of MN specific antibodies. A typical and preferred MN-specific antibody, monoclonal antibody M75 (MAb M75), its hybridoma (VU-M75), is ATCC designation number HB11128, American Type Culture Collection (ATCC), Manassas, Va. Deposited. The M75 antibody is used to discover and identify the MN protein, eg, fresh, frozen, or fixed in formalin-, alcohol-, acetone-, or otherwise, and / or paraffin-embedded and deparaffinized. M75 antibodies can be used to easily identify MN antigens in Western blots by radioimmunoassay and immunohistochemistry in isolated tissue samples. Another representative and preferred MN-specific antibody, Mab MN12, is secreted by the hybridoma MN12.2.2 deposited with the ATCC as designated HB11647. Example 1 of Zavada et al., US Pat. No. 5,637,097 provides representative results demonstrating the carcinogenicity of the MN gene from immunohistochemical staining of tissues using MAb M75.
</span>
    </p>
    <p num="0015" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  免疫優性エピトープは事実上、Ｍ７５ ｍａｂ、特にＮ末端ＰＧ領域において４回等しく反復されるアミノ酸配列ＰＧＥＥＤＬＰ（配列番号１１）に関する反復性エピトープなど、ＭＮ／ＣＡ ＩＸのＰＧドメイン内にあるものと考えられている［非特許文献９］。
</span>
&nbsp;&nbsp;Immunodominant epitopes are virtually considered to be within the PG domain of MN / CA IX, such as the repetitive epitope for the M75 mab, particularly the amino acid sequence PGEEDLP (SEQ ID NO: 11) that is repeated four times equally in the N-terminal PG region. [Non-Patent Document 9].
</span>
    </p>
    <p num="0016" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｍ７５ ｍａｂは、非特許文献２で最初に報告され、例えば、ザバダ（Ｚａｖａｄａ）らの特許文献４および特許文献５など多くの米国特許および外国特許において、全てのＭＮ／ＣＡ ＩＸ特異的抗体、ポリクローナルおよびモノクローナルならびにそれらの断片を用いて、具体的ならびに包括的に主張されている。［ザバダらの特許文献１；特許文献６〜２０も参照のこと］。これらザバダらの米国特許および外国特許は、参照することにより本明細書に援用される。
</span>
&nbsp;&nbsp;M75 mab was first reported in <figure-callout id="2" label="Non-Patent Document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-Patent Document</a></figure-callout> 2, including all MN / CA IX specific antibodies, polyclonal in many US patents and foreign patents such as Zavada et al. And allegedly and comprehensively using monoclonals and fragments thereof. [See also Zabada et al., <figure-callout id="1" label="Patent Document" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Patent Document</a></figure-callout> 1; These Zabada et al. US patents and foreign patents are hereby incorporated by reference.
</span>
    </p>
    <p num="0017" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡ ＩＸは、二酸化炭素と重炭酸イオンとの間での可逆的変換を触媒する亜鉛金属酵素のうちのα炭酸脱水酵素群の高活性な種である［非特許文献４；非特許文献１；非特許文献１０〜１２］。ＣＡ ＩＸは、哺乳動物に存在する１４のイソ体のうちの１つであり、細胞質（ＣＡ Ｉ、ＩＩ、ＩＩＩ、ＶＩＩ）、ミトコンドリア（ＣＡ ＶＡ、ＶＢ）、分泌胞（ＣＡ ＶＩ）および細胞膜（ＣＡ ＩＶ、ＩＸ、ＸＩＩ、ＸＩＶ）など、種々の細胞成分の位置を占めている。イソ酵素の幾つかは、広範囲の組織にわたって分布しており（ＣＡ Ｉ、ＩＩ、ＣＡ ＩＶ）、他のイソ酵素は、特定の器官に限定されており（唾液腺のＣＡ ＶＩ）、２つのイソ体は、癌組織に関連している（ＣＡ ＩＸ、ＸＩＩ）［非特許文献１０；非特許文献１３］。酵素活性および動態学的性質、ならびにスルホンアミド阻害剤に対する感受性は、高感受性（ＣＡ ＩＩ、ＣＡ ＩＸ、ＣＡ  ＸＩＩ、ＣＡ ＩＶ）から低感受性（ＣＡ ＩＩＩ）まで異なっている［非特許文献１４］。ＣＡ関連タンパク質と称される幾つかのイソ体（ＣＡ−ＲＰ ＶＩＩＩ、Ｘ、ＸＩ）は、活性部位の保存が不完全なため触媒活性はない。同じ群のタンパク質の遺伝的に関連する種内で非常に変動があることが、多様な生理学的かつ病理学的過程におけるそれらの使用根拠をなしている。この触媒活性は、代謝活性組織における酸−塩基バランスの維持およびイオン類と水との交換に関して基本的に関連性がある。この活性を介して、ＣＡ類は、事実上、呼吸、体液の産生（硝子体液、胃液、脳脊髄液）、骨吸収、腎酸性化などに寄与する（非特許文献１０）。
</span>
&nbsp;&nbsp;CA IX is a highly active species of the α-carbonic anhydrase group among zinc metalloenzymes that catalyze reversible conversion between carbon dioxide and bicarbonate ions [<figure-callout id="4" label="Non-patent document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-patent document</a></figure-callout> 4; <figure-callout id="1" label="Non-patent document" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-patent document</a></figure-callout> 1; <figure-callout id="10" label="Non-patent documents" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-patent documents</a></figure-callout> 10 to 12]. CA IX is one of 14 isoforms present in mammals, and includes cytoplasm (CA I, II, III, VII), mitochondria (CA VA, VB), secretory vesicle (CA VI) and cell membrane ( CA IV, IX, XII, XIV) and other cell components are occupied. Some of the isoenzymes are distributed over a wide range of tissues (CA I, II, CA IV), and other isoenzymes are restricted to specific organs (CA VI of salivary glands). Is associated with cancer tissue (CA IX, XII) [<figure-callout id="10" label="Non-patent document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-patent document</a></figure-callout> 10; Non-patent document 13]. Enzymatic activity and kinetic properties, and sensitivity to sulfonamide inhibitors, vary from high sensitivity (CA II, CA IX, CA XII, CA IV) to low sensitivity (CA III) [14]. Some isoforms called CA-related proteins (CA-RP VIII, X, XI) have no catalytic activity due to incomplete preservation of the active site. The great variability within the genetically related species of the same group of proteins forms the basis for their use in diverse physiological and pathological processes. This catalytic activity is fundamentally related to the maintenance of acid-base balance in metabolically active tissues and the exchange of ions and water. Through this activity, CAs substantially contribute to respiration, production of body fluids (vitreous fluid, gastric fluid, cerebrospinal fluid), bone resorption, renal acidification, and the like (Non-patent Document 10).
</span>
    </p>
    <p num="0018" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡ ＩＸイソ酵素は、基礎研究ならびに臨床研究の重要な対象となる幾つかの性質を含んでいる。第一に、ＣＡ ＩＸの発現は、多種多様のヒト腫瘍と極めて密に関連するが、一方、その発現は一般に、対応する正常組織には存在しない［非特許文献５；非特許文献１５〜２１］。これは、−１０／−３位における転写<u class="style-scope patent-text">開始</u>部位に近位の最小ＣＡ９プロモーターに局在化した低酸素状態応答因子（ＨＲＥ）に結合する低酸素状態誘導因子（ＨＩＦ）を介してＣＡ９遺伝子の転写を強力に活性化する腫瘍低酸素状態に主に関連している［非特許文献８］。ＨＩＦ転写因子は、腫瘍細胞の生存および低酸素ストレスへの適応または腫瘍細胞死に導く遺伝子の活性化により、弱く酸素化された腫瘍細胞の発現プロフィールを有意に変化させる。その結果、低酸素状態は、浸潤および転移する能力が増大したより攻撃的な腫瘍細胞を選択し、したがって、予後不良および抗癌治療に対する応答不良に本質的に関連する［非特許文献２２］。
</span>CA IX isoenzymes contain several properties that are important targets for basic as well as clinical research. First, the expression of CA IX is very closely associated with a wide variety of human tumors, whereas its expression is generally absent from the corresponding normal tissue [<figure-callout id="5" label="Non-Patent Document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-Patent Document</a></figure-callout> 5; Non-Patent Documents 15-21]. ]. This is due to the hypoxia inducing factor (HIF) binding to the hypoxia responsive factor (HRE) localized to the minimal CA9 promoter proximal to the transcription <u class="style-scope patent-text">start</u> site at positions -10 / -3. It is mainly associated with tumor hypoxia, which strongly activates transcription [8]. HIF transcription factors significantly alter the expression profile of weakly oxygenated tumor cells by activating genes that lead to tumor cell survival and adaptation to hypoxic stress or tumor cell death. As a result, hypoxia selects more aggressive tumor cells with increased ability to infiltrate and metastasize, and is therefore inherently associated with poor prognosis and poor response to anti-cancer treatment [22].</span>
    </p>
    <p num="0019" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  腫瘍低酸素状態は、癌発生および癌治療に関して大いに関連を有する重要な現象であるので［非特許文献２３］、ＭＮは、診断／予測値を有する固有の低酸素マーカーとして、ならびに有望な治療標的として重要な可能性を有している［非特許文献８；非特許文献２４〜２８］。提案された臨床適用の有利な点として、ＣＡ ＩＸは、癌細胞の表面に露出した大きな細胞外部分を有する不可欠な細胞膜タンパク質であり、したがって特異的モノクローナル抗体などの標的手段によりアクセス可能である。さらに、ＣＡ ＩＸは、細胞外ＣＡドメインのＮ末端伸長を形成する独特なプロテオグリカン関連領域（ＰＧ）の存在により他のＣＡイソ酵素とは異なり、他のイソ酵素との交差認識の排除が可能になる［非特許文献１］。ＣＡ ＩＸは、細胞接着の調整およびｐＨの調節の双方を介して腫瘍生物学において積極的な役割を果たしていると思われる（非特許文献２９〜３１）。ＣＡ ＩＸは、重炭酸イオン輸送メタボロン（metabolon）に関与しており、低酸素状態に応答して細胞外微小環境の酸性化に寄与している（非特許文献３２、非特許文献３０）。さらに、ＣＡ ＩＸの細胞内ドメイン（ＩＣ）は、少なくとも腎細胞癌において腫瘍形成的な第三の役割を果たしている可能性がある：チロシンリン酸化ＣＡ ＩＸ（ＥＧＦＲを介して媒介）は、ＰＩ−３Ｋの調節サブユニット（ｐ８５）と相互作用し、Ａｋｔの活性化をもたらす［非特許文献３３］。発癌に寄与するその多くの潜在的活性のため、その機能の抑止のためにＣＡ ＩＸタンパク質を標的にすることは、治療効果を有することが期待されている。しかしながら、ＣＡ ＩＸの基礎的な分子的および機能的態様の多くは知られていない；そのうちの１つは、ＣＡ ＩＸの選択的スプライシングの可能性であった。
</span>
&nbsp;&nbsp;Since tumor hypoxia is an important phenomenon with great relevance for cancer development and cancer treatment [23], MN is a unique hypoxic marker with diagnostic / predictive value, and a promising therapeutic target. [<figure-callout id="8" label="Non-patent document" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Non-patent document</a></figure-callout> 8; Non-patent documents 24-28]. As an advantage of the proposed clinical application, CA IX is an essential cell membrane protein with a large extracellular portion exposed on the surface of cancer cells and is therefore accessible by targeting means such as specific monoclonal antibodies. In addition, CA IX differs from other CA isoenzymes due to the presence of a unique proteoglycan-related region (PG) that forms the N-terminal extension of the extracellular CA domain, allowing the elimination of cross-recognition with other isoenzymes [Non-Patent Document 1]. CA IX appears to play an active role in tumor biology through both cell adhesion regulation and pH regulation (Non-Patent Documents 29-31). CA IX is involved in bicarbonate ion transport metabolon and contributes to acidification of the extracellular microenvironment in response to hypoxia (Non-patent Documents 32 and 30). Furthermore, the intracellular domain (IC) of CA IX may play a third oncogenic role at least in renal cell carcinoma: tyrosine phosphorylated CA IX (mediated via EGFR) is PI- It interacts with the 3K regulatory subunit (p85) resulting in Akt activation [33]. Because of its many potential activities that contribute to carcinogenesis, targeting the CA IX protein for the suppression of its function is expected to have a therapeutic effect. However, many of the basic molecular and functional aspects of CA IX are not known; one of them was the possibility of alternative splicing of CA IX.
</span>
    </p>
    <p num="0020" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  選択的スプライシングは、タンパク質の構造的および機能的多様化に寄与する重要な分子機構である。選択的スプライシングは、エクソン封入(exon inclusion)の差異から生じることが多く、ドメイン組成、細胞内局在性、相互作用の可能性、およびシグナル伝達能力における変化、ならびにタンパク質レベルにおける他の変化をもたらす。最近のゲノムテクノロジーにより得られたデータでは、ヒト遺伝子の６０％以上が選択的にスプライスされることが示されている。また、選択的スプライシングの変異体発現の不均衡は、細胞表現型に著しく影響を及ぼし、種々の病状に役割を果たし得る証拠が増加しつつある（非特許文献３４）。
</span>
&nbsp;&nbsp;Alternative splicing is an important molecular mechanism that contributes to structural and functional diversification of proteins. Alternative splicing often results from differences in exon inclusion, resulting in changes in domain composition, subcellular localization, potential interactions, and signaling capacity, as well as other changes at the protein level . Data obtained with recent genomic technologies show that more than 60% of human genes are alternatively spliced. In addition, alternative splicing variant expression imbalances significantly affect cellular phenotypes and increasing evidence that they may play a role in various disease states (Non-Patent Document 34).
</span>
    </p>
    <p num="0021" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明は、ＣＡ９遺伝子発現が選択的スプライシングを含むことの発見に基づくものである。本明細書では、ＭＮ ｍＲＮＡの選択的にスプライスされた（ＡＳ）マウスおよびヒト変異体について記載する。ヒトＡＳ変異体は、腫瘍において、完全長（ＦＬ）のＣＡ９ ｍＲＮＡよりも量が少ないが、正常組織および酸素正常状態下で検出することができることを、本発明者は実証している。ヒトＡＳ ＣＡ９ ｍＲＮＡは、エクソン８および９を含まず、切断されたＣＡ ＩＸタンパク質をコードしている。その結果、ＡＳ ＣＡ ＩＸは、細胞膜にとどめられず、触媒活性の減少を示す。ＨｅＬａ細胞における過剰発現の際、ＡＳ ＣＡ ＩＸは、低酸素状態に誘導された細胞外酸性化を減少させ、ＨｅＬａスフェロイドの増殖を損なう。ＡＳ変異体は、正常表現型を有する酸素正常状態の細胞内に存在し得ることから、ＡＳ変異体は、ＣＡ９遺伝子の低酸素関連発現および腫瘍関連発現を評価するために設計された診断および／または予後診断試験において偽陽性結果を生じさせる可能性がある。さらに、ＡＳ型のＣＡ ＩＸタンパク質は、特に、ＦＬレベルが比較的低い場合の中等度の低酸素状態でＦＬ型のＣＡ ＩＸを機能的に阻害し得る。
</span>
&nbsp;&nbsp;The present invention is based on the discovery that CA9 gene expression includes alternative splicing. Described herein are alternatively spliced (AS) mouse and human variants of MN mRNA. The inventor has demonstrated that human AS variants are less abundant in tumors than full-length (FL) CA9 mRNA, but can be detected under normal tissue and normoxic conditions. Human AS CA9 mRNA does not contain <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9 and encodes a truncated CA IX protein. As a result, AS CA IX is not restricted to the cell membrane and shows a decrease in catalytic activity. Upon overexpression in HeLa cells, AS CA IX reduces extracellular acidification induced by hypoxia and impairs the growth of HeLa spheroids. Since AS variants can be present in normoxic cells with a normal phenotype, AS variants are diagnostic and / or designed to assess hypoxia-related and tumor-related expression of the CA9 gene. Or it may produce false positive results in prognostic tests. Furthermore, AS-type CA IX proteins can functionally inhibit FL-type CA IX, particularly in moderate hypoxia when FL levels are relatively low.
</span>
    </p>
  </background-art>
  <citation-list class="style-scope patent-text">
    <patent-literature class="style-scope patent-text">
      <p num="0022" class="style-scope patent-text">
        <patcit num="1" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第５，３８７，６７６号明細書</span>US Pat. No. 5,387,676</span>
          </text>
        </patcit>
        <patcit num="2" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">国際公開第９３／１８１５２号パンフレット</span>International Publication No. 93/18152 Pamphlet</span>
          </text>
        </patcit>
        <patcit num="3" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">国際公開第９５／３４６５０号パンフレット</span>WO95 / 34650 pamphlet</span>
          </text>
        </patcit>
        <patcit num="4" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第５，９８１，７１１号明細書</span>US Pat. No. 5,981,711</span>
          </text>
        </patcit>
        <patcit num="5" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">欧州特許出願公開第０  ６３７  ３３６Ｂ１号明細書</span>European Patent Application Publication No. 0 637 336B1</span>
          </text>
        </patcit>
        <patcit num="6" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第５，９５５，０７５号明細書</span>US Pat. No. 5,955,075</span>
          </text>
        </patcit>
        <patcit num="7" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第５，９７２，３５３号明細書</span>US Pat. No. 5,972,353</span>
          </text>
        </patcit>
        <patcit num="8" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第５，９８９，８３８号明細書</span>US Pat. No. 5,989,838</span>
          </text>
        </patcit>
        <patcit num="9" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，００４，５３５号明細書</span>US Pat. No. 6,004,535</span>
          </text>
        </patcit>
        <patcit num="10" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，０５１，２２６号明細書</span>US Pat. No. 6,051,226</span>
          </text>
        </patcit>
        <patcit num="11" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，０６９，２４２号明細書</span>US Pat. No. 6,069,242</span>
          </text>
        </patcit>
        <patcit num="12" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，０９３，５４８号明細書</span>US Pat. No. 6,093,548</span>
          </text>
        </patcit>
        <patcit num="13" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，２０４，３７０号明細書</span>US Pat. No. 6,204,370</span>
          </text>
        </patcit>
        <patcit num="14" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，２０４，８８７号明細書</span>US Pat. No. 6,204,887</span>
          </text>
        </patcit>
        <patcit num="15" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，２９７，０４１号明細書</span>US Pat. No. 6,297,041</span>
          </text>
        </patcit>
        <patcit num="16" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">米国特許第６，２９７，０５１号明細書</span>US Pat. No. 6,297,051</span>
          </text>
        </patcit>
        <patcit num="17" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">オーストラリア国特許第６６９６９４号明細書</span>Australian Patent No. 669694</span>
          </text>
        </patcit>
        <patcit num="18" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">カナダ国特許第２，１３１，８２６号明細書</span>Canadian Patent No. 2,131,826</span>
          </text>
        </patcit>
        <patcit num="19" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">独国特許第６９３２５５７７．３号明細書</span>German Patent No. 693255557.3</span>
          </text>
        </patcit>
        <patcit num="20" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">韓国特許第２８２２８４号明細書</span>Korean Patent No. 282284 Specification</span>
          </text>
        </patcit>
      </p>
    </patent-literature>
    <non-patent-literature class="style-scope patent-text">
      <p num="0023" class="style-scope patent-text">
        <nplcit num="1" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">オパブスキー（Ｏｐａｖｓｋｙ）ら、Ｇｅｎｏｍｉｃｓ３３（３）：４８０−４８７頁（１９９６年）</span>Opavsky et al., Genomics 33 (3): 480-487 (1996).</span>
          </text>
        </nplcit>
        <nplcit num="2" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ウエムラ（Ｕｅｍｕｒａ）ら「Ｅｘｐｒｅｓｓｉｏｎ  ｏｆ  Ｔｕｍｏｒ−Ａｓｓｏｃｉａｔｅｄ  Ａｎｔｉｇｅｎ  ＭＮ／Ｇ２５０  ｉｎ  Ｕｒｏｌｏｇｉｃ  Ｃａｒｃｉｎｏｍａ：Ｐｏｔｅｎｔｉａｌ  Ｔｈｅｒａｐｅｕｔｉｃ  Ｔａｒｇｅｔ」、Ｊ．Ｕｒｏｌ．、１５４（補遺４）：３７７頁（Ａｂｓｔｒａｃｔ  １４７５；１９９７年）</span>Uemura et al., “Expression of Tumor-Associated Antigen MN / G250 in Urological Carcinoma: Potential Therapeutic Target”, J. Am. Urol. 154 (Appendix 4): 377 (Abstract 1475; 1997).</span>
          </text>
        </nplcit>
        <nplcit num="3" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、Ｖｉｒｏｌｏｇｙ１８７：６２０−６２６頁（１９９２年）</span>Pastorekova et al., Virology 187: 620-626 (1992)</span>
          </text>
        </nplcit>
        <nplcit num="4" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">パストレク（Ｐａｓｔｒｅｋ）ら、Ｏｎｃｏｇｅｎｅ  ９：２７８８−２８８８頁（１９９４年）</span>Pastrek et al., Oncogene 9: 2788-2888 (1994)</span>
          </text>
        </nplcit>
        <nplcit num="5" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ザバダ（Ｚａｖａｄａ）ら、Ｉｎｔ  Ｊ  Ｃａｎｃｅｒ、５４：２６８−２７４頁（１９９３年）</span>Zavada et al., Int J Cancer, 54: 268-274 (1993).</span>
          </text>
        </nplcit>
        <nplcit num="6" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">リースコブスカ（Ｌｉｅｓｋｏｖｓｋａ）ら、Ｎｅｏｐｌａｓｍａ、４６：１７−２４頁（１９９９年）</span>Lieskovska et al., Neoplasma, 46: 17-24 (1999).</span>
          </text>
        </nplcit>
        <nplcit num="7" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">カルツ（Ｋａｌｕｚ）ら、Ｃａｎｃｅｒ  Ｒｅｓｅａｒｃｈ、６２：４４６９−４４７７頁（２００２年）</span>Kaluz et al., Cancer Research, 62: 4469-4477 (2002).</span>
          </text>
        </nplcit>
        <nplcit num="8" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ウィコッフ（Ｗｙｋｏｆｆ）ら、Ｃａｎｃｅｒ  Ｒｅｓｅａｒｃｈ、６０：７０７５−７０８３頁（２０００年）</span>Wykoff et al., Cancer Research, 60: 7075-7083 (2000).</span>
          </text>
        </nplcit>
        <nplcit num="9" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ザバダ（Ｚａｖａｄａ）ら、Ｂｒ．Ｊ．Ｃａｎｃｅｒ８２（１１）：１８０８−１８１３頁（２０００年）</span>Zavada et al., Br. J. et al. Cancer 82 (11): 1808-1813 (2000)</span>
          </text>
        </nplcit>
        <nplcit num="10" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">チェグウィッデン（Ｃｈｅｇｗｉｄｄｅｎ）ら、ＥＸＳ９０：３４３−３６３頁（２０００年）</span>Chegwidden et al., EXS 90: 343-363 (2000)</span>
          </text>
        </nplcit>
        <nplcit num="11" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ウィンゴ（Ｗｉｎｇｏ）ら、Ｂｉｏｃｈｅｍｉｃａｌ  ａｎｄ  Ｂｉｏｐｈｙｓｉｃａｌ  Ｒｅｓｅａｒｃｈ  Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ２８８：６６６−６６９頁（２００１年）</span>Wingo et al., Biochemical and Biophysical Research Communications 288: 666-669 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="12" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、Ｊ  Ｅｎｚ  Ｉｎｈｉｂ  Ｍｅｄ  Ｃｈｅｍ１９：１９９−２２９頁（２００４年）</span>Pastorekova et al., J Enz Inhib Med Chem 19: 199-229 (2004).</span>
          </text>
        </nplcit>
        <nplcit num="13" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）およびパストレク（Ｐａｓｔｏｒｅｋ）、第９章、Ｃａｒｂｏｎｉｃ  Ａｎｈｙｄｒａｓｅ：Ｉｔｓ  Ｉｎｈｉｂｉｔｏｒｓ  ａｎｄ  Ａｃｔｉｖａｔｏｒｓ（スプラン（Ｓｕｐｕｒａｎ）ら編；ＣＲＣプレス（ロンドンなど）２００４年）</span>Pastorekova and Pastorek, <figure-callout id="9" label="Chapter" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Chapter</a></figure-callout> 9, Carbon Anhydrase: Its Inhibitors and Activators (Edited by Spuran et al .; CRC Press (London, etc.) 2004)</span>
          </text>
        </nplcit>
        <nplcit num="14" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">スプラン（Ｓｕｐｕｒａｎ）およびスコッザファバ（Ｓｃｏｚｚａｆａｖａ）、Ｊ．Ｅｎｚｙｍ  Ｉｎｈｉｂ．１５（６）：５９７−６１０頁（２０００年）</span>Supran and Scozzafava, J. Am. Enzym Inhib. 15 (6): 597-610 (2000)</span>
          </text>
        </nplcit>
        <nplcit num="15" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">リアオ（Ｌｉａｏ）ら、Ａｍ．Ｊ．Ｐａｔｈｏｌ．１４５（３）：５９８−６０９頁（１９９４年）</span>Liao et al., Am. J. et al. Pathol. 145 (3): 598-609 (1994)</span>
          </text>
        </nplcit>
        <nplcit num="16" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ターナー（Ｔｕｒｎｅｒ）ら、Ｈｕｍａｎ  Ｐａｔｈｏｌ．２８（６）：７４０−７４４頁（１９９７年）</span>Turner et al., Human Pathol. 28 (6): 740-744 (1997)</span>
          </text>
        </nplcit>
        <nplcit num="17" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">リアオ（Ｌｉａｏ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．５７：２８２７−２８３１頁（１９９７年）</span>Liao et al., Cancer Res. 57: 2827-2831 (1997)</span>
          </text>
        </nplcit>
        <nplcit num="18" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">サーニオ（Ｓａａｒｎｉｏ）ら、Ａｍ  Ｊ  Ｐａｔｈｏｌ  １５３：２７９−２８５頁（１９９８年）</span>Saario et al., Am J Pathol 153: 279-285 (1998).</span>
          </text>
        </nplcit>
        <nplcit num="19" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ベルミレン（Ｖｅｒｍｙｌｅｎ）ら、Ｅｕｒ．Ｒｅｓｐｉｒ．Ｊ．１４：８０６−８１１頁（１９９９年）</span>Vermylen et al., Eur. Respir. J. et al. 14: 806-811 (1999)</span>
          </text>
        </nplcit>
        <nplcit num="20" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">イワノフ（Ｉｖａｎｏｖ）ら、Ｊ．Ｐａｔｈｏｌ．１５８（３）：９０５−９１９頁（２００１年）</span>Ivanov et al. Pathol. 158 (3): 905-919 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="21" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">バートソバ（Ｂａｒｔｏｓｏｖａ）ら、Ｊ．Ｐａｔｈｏｌ．１９７：３１４−３２１頁（２００２年）</span>Bartosova et al., J. MoI. Pathol. 197: 314-321 (2002)</span>
          </text>
        </nplcit>
        <nplcit num="22" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ハリス  ＡＬ．（Ｈａｒｒｉｓ  ＡＬ．）、Ｎａｔｕｒｅ  Ｒｅｖ  Ｃａｎｃｅｒ２：３８−４７頁（２００２年）</span>Harris AL. (Harris AL.), Nature Rev Cancer 2: 38-47 (2002).</span>
          </text>
        </nplcit>
        <nplcit num="23" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ホッケル（Ｈｏｃｋｅｌ）およびバウペル（Ｖａｕｐｅｌ）、Ｓｅｍｉｎ．Ｏｎｃｏｌ．２８（２  補遺ｌ８）：３６−４１頁（２００１年）</span>Hockel and Vaupel, Semin. Oncol. 28 (2 Addendum 18): 36-41 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="24" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ウィコッフ（Ｗｙｋｏｆｆ）ら、Ａｍ．Ｊ．Ｐａｔｈｏｌ．１５８（３）：１０１１−１０１９頁（２００１年）</span>Wykoff et al., Am. J. et al. Pathol. 158 (3): 1011-1019 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="25" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ビースレイ（Ｂｅａｓｌｅｙ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．６１（１３）：５２６２−５２６７頁（２００１年）</span>Beasley et al., Cancer Res. 61 (13): 5262-5267 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="26" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ギアトロマノラキ（Ｇｉａｔｒｏｍａｎｏｌａｋｉ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．６１（２１）：７９９２−７９９８頁（２００１年）</span>Giatromanolaki et al., Cancer Res. 61 (21): 7992-7998 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="27" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">コーコーラキス（Ｋｏｕｋｏｕｒａｋｉｓ）ら、Ｃｌｉｎ．Ｃａｎｃｅｒ  Ｒｅｓ．７（１１）：３３９９−３４０３頁（２００１年）</span>Kokokurakis et al., Clin. Cancer Res. 7 (11): 3399-3403 (2001)</span>
          </text>
        </nplcit>
        <nplcit num="28" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ポッター（Ｐｏｔｔｅｒ）およびハリス（Ｈａｒｒｉｓ）、Ｂｒ  Ｊ  Ｃａｎｃｅｒ８９：２−７頁（２００３年）</span>Potter and Harris, Br J Cancer 89: 2-7 (2003)</span>
          </text>
        </nplcit>
        <nplcit num="29" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">スバストバ（Ｓｖａｓｔｏｖａ）ら、Ｅｘｐ  Ｃｅｌｌ  ＲＥｓ２９０：３３２−３４５頁（２００３年）</span>Svastova et al., Exp Cell REs 290: 332-345 (2003)</span>
          </text>
        </nplcit>
        <nplcit num="30" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">スバストバ（Ｓｖａｓｔｏｖａ）ら、ＦＥＢＳ  Ｌｅｔｔｅｒｓ５７７：４３９−４４５頁（２００４年）</span>Svastova et al., FEBS Letters 577: 439-445 (2004).</span>
          </text>
        </nplcit>
        <nplcit num="31" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">スウィータッチ（Ｓｗｉｅｔａｃｈ）ら、Ｃａｎｃｅｒ  Ｍｅｔａｓｔａｓｉｓ  Ｒｅｖ、ＤＯＩ  １０，１００７／ｓ１０５５５−００７−９０６４−０（２００７年）</span>Sweeach et al., Cancer Metastases Rev, <figure-callout id="10" label="DOI" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">DOI</a></figure-callout> 10,1007 / s10555-007-9064-0 (2007)</span>
          </text>
        </nplcit>
        <nplcit num="32" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">モーガン（Ｍｏｒｇａｎ）ら、Ａｍ  Ｊ  Ｐｈｙｓｉｏｌ−Ｃｅｌｌ  Ｐｈｙｓｉｏｌ２９３（２）：Ｃ７３８−Ｃ７４８頁（２００７年）</span>Morgan et al., Am J Physiol-Cell Physiol 293 (2): C738-C748 (2007)</span>
          </text>
        </nplcit>
        <nplcit num="33" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ドライ（Ｄｏｒａｉ）ら、Ｅｕｒ．Ｊ  Ｃａｎｃｅｒ４１：２９３５−２９４７頁（２００５年）</span>Dorai et al., Eur. J Cancer 41: 2935-2947 (2005)</span>
          </text>
        </nplcit>
        <nplcit num="34" class="style-scope patent-text">
          <text class="style-scope patent-text">
            <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マトリン（Ｍａｔｌｉｎ）ら、Ｎａｔ  Ｒｅｖ  Ｍｏｌ  Ｃｅｌｌ  Ｂｉｏｌ６：３８６−３９８頁（２００５年）</span>Matlin et al., Nat Rev Mol Cell Biol 6: 386-398 (2005).</span>
          </text>
        </nplcit>
      </p>
    </non-patent-literature>
  </citation-list>
  
  <summary-of-invention class="style-scope patent-text">
    <tech-problem class="style-scope patent-text">
      <p num="0024" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明は、低酸素状態で誘導された膜結合腫瘍関連ＭＮタンパク質をコードする完全長（ＦＬ）ＣＡ９ ｍＲＮＡ転写体に加えて、細胞膜にとどめられないＡＳのＭＮタンパク質（ＡＳのＭＮ／ＣＡ ＩＸまたはＡＳ ＣＡ ＩＸ）をコードする、構成的に産生された、選択的にスプライスされた（ＡＳ）ＣＡ９ ｍＲＮＡ転写体もまた存在するという発見に基づいている。本発明の治療的態様の基礎となるさらなる発見は、ＡＳ型のＣＡ ＩＸがＦＬ型のＣＡ ＩＸの機能を阻害することである。ＣＡ ＩＸのＡＳ変異体の低酸素状態および腫瘍に無関係な産生は、ＣＡ ＩＸの診断、予後診断および治療態様に多くの密接な関係を有する。
</span>
&nbsp;&nbsp;In addition to the full-length (FL) CA9 mRNA transcript that encodes a membrane-bound tumor-associated MN protein induced under hypoxia, the present invention includes an AS MN protein (AS MN / CA IX or AS It is based on the discovery that there is also a constitutively produced, alternatively spliced (AS) CA9 mRNA transcript that encodes (AS CA IX). A further discovery underlying the therapeutic aspect of the present invention is that AS-type CA IX inhibits the function of FL-type CA IX. Hypoxic and tumor-independent production of AS mutants of CA IX has many close implications for the diagnosis, prognosis and therapeutic aspects of CA IX.
</span>
      </p>
    </tech-problem>
    <tech-solution class="style-scope patent-text">
      <p num="0025" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明の一態様は、脊椎動物、好ましくは哺乳動物、より好ましくはヒトにおける、異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患に対する診断法および／または予後診断法に関するものであり、これらの方法は、完全長［ＦＬ］および選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡ発現、あるいは、ＡＳ型およびＦＬ型のＭＮ／ＣＡ ＩＸ発現を識別する工程を有してなる。
</span>
&nbsp;&nbsp;One aspect of the invention relates to diagnostic and / or prognostic methods for preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression in vertebrates, preferably mammals, more preferably humans And these methods comprise the steps of identifying full-length [FL] and alternatively spliced [AS] MN / CA9 mRNA expression, or AS-type and FL-type MN / CA IX expression. Become.
</span>
      </p>
      <p num="0026" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  前記方法は、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡの発現および／またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡの発現を検出、または検出および定量化するために１種類以上のプローブおよび／またはプライマーの使用を含んで差し支えなく；好ましくは、前記方法は：（ａ）選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡを検出するためのプローブおよび／またはプライマー；（ｂ）ＦＬのＭＮ／ＣＡ９ ｍＲＮＡは検出せず、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡを検出するためのプローブおよび／またはプライマー；および／または（ｃ）ＦＬのＭＮ／ＣＡ９ ｍＲＮＡとＡＳのＭＮ／ＣＡ９ ｍＲＮＡの双方を検出するためのプローブおよび／またはプライマーの使用を含んでなる。本発明の一態様において、診断法および／または予後診断法は、例えば、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡには存在しないが、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡには存在するスプライスジャンクション、またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡに存在しないがＦＬのＭＮ／ＣＡ９ ｍＲＮＡに存在する核酸配列を、プローブの標的にすることにより、選択的にスプライスされたＭＮ／ＣＡ９核酸と完全長ＭＮ／ＣＡ９核酸との間の差異を利用する。同様に、例えば、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡには見られず、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡにのみ見られる領域を増幅するために一対のプライマーを設計することができ、または逆の設計もできる。本開示に鑑みて当業者は、本発明の診断法／予後診断法に有用であると思われる任意の数のプローブおよび／またはプライマー／プライマー対を設計することができるであろう。
</span>
&nbsp;&nbsp;The method can include the use of one or more probes and / or primers to detect or detect and quantify the expression of FL MN / CA9 mRNA and / or AS MN / CA9 mRNA. Preferably, the method comprises: (a) probes and / or primers for detecting full-length [FL] MN / CA9 mRNA without detecting alternatively spliced [AS] MN / CA9 mRNA; b) Probes and / or primers for detecting AS MN / CA9 mRNA without detecting FL MN / CA9 mRNA; and / or (c) FL MN / CA9 mRNA and AS MN / CA9 mRNA. Use of probes and / or primers to detect both. In one aspect of the invention, the diagnostic and / or prognostic methods are, for example, a splice junction that is not present in the MN / CA9 mRNA of FL but present in the MN / CA9 mRNA of AS, or the MN / CA9 of AS. Utilizing the difference between alternatively spliced MN / CA9 and full-length MN / CA9 nucleic acids by targeting the nucleic acid sequence not present in the mRNA but present in the MN / CA9 mRNA of FL to the probe To do. Similarly, for example, a pair of primers can be designed to amplify a region not found in FL MN / CA9 mRNA but only in AS MN / CA9 mRNA, or vice versa. In view of this disclosure, one of ordinary skill in the art will be able to design any number of probes and / or primer / primer pairs that would be useful in the diagnostic / prognostic methods of the present invention.
</span>
      </p>
      <p num="0027" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒトにおける前新生物疾患／新生物疾患に対する好ましい診断法／予後診断法において、本発明の１種類以上の特に好ましいプローブおよび／またはプライマーは、配列番号９７〜１０１および配列番号９７〜１０１と少なくとも８０％相同、好ましくは配列番号９７〜１０１と少なくとも９０％相同である核酸配列からなる群から選択される。ＦＬおよび／またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現を検出、または検出および定量化するために１種類以上のプローブおよび／またはプライマーの使用を含んでなる前記の方法は、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡ：ＡＳのＭＮ／ＣＡ９ ｍＲＮＡの比、または経時的にＦＬのＭＮ／ＣＡ９ ｍＲＮＡ：ＡＳのＭＮ／ＣＡ９ ｍＲＮＡの比の変化を測定することをさらに含むことができる。
</span>
&nbsp;&nbsp;In preferred diagnostic / prognostic methods for preneoplastic / neoplastic diseases in humans, one or more particularly preferred probes and / or primers of the present invention are at least 80 with SEQ ID NOs: 97-101 and 97-101. % Homologous, preferably selected from the group consisting of nucleic acid sequences that are at least 90% homologous to SEQ ID NOs: 97-101. Said method comprising the use of one or more probes and / or primers for detecting or detecting and quantifying FL and / or AS MN / CA9 mRNA expression comprises: FL MN / CA9 mRNA: AS And measuring the change in the ratio of MN / CA9 mRNA of the MN / CA9 mRNA over time, or the ratio of MN / CA9 mRNA of the FL: AS / MN9 / CA9 mRNA over time.
</span>
      </p>
      <p num="0028" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、前記ＡＳのＭＮ／ＣＡ９ ｍＲＮＡの発現を、正常なＭＮ／ＣＡ９遺伝子発現を示すために使用することができ、かつ、前記ＦＬのＭＮ／ＣＡ９ ｍＲＮＡ発現を、異常なＭＮ／ＣＡ９遺伝子発現を示すために使用することができ、特にＡＳおよび／またはＦＬのＭＮ／ＣＡ９ ｍＲＮＡ発現のレベルを使用できる。あるいは、または加えて、前記ＡＳのＭＮ／ＣＡ９ ｍＲＮＡの発現を、酸素正常状態のＭＮ／ＣＡ９遺伝子発現を示すために使用することができ、また、前記ＦＬのＭＮ／ＣＡ９ ｍＲＮＡの発現を、低酸素状態のＭＮ／ＣＡ９遺伝子発現を示すために使用することができる。また、前記ＭＮのＡＳおよび／またはＦＬ ｍＲＮＡ発現のレベルは、特定の指示的値となるであろう。
</span>
&nbsp;&nbsp;Further, the MN / CA9 mRNA expression of the AS can be used to indicate normal MN / CA9 gene expression, and the MN / CA9 mRNA expression of the FL can be used to express abnormal MN / CA9 gene expression. In particular, the level of AS and / or FL MN / CA9 mRNA expression can be used. Alternatively, or in addition, the AS MN / CA9 mRNA expression can be used to indicate normoxic MN / CA9 gene expression, and the FL MN / CA9 mRNA expression can be reduced It can be used to show MN / CA9 gene expression in the oxygen state. Also, the level of AS and / or FL mRNA expression of the MN will be a specific indicator value.
</span>
      </p>
      <p num="0029" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＦＬおよび／またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡの発現を検出、または検出および定量化するために、１種類以上のプローブおよび／またはプライマーの使用を含んでなる前記方法は、核酸増幅方法、好ましくは、ＰＣＲ、ＲＴ−ＰＣＲ、リアルタイムＰＣＲまたは定量的リアルタイムＲＴ−ＰＣＲから選択される増幅方法、および当業者に知られている同等の核酸増幅方法の使用をさらに含むことができる。あるいは、ＦＬおよび／またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡの発現を検出、または検出および定量化するための前記方法は、マイクロアレイチップの使用を含むことができる。例えば、前記マイクロアレイチップは、選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡに結合するプローブ、および／またはＦＬのＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡに結合するプローブを含むことができ、このようなチップ上の前記プローブの戦略的配置は、当該技術分野の範囲内にある。
</span>
&nbsp;&nbsp;Said method comprising the use of one or more probes and / or primers for detecting or detecting and quantifying the expression of FL and / or AS MN / CA9 mRNA comprises a nucleic acid amplification method, preferably It can further include the use of amplification methods selected from PCR, RT-PCR, real-time PCR or quantitative real-time RT-PCR, and equivalent nucleic acid amplification methods known to those skilled in the art. Alternatively, the method for detecting or detecting and quantifying FL and / or AS MN / CA9 mRNA expression may comprise the use of a microarray chip. For example, the microarray chip does not bind to selectively spliced [AS] MN / CA9 mRNA, but binds to full-length [FL] MN / CA9 mRNA and / or FL MN / CA9 mRNA. May include probes that bind to MN / CA9 mRNA of AS, but the strategic placement of such probes on such a chip is within the skill of the art.
</span>
      </p>
      <p num="0030" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  別の態様において、本発明は、ＦＬのＭＮ／ＣＡ ＩＸ発現とＡＳのＭＮ／ＣＡ ＩＸ発現とを識別する工程を有してなり、哺乳動物における異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患に係わる診断方法および／または予後診断方法に関する。前記方法は、前新生物組織／新生物組織においてＦＬのＭＮ／ＣＡ ＩＸ発現とＡＳのＭＮ／ＣＡ ＩＸ発現とを識別するために１種類以上の抗体の使用を含んでなることが好ましい。前記方法は、前記組織においてＡＳのＭＮ／ＣＡ ＩＸを検出、または検出および定量化することを含むことができ；前記組織においてＦＬのＭＮ／ＣＡ ＩＸレベル対ＡＳのＭＮ／ＣＡ ＩＸレベルの比を測定することをさらに含むことができる。さらに前記ＦＬのＭＮ／ＣＡ ＩＸ：ＡＳのＭＮ／ＣＡ ＩＸの比は、前記組織における低酸素状態の存在または程度を示すために使用することができる。
</span>
&nbsp;&nbsp;In another aspect, the present invention comprises the step of distinguishing between MN / CA IX expression of FL and MN / CA IX expression of AS, wherein the neoplasia associated with aberrant MN / CA IX expression in a mammal. The present invention relates to a diagnostic method and / or a prognostic method related to a biological disease / neoplastic disease. Preferably, the method comprises the use of one or more antibodies to distinguish between MN / CA IX expression of FL and MN / CA IX expression of AS in preneoplastic / neoplastic tissue. The method may comprise detecting or detecting and quantifying AS MN / CA IX in the tissue; determining the ratio of FL MN / CA IX level to AS MN / CA IX level in the tissue. Can further comprise measuring. Further, the FL MN / CA IX: AS MN / CA IX ratio can be used to indicate the presence or extent of hypoxia in the tissue.
</span>
      </p>
      <p num="0031" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明の好ましい一実施形態において、診断方法／予後診断方法は、脊椎動物の組織におけるＦＬのＭＮ／ＣＡ ＩＸおよびＡＳのＭＮ／ＣＡ ＩＸを検出、または検出および定量化する工程を有してなり、該工程は：<br class="style-scope patent-text">
  （ａ）前記サンプルを、少なくとも２種の抗体、少なくとも２種の抗原結合性抗体断片、または抗体と抗原結合性抗体断片の混合物とを同時にまたは連続的に接触させて、少なくとも１種の抗体／抗体断片をＡＳのＭＮ／ＣＡ ＩＸタンパク質には結合しないが、ＦＬのＭＮ／ＣＡ ＩＸタンパク質に特異的に結合させ、少なくとも他の１種の抗体／抗体断片をＦＬのＭＮ／ＣＡ ＩＸとＡＳのＭＮ／ＣＡ ＩＸの双方に特異的に結合させる工程と；<br class="style-scope patent-text">
  （ｂ）前記サンプルにおいて前記抗体／抗体断片の結合を検出および定量化する工程と；<br class="style-scope patent-text">
  （ｃ）前記差異的に結合する抗体／抗体断片の結合を比較してＦＬのＭＮ／ＣＡ ＩＸとＡＳのＭＮ／ＣＡ ＩＸの相対的レベルを特定する工程と、<br class="style-scope patent-text">
を有してなる。
</span>In a preferred embodiment of the present invention, the diagnostic / prognostic method comprises the step of detecting or detecting and quantifying FL MN / CA IX and AS MN / CA IX in vertebrate tissue. The process includes: <br class="style-scope patent-text"> (A) contacting the sample with at least two antibodies, at least two antigen-binding antibody fragments, or a mixture of antibodies and antigen-binding antibody fragments simultaneously or sequentially to produce at least one antibody / The antibody fragment does not bind to the AS MN / CA IX protein, but specifically binds to the FL MN / CA IX protein and at least one other antibody / antibody fragment binds to the FL MN / CA IX and AS Specifically binding to both MN / CA IX; <br class="style-scope patent-text"> (B) detecting and quantifying the antibody / antibody fragment binding in the sample; <br class="style-scope patent-text"> (C) comparing the differentially binding antibody / antibody fragment binding to determine the relative levels of MN / CA IX of FL and MN / CA IX of AS; <br class="style-scope patent-text"> It has.</span>
      </p>
      <p num="0032" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＳのＭＮ／ＣＡ ＩＸには結合しないが、ＦＬのＭＮ／ＣＡ ＩＸに特異的に結合する前記１種類以上の抗体／抗体断片が、ＭＮ／ＣＡ ＩＸの炭酸脱水酵素（ＣＡ）ドメインに特異的であり；ＦＬのＭＮ／ＣＡ ＩＸおよびＡＳのＭＮ／ＣＡ ＩＸの双方に特異的に結合する前記１種類以上の抗体／抗体断片が、ＭＮ／ＣＡ ＩＸのプロテオグリカン様（ＰＧ）ドメインに特異的であることが好ましい。さらにより好ましくは、ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な前記抗体が、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在のＢＣＣＭ（商標）／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体であり；ＭＮ／ＣＡ ＩＸのＰＧドメインに特異的な前記抗体が、ＡＴＣＣ指定番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクション（ＡＴＣＣ）に寄託されたハイブリドーマＶＵ−Ｍ７５により産生されるＭ７５モノクローナル抗体である。
</span>
&nbsp;&nbsp;The one or more antibodies / antibody fragments that bind specifically to MN / CA IX of FL but not to MN / CA IX of AS are specific for the carbonic anhydrase (CA) domain of MN / CA IX Said one or more antibody / antibody fragments that specifically bind to both MN / CA IX of FL and MN / CA IX of AS are specific for the proteoglycan-like (PG) domain of MN / CA IX. Preferably there is. Even more preferably, said antibody specific for the CA domain of MN / CA IX is produced by the hybridoma VU-V / 10 deposited at BCCM ™ / LMBP in Ghent, Belgium under the accession number LMBP6009CB. M75 produced by the hybridoma VU-M75 deposited with the American Type Culture Collection (ATCC) as ATCC Designation Number HB11128, the antibody specific for the PG domain of MN / CA IX It is a monoclonal antibody.
</span>
      </p>
      <p num="0033" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに本発明は、脊椎動物における異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患の診断および／または予後診断方法に関するものであり、適切な脊椎動物の組織サンプルにおける選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸタンパク質は検出せず、完全長［ＦＬ］ＭＮ／ＣＡ ＩＸタンパク質を検出、または検出および定量化する工程を有してなり、該工程は：<br class="style-scope patent-text">
  （ａ）前記サンプルを抗体または抗体断片に接触させるステップであって、前記抗体または抗体断片が、ＡＳのＭＮ／ＣＡ ＩＸには結合しないが、ＦＬのＭＮ／ＣＡ ＩＸに特異的に結合する工程と；<br class="style-scope patent-text">
  （ｂ）前記サンプルにおける前記抗体／抗体断片の結合を検出および定量化する工程と、<br class="style-scope patent-text">
を有してなる。前記脊椎動物は、哺乳動物であることが好ましく、前記哺乳動物はヒトであることがさらに好ましい。
</span>The invention further relates to a method for diagnosis and / or prognosis of preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression in vertebrates, selectively in appropriate vertebrate tissue samples. It does not detect spliced [AS] MN / CA IX protein, and has the steps of detecting or detecting and quantifying full-length [FL] MN / CA IX protein, the steps comprising: <br class="style-scope patent-text"> (A) contacting the sample with an antibody or antibody fragment, wherein the antibody or antibody fragment does not bind to MN / CA IX of AS but specifically binds to MN / CA IX of FL When; <br class="style-scope patent-text"> (B) detecting and quantifying the antibody / antibody fragment binding in the sample; <br class="style-scope patent-text"> It has. The vertebrate is preferably a mammal, and more preferably the mammal is a human.</span>
      </p>
      <p num="0034" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＳのＭＮ／ＣＡ ＩＸには結合しないが、ＦＬのＭＮ／ＣＡ ＩＸに特異的に結合する代表的な好ましい抗体または抗体断片は、ＭＮ／ＣＡ ＩＸの炭酸脱水酵素（ＣＡ）ドメインに特異的であるものである。より好ましくは、ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な前記抗体は、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体である。
</span>
&nbsp;&nbsp;Representative preferred antibodies or antibody fragments that do not bind AS MN / CA IX but specifically bind to FL MN / CA IX are specific for the carbonic anhydrase (CA) domain of MN / CA IX. There is something. More preferably, said antibody specific for the CA domain of MN / CA IX is produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP in Ghent, Belgium under accession number LMBP6009CB. It is a monoclonal antibody.
</span>
      </p>
      <p num="0035" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明の特に好ましい態様は、脊椎動物、好ましくは哺乳動物における異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患の診断および／または予後診断方法に関するものであり、それらの方法は、脊椎動物、好ましくは哺乳動物の前新生物疾患／新生物サンプルにおいて選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡを検出、または検出および定量化する工程を有してなり、前記サンプルからのｍＲＮＡを、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡに特異的に結合するプライマーまたはプローブに接触させる工程を有してなる。
</span>
&nbsp;&nbsp;Particularly preferred embodiments of the present invention relate to methods for the diagnosis and / or prognosis of preneoplastic / neoplastic diseases associated with aberrant MN / CA IX expression in vertebrates, preferably mammals. Does not detect [AS] MN / CA9 mRNA selectively spliced in vertebrate, preferably mammalian preneoplastic disease / neoplasm samples, or detects full-length [FL] MN / CA9 mRNA, or Detecting and quantifying, wherein the mRNA from the sample is contacted with a primer or probe that does not bind to AS MN / CA9 mRNA but specifically binds to FL MN / CA9 mRNA. It has.
</span>
      </p>
      <p num="0036" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明はさらに、哺乳動物における選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡ発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡ発現とを識別するために使用される核酸プローブおよび／またはプライマーに関する。上記のとおり、本開示に基づくようなプローブ／プライマーの設計は、当該技術分野の範囲内にある。好ましくは、前記哺乳動物はヒトであり、前記プローブおよび／またはプライマーは、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡは検出せず、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用され、前記プローブまたはプライマーは、ＭＮ／ＣＡ９遺伝子のエクソン７および１０のスプライスジャンクションに結合する核酸を含んでなる。より好ましくは、前記プローブまたはプライマーは、配列番号１０１の配列または配列番号１０１と少なくとも８０％相同、より好ましくは、配列番号１０１と少なくとも９０％相同である配列を有する。あるいは、前記哺乳動物はヒトであり、前記プローブおよび／またはプライマーは、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡは検出せずＦＬのＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用され、前記プローブまたはプライマーは、ヒトＭＮ／ＣＡ９遺伝子のエクソン８またはエクソン９に結合するか、またはヒトＭＮ／ＣＡ９遺伝子のエクソン７と８のスプライスジャンクション、エクソン８と９のスプライスジャンクション、もしくはエクソン９と１０のスプライスジャンクションに結合する核酸を含んでなる。より好ましくは、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡは検出せずヒトＦＬのＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される前記プローブまたはプライマーは、配列番号１００の配列または配列番号１００と少なくとも８０％相同、より好ましくは、配列番号１００と少なくとも９０％相同である配列を有する。本発明はさらに、このようなプローブまたはプライマーを発現するベクター、および／またはこのようなベクターを含んでなる宿主細胞、および１種類以上のこのようなプローブを含んでなるマイクロアレイチップに関する。
</span>
&nbsp;&nbsp;The invention further relates to nucleic acid probes and / or primers used to distinguish between alternatively spliced [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in mammals. As noted above, probe / primer design as per this disclosure is within the skill of the art. Preferably, said mammal is a human and said probe and / or primer does not detect MN / CA9 mRNA in FL, but is used to detect MN / CA9 mRNA in AS, said probe or primer comprising: A nucleic acid that binds to the splice junctions of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 10 of the MN / CA9 gene. More preferably, the probe or primer has the sequence of SEQ ID NO: 101 or a sequence that is at least 80% homologous to SEQ ID NO: 101, more preferably at least 90% homologous to SEQ ID NO: 101. Alternatively, the mammal is a human and the probe and / or primer is used to detect MN / CA9 mRNA in FL without detecting MN / CA9 mRNA in AS, and the probe or primer is in human MN A nucleic acid that binds to <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 or <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 of the / CA9 gene, or to the splice junction of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8, the splice junction of <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, or the splice junction of <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10 of the human MN / CA9 gene Comprising. More preferably, the probe or primer used to detect human FL MN / CA9 mRNA without detecting AS MN / CA9 mRNA is at least 80% homologous to the sequence of SEQ ID NO: 100 or SEQ ID NO: 100; More preferably, it has a sequence that is at least 90% homologous to SEQ ID NO: 100. The present invention further relates to vectors that express such probes or primers, and / or host cells comprising such vectors, and microarray chips comprising one or more such probes.
</span>
      </p>
      <p num="0037" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明はさらに、哺乳動物における選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡ発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡ発現とを識別するために使用される一対のプローブおよび／またはプライマーに関する。前記一対のプローブおよび／またはプライマーは、完全長［ＦＬ］ヒトＭＮ／ＣＡ９ ｍＲＮＡは検出せず、選択的にスプライスされた［ＡＳ］ヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用することができる。完全長［ＦＬ］ヒトＭＮ／ＣＡ９ ｍＲＮＡは検出せず、選択的にスプライスされた［ＡＳ］ヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される代表的な好ましい一対のプローブまたはプライマーは、配列番号９９および１０１、または配列番号９９および１０１と少なくとも８０％相同、より好ましくは少なくとも９０％相同である核酸配列からなる。
</span>
&nbsp;&nbsp;The present invention further relates to a pair of probes and / or primers used to distinguish between alternatively spliced [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in mammals. . The pair of probes and / or primers does not detect full-length [FL] human MN / CA9 mRNA, but can be used to detect alternatively spliced [AS] human MN / CA9 mRNA. A typical preferred pair of probes or primers used to detect alternatively spliced [AS] human MN / CA9 mRNA, not full-length [FL] human MN / CA9 mRNA, is SEQ ID NO: 99 and 101, or a nucleic acid sequence that is at least 80% homologous to SEQ ID NOs 99 and 101, more preferably at least 90% homologous.
</span>
      </p>
      <p num="0038" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  あるいは、前記一対のプローブおよび／またはプライマーは、選択的にスプライスされた［ＡＳ］ヒトＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］ヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される。ＦＬ ｍＲＮＡのみを検出するために使用される代表的な好ましい一対のプローブまたはプライマーは、配列番号９９および１００、または配列番号９９および１００と少なくとも８０％相同、より好ましくは少なくとも９０％相同である核酸配列からなる。本発明のさらなる実施形態において、一対のプローブまたはプライマーは、ＡＳヒトＭＮ／ＣＡ９ ｍＲＮＡおよびＦＬヒトＭＮ／ＣＡ９ ｍＲＮＡの双方を検出するために使用され、前記ＡＳ  ｍＲＮＡと前記ＦＬ ｍＲＮＡは長さにより識別される。ＡＳとＦＬの双方のヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される前記一対のプローブおよび／またはプライマーは、配列番号９７および９８、または配列番号９７および９８と少なくとも８０％相同、より好ましくは少なくとも９０％相同である核酸配列からなることが好ましい。
</span>
&nbsp;&nbsp;Alternatively, the pair of probes and / or primers does not detect selectively spliced [AS] human MN / CA9 mRNA, but is used to detect full-length [FL] human MN / CA9 mRNA. A typical preferred pair of probes or primers used to detect only FL mRNA is SEQ ID NO: 99 and 100, or a nucleic acid that is at least 80% homologous to SEQ ID NO: 99 and 100, more preferably at least 90% homologous. Consists of an array. In a further embodiment of the invention, a pair of probes or primers is used to detect both AS human MN / CA9 mRNA and FL human MN / CA9 mRNA, the AS mRNA and FL mRNA being distinguished by length. Is done. The pair of probes and / or primers used to detect both AS and FL human MN / CA9 mRNA is SEQ ID NO: 97 and 98, or at least 80% homologous to SEQ ID NOs: 97 and 98, more preferably It preferably consists of a nucleic acid sequence that is at least 90% homologous.
</span>
      </p>
      <p num="0039" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明はさらに、哺乳動物における選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸをコードする単離された核酸に関する。前記ＡＳのＭＮ／ＣＡ ＩＸは、約４３〜約４８ｋＤａの分子量を有することが好ましい。本発明はさらに、このような核酸またはその断片を発現するベクター、このようなベクターを含んでなる宿主細胞および／または組換え、合成または他の生物学的手段によるＡＳのＭＮ／ＣＡ ＩＸタンパク質およびポリペプチドの産生に関する。
</span>
&nbsp;&nbsp;The invention further relates to an isolated nucleic acid encoding alternatively spliced [AS] MN / CA IX in a mammal. The AS MN / CA IX preferably has a molecular weight of about 43 to about 48 kDa. The present invention further provides vectors expressing such nucleic acids or fragments thereof, host cells comprising such vectors and / or AS MN / CA IX proteins by recombinant, synthetic or other biological means and It relates to the production of polypeptides.
</span>
      </p>
      <p num="0040" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  前記単離された核酸によりコードされた、代表的な好ましいＡＳ型のＭＮ／ＣＡ ＩＸのは、ＭＮ／ＣＡ ＩＸのＰＧドメインに特異的な抗体により特異的に結合されるが、ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な抗体により結合されないことをさらに特徴とする。本発明のさらにより好ましい実施形態において、前記ＡＳ型のＭＮ／ＣＡ ＩＸは、ＡＴＣＣ番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクションに寄託されたハイブリドーマＶＵ−Ｍ７５から分泌されるＭ７５モノクローナル抗体により特異的に結合されるが、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体には結合されない。
</span>
&nbsp;&nbsp;Representative preferred AS-type MN / CA IX encoded by the isolated nucleic acid is specifically bound by an antibody specific for the PG / domain of MN / CA IX, but MN / CA IX It is further characterized in that it is not bound by an antibody specific for the CA domain of. In an even more preferred embodiment of the invention, said AS-type MN / CA IX is specifically expressed by the M75 monoclonal antibody secreted from the hybridoma VU-M75 deposited with the American Type Culture Collection as ATCC No. HB11128. Although not bound, it does not bind to the V / 10 monoclonal antibody produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP in Ghent, Belgium under the registration number LMBP6009CB.
</span>
      </p>
      <p num="0041" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、前記哺乳動物がヒトであり、前記単離された核酸が、ＭＮ／ＣＡ９のエクソン８およびエクソン９に相当するヌクレオチドを欠失させることを特徴とする。さらにより好ましくは、前記単離ヒト核酸が、配列番号１０８、または配列番号１０８と少なくとも８０％相同、より好ましくは配列番号１０８と少なくとも９０％相同の核酸配列を有する。好ましくは、配列番号１０８または密接に関連する配列によりコードされたＡＳ型の代表的なヒトＭＮ／ＣＡ ＩＸは、ＡＴＣＣ番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクションに寄託されたハイブリドーマＶＵ−Ｍ７５から分泌されるＭ７５モノクローナル抗体により特異的に結合されるが、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体により結合されない。
</span>
&nbsp;&nbsp;More preferably, the mammal is a human and the isolated nucleic acid lacks nucleotides corresponding to <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 and <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 of MN / CA9. Even more preferably, said isolated human nucleic acid has SEQ ID NO: 108, or a nucleic acid sequence that is at least 80% homologous to SEQ ID NO: 108, more preferably at least 90% homologous to SEQ ID NO: 108. Preferably, an AS-type representative human MN / CA IX encoded by SEQ ID NO: 108 or closely related sequences is secreted from the hybridoma VU-M75 deposited with the American Type Culture Collection as ATCC No. HB11128. Specifically, but not by the V / 10 monoclonal antibody produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP in Ghent, Belgium under the registration number LMBP6009CB. .
</span>
      </p>
      <p num="0042" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに本発明は、他の型のＭＮ／ＣＡ ＩＸには結合しないが、ＡＳ型のＭＮ／ＣＡ ＩＸに特異的に結合する抗体または抗原結合抗体に関する。例えば、このようなＡＳ特異的抗体は、ＡＳ型のＭＮ／ＣＡ ＩＸに特異的に結合するが、ＦＬ型のＭＮ／ＣＡ ＩＸに特異的に結合しない抗体または抗原結合抗体であり得るか；またはＡＳのＭＮ／ＣＡ ＩＸに特異的に結合するが、可溶性ＭＮ／ＣＡ ＩＸ（ｓ−ＣＡ ＩＸ）に特異的に結合しない抗体または抗原結合抗体であり得る。
</span>
&nbsp;&nbsp;The present invention further relates to antibodies or antigen-binding antibodies that do not bind to other types of MN / CA IX but specifically bind to AS type MN / CA IX. For example, such an AS-specific antibody may be an antibody or antigen-binding antibody that specifically binds AS type MN / CA IX but does not specifically bind FL type MN / CA IX; or It may be an antibody or antigen-binding antibody that specifically binds to AS MN / CA IX but does not specifically bind to soluble MN / CA IX (s-CA IX).
</span>
      </p>
      <p num="0043" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  哺乳動物における前新生物疾患／新生物疾患を治療するための治療方法が、さらに本明細書に開示されており、前記疾患は、ＭＮ／ＣＡ ＩＸの異常発現に関連し、本方法は、完全長［ＦＬ］ＭＮ／ＣＡ ＩＸのレベルと比較して選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを増加させる薬剤を含む組成物を治療に有効な量で前記哺乳動物に投与する工程を有してなる。前記ＡＳのＭＮ／ＣＡ ＩＸはまた、ＦＬのＭＮ／ＣＡ ＩＸの活性を阻害するＡＳのＭＮ／ＣＡ ＩＸの任意のタンパク質またはポリペプチド断片を含むことも考えられる。前記ＡＳのＭＮ／ＣＡ ＩＸの相対的レベルの増加により、前記ＦＬのＭＮ／ＣＡ ＩＸの炭酸脱水酵素の活性が阻害されることが好ましい。前記薬剤は、生理学的に許容できる担体中のＡＳのＭＮ／ＣＡ ＩＸ自体、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡを発現するベクター、ＡＳのＭＮ／ＣＡ ＩＸの発現は遮断しないがＦＬのＭＮ／ＣＡ ＩＸの発現を遮断するアンチセンスオリゴヌクレオチド、前記アンチセンスオリゴヌクレオチドを発現するベクター、ＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡ、または前記ＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡを発現するベクターであり得る。
</span>
&nbsp;&nbsp;Further disclosed herein is a therapeutic method for treating a preneoplastic / neoplastic disease in a mammal, said disease being associated with abnormal expression of MN / CA IX, wherein the method comprises A composition comprising a drug that increases the level of [AS] MN / CA IX selectively spliced compared to the level of long [FL] MN / CA IX is administered to said mammal in a therapeutically effective amount It has a process. The AS MN / CA IX may also include any protein or polypeptide fragment of AS MN / CA IX that inhibits the activity of FL MN / CA IX. Preferably, the increase in the relative level of the MN / CA IX of the AS inhibits the activity of the carbonic anhydrase of the MN / CA IX of the FL. The agent includes AS MN / CA IX itself in a physiologically acceptable carrier, a vector expressing AS MN / CA9 mRNA, does not block AS MN / CA IX expression, but FL MN / CA IX An antisense oligonucleotide that blocks expression, a vector that expresses the antisense oligonucleotide, an siRNA specific to the FL MN / CA9 isoform, or an siRNA specific to the FL MN / CA9 isoform Vector.
</span>
      </p>
      <p num="0044" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  例えば、前記薬剤は、エクソン７と８、エクソン８と９、またはエクソン９と１０のスプライスジャンクションに標的化されるＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡであり得る。あるいは、前記薬剤は、ＡＳおよび／またはＦＬのＭＮ／ＣＡ９の前ｍＲＮＡスプライシングを調節するアンチセンスオリゴヌクレオチドである。
</span>
&nbsp;&nbsp;For example, the agent can be an siRNA specific for the MN / CA9 isoform of FL targeted to the splice junctions of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8, <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, or <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10. Alternatively, the agent is an antisense oligonucleotide that modulates pre-mRNA splicing of AS and / or FL MN / CA9.
</span>
      </p>
      <p num="0045" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  別の態様において、本発明は、完全長［ＦＬ］ＭＮ／ＣＡ ＩＸのレベルに比して選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを増加させるオリゴヌクレオチドに関するものであって、前記オリゴヌクレオチドは、異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患の治療に使用される。例えば、前記オリゴヌクレオチドは、ＡＳのＭＮ／ＣＡ９の前ｍＲＮＡには相補的ではないが、ＦＬのＭＮ／ＣＡ９の前ｍＲＮＡに相補的なアンチセンスオリゴヌクレオチドである可能性があり；好ましくは、前記オリゴヌクレオチドは、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡのエクソン７と８、エクソン８と９、またはエクソン９と１０のスプライスジャンクションに相補的である。あるいは、ＦＬのＭＮ／ＣＡ ＩＸのレベルに比してＡＳ  ＦＬのＭＮ／ＣＡのレベルを増加させる前記オリゴヌクレオチドは、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡには相補的ではないが、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡに相補的であるｓｉＲＮＡであり得る。
</span>
&nbsp;&nbsp;In another aspect, the invention relates to an oligonucleotide that increases the level of [AS] MN / CA IX selectively spliced relative to the level of full-length [FL] MN / CA IX, comprising: Said oligonucleotides are used for the treatment of preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression. For example, the oligonucleotide may be an antisense oligonucleotide that is not complementary to the AS MN / CA9 pre-mRNA but complementary to the FL MN / CA9 pre-mRNA; The oligonucleotides are complementary to the splice junctions of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8, <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, or <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10 of the FL MN / CA9 mRNA. Alternatively, said oligonucleotide that increases the level of AS FL MN / CA9 mRNA relative to the level of FL MN / CA IX is not complementary to AS MN / CA9 mRNA, but FL MN / CA9 mRNA SiRNA that is complementary to
</span>
      </p>
      <p num="0046" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明はまた、ＡＳのＭＮ／ＣＡ ＩＸを発現する細胞を、この細胞において前記ＡＳのＭＮ／ＣＡ ＩＸのレベルを調節すると思われる薬剤に接触させ、前記ＡＳのＭＮ／ＣＡ ＩＸのレベルの変化を検出および定量化する工程を有してなる、選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを調節することができる薬剤を同定するインビトロ方法に関する。
</span>
&nbsp;&nbsp;The present invention also involves contacting a cell expressing AS MN / CA IX with an agent that is thought to modulate the level of AS MN / CA IX in the cell, and changing the level of AS MN / CA IX. Relates to an in vitro method for identifying an agent capable of modulating the level of selectively spliced [AS] MN / CA IX comprising the step of detecting and quantifying.
</span>
      </p>
      <p num="0047" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
引用文献<br class="style-scope patent-text">
  以下の引用文献は、ＭＮ／ＣＡ９遺伝子およびＭＮ／ＣＡ ＩＸタンパク質、または選択的にスプライスされたｍＲＮＡに関する最新情報を本明細書に引用するか、または提供する。本明細書に引用されるリストに挙げられた引用文献ならびに他の引用文献の全ては、参照することにより具体的に援用される。
</span>Citations The following citations cited herein provide or provide updated information regarding the MN / CA9 gene and MN / CA IX protein, or alternatively spliced mRNA. All of the cited references as well as other cited references listed in this specification are specifically incorporated by reference.</span>
      </p>
      <p num="0048" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・アンダーソン（Ａｎｄｅｒｓｏｎ）ら、Ｏｎｃｏｇｅｎｅ  ２５：６１−６９頁（２００６年）<br class="style-scope patent-text">
  ・アルバレツ−ペレツ（Ａｌｖａｒｅｚ−Ｐｅｒｅｚ）ら、ＭＡＧＭＡ  １８：２９３−３０１頁（２００５年）<br class="style-scope patent-text">
  ・バートソバ（Ｂａｒｔｏｓｏｖａ）ら、Ｊ．Ｐａｔｈｏｌ．１９７：３１４−３２１頁（２００２年）<br class="style-scope patent-text">
  ・ビースレイ（Ｂｅａｓｌｅｙ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．６１（１３）：５２６２−５２６７頁（２００１年）<br class="style-scope patent-text">
  ・セッチ（Ｃｅｃｃｈｉ）ら、Ｊ  Ｍｅｄ  Ｃｈｅｍ  ４８：４８３４−４１頁（２００５年）<br class="style-scope patent-text">
 ・チェグウィッデン（Ｃｈｅｇｗｉｄｄｅｎ）ら、ＥＸＳ  ９０：３４３−３６３頁（２０００年）<br class="style-scope patent-text">
 ・クラスチナ（Ｃｈｒａｓｔｉｎａ）ら、Ｉｎｔ．Ｊ  Ｃａｎｃｅｒ  １０５：８７３−８８１頁（２００３年）<br class="style-scope patent-text">
 ・ドライ（Ｄｏｒａｉ）ら、Ｅｕｒ．Ｊ  Ｃａｎｃｅｒ  ４１：２９３５−２９４７頁（２００５年）<br class="style-scope patent-text">
 ・ガルシア−ブランコ（Ｇａｒｃｉａ−Ｂｌａｎｃｏ）、Ｃｕｒｒ  Ｏｐｉｎ  Ｍｏｌ  Ｔｈｅｒ．，７（５）：４７６−８２頁（２００５年）<br class="style-scope patent-text">
 ・ギアトロマノラキ（Ｇｉａｔｒｏｍａｎｏｌａｋｉ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．６１（２１）：７９９２−７９９８頁（２００１年）<br class="style-scope patent-text">
 ・ゴーシー（Ｇｏｔｈｉｅ）ら、Ｊ  Ｂｉｏｌ  Ｃｈｅｍ  ２７５：６９２２−６９２７頁（２０００年）<br class="style-scope patent-text">
 ・ガット（Ｇｕｔ）ら、Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ  １２３：１８８９−１９０３頁（２００２年）<br class="style-scope patent-text">
 ・ハリス（Ｈａｒｒｉｓ）  ＡＬ．，Ｎａｔｕｒｅ  Ｒｅｖ  Ｃａｎｃｅｒ  ２：３８−４７頁（２００２年）<br class="style-scope patent-text">
 ・フー（Ｈｅ）ら、Ｏｎｃｏｇｅｎｅ  ２５：１９２−２２０２頁（２００６年）<br class="style-scope patent-text">
 ・ホッケル（Ｈｏｃｋｅｌ）およびバウペル（Ｖａｕｐｅｌ）、Ｓｅｍｉｎ．Ｏｎｃｏｌ．２８（２  補遺８）：３６−４１頁（２００１年）<br class="style-scope patent-text">
 ・イワノフ（Ｉｖａｎｏｖ）ら、Ｊ．Ｐａｔｈｏｌ．１５８（３）：９０５−９１９頁（２００１年）<br class="style-scope patent-text">
 ・カルツ（Ｋａｌｕｚ）ら、Ｃａｎｃｅｒ  Ｒｅｓ  ６２：４４６９−４４７７頁（２００２年）<br class="style-scope patent-text">
 ・キベラ（Ｋｉｖｅｌａ）ら、Ｗｏｒｌｄ  Ｊ  Ｇａｓｔｒｏｅｎｔｅｒｏｌ  １１：１５５−１６３頁（２００５年）<br class="style-scope patent-text">
 ・コーコーラキス（Ｋｏｕｋｏｕｒａｋｉｓ）ら、Ｃｌｉｎ．Ｃａｎｃｅｒ  Ｒｅｓ．７（１１）：３３９９−３４０３頁（２００１年）<br class="style-scope patent-text">
 ・リアオ（Ｌｉａｏ）ら、Ａｍ．Ｊ．Ｐａｔｈｏｌ．１４５（３）：５９８−６０９頁（１９９４年）<br class="style-scope patent-text">
 ・リアオ（Ｌｉａｏ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．５７：２８２７−２８３１頁（１９９７年）<br class="style-scope patent-text">
 ・リースコブスカ（Ｌｉｅｓｋｏｖｓｋａ）ら、Ｎｅｏｐｌａｓｍａ  ４６：１７−２４頁（１９９９年）<br class="style-scope patent-text">
 ・マトリン（Ｍａｔｌｉｎ）ら、Ｎａｔ  Ｒｅｖ  Ｍｏｌ  Ｃｅｌｌ  Ｂｉｏｌ  ６：３８６−３９８頁（２００５年）<br class="style-scope patent-text">
 ・モーガン（Ｍｏｒｇａｎ）ら、Ａｍ  Ｊ  Ｐｈｙｓｉｏｌ  −  Ｃｅｌｌ  Ｐｈｙｓｉｏｌ  ２９３（２）：Ｃ７３８−Ｃ７４８頁（２００７年）<br class="style-scope patent-text">
 ・オリーブ（Ｏｌｉｖｅ）ら、Ｃａｎｃｅｒ  Ｒｅｓ  ６１：８９２４−８９２９頁（２００１年）<br class="style-scope patent-text">
 ・オパブスキー（Ｏｐａｖｓｋｙ）ら、Ｇｅｎｏｍｉｃｓ  ３３（３）：４８０−４８７頁（１９９６年）<br class="style-scope patent-text">
 ・オルトバ−ガット（Ｏｒｔｏｖａ−Ｇｕｔ）、Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ  １２３：１８８９−１９０３頁（２００２年）<br class="style-scope patent-text">
 ・パジャレス（Ｐａｊａｒｅｓ）ら、Ｌａｎｃｅｔ  Ｏｎｃｏｌ．、８（４）：３４９−５７頁（２００７年）<br class="style-scope patent-text">
 ・パストレク（Ｐａｓｔｏｒｅｋ）ら、Ｏｎｃｏｇｅｎｅ  ９：２８７７−２８８８頁（１９９４年）<br class="style-scope patent-text">
 ・パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）およびパストレク（Ｐａｓｔｏｒｅｋ）、第９章、Ｃａｒｂｏｎｉｃ  Ａｎｈｙｄｒａｓｅ：Ｉｔｓ  Ｉｎｈｉｂｉｔｏｒｓ  ａｎｄ  Ａｃｔｉｖａｔｏｒｓ［スプラン（Ｓｕｐｕｒａｎ）ら編；ＣＲＣ  Ｐｒｅｓｓ（ロンドンなど）２００４年］<br class="style-scope patent-text">
 ・パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、Ｖｉｒｏｌｏｇｙ  １８７：６２０−６２６頁（１９９２年）<br class="style-scope patent-text">
 ・パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ  １１２：３９８−４０８頁（１９９７年）<br class="style-scope patent-text">
 ・パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、Ｊ  Ｅｎｚ  Ｉｎｈｉｂ  Ｍｅｄ  Ｃｈｅｍ  １９：１９９−２２９頁（２００４年）<br class="style-scope patent-text">
 ・ポッター（Ｐｏｔｔｅｒ）およびハリス（Ｈａｒｒｉｓ）、Ｂｒ  Ｊ  Ｃａｎｃｅｒ  ８９：２−７頁（２００３年）<br class="style-scope patent-text">
 ・ロバートソン（Ｒｏｂｅｒｔｓｏｎ）ら、Ｃａｎｃｅｒ  Ｒｅｓ  ６４：６１６０−６１６５頁（２００４年）<br class="style-scope patent-text">
 ・ロビンソン（Ｒｏｂｉｎｓｏｎ）およびストリンガー（Ｓｔｒｉｎｇｅｒ）、Ｊ  Ｃｅｌｌ  Ｓｃｉ  １１４：８５３−８６５頁（２００１年）<br class="style-scope patent-text">
 ・ロメロ−ラミレツ（Ｒｏｍｅｒｏ−Ｒａｍｉｒｅｚ）ら、Ｃａｎｃｅｒ  Ｒｅｓ  ６４：５９４３−５９４７頁（２００４年）<br class="style-scope patent-text">
 ・ロイ（Ｒｏｙ）ら、Ｎｕｃｌ  Ａｃｉｄ  Ｒｅｓ  ３３：５０２６−５０３３頁（２００５年）<br class="style-scope patent-text">
 ・サーニオ（Ｓａａｒｎｉｏ）ら、Ａｍ  Ｊ  Ｐａｔｈｏｌ  １５３：２７９−２８５頁（１９９８年）<br class="style-scope patent-text">
 ・スコセイム（Ｓｋｏｔｈｅｉｍ）およびネス（Ｎｅｅｓ）、Ｉｎｔ  Ｊ  Ｂｉｏｃｈｅｍ  Ｃｅｌｌ  Ｂｉｏｌ．、３９（７−８）：１４３２−４９頁（２００７年）<br class="style-scope patent-text">
 ・スレブロウ（Ｓｒｅｂｒｏｗ）およびコーンブリット（Ｋｏｒｎｂｌｉｈｔｔ）、Ｊ  Ｃｅｌｌ  Ｓｃｉ．，１１９（第１３部）：２６３５−４１頁（２００６年）<br class="style-scope patent-text">
 ・スプラン（Ｓｕｐｕｒａｎ）およびスコッザファバ（Ｓｃｏｚｚａｆａｖａ）、Ｊ．Ｅｎｚｙｍｅ  Ｉｎｈｉｂ．１５（６）：５９７−６１０頁（２０００年）<br class="style-scope patent-text">
 ・スバストバ（Ｓｖａｓｔｏｖａ）ら、Ｅｘｐ  Ｃｅｌｌ  Ｒｅｓ  ２９０：３３２−３４５頁（２００３年）<br class="style-scope patent-text">
 ・スバストバ（Ｓｖａｓｔｏｖａ）ら、ＦＥＢＳ  Ｌｅｔｔｅｒｓ  ５７７：４３９−４４５頁（２００４年）<br class="style-scope patent-text">
 ・スウィータッチ（Ｓｗｉｅｔａｃｈ）ら、Ｃａｎｃｅｒ  Ｍｅｔａｓｔａｓｉｓ  Ｒｅｖ、ＤＯＩ  １０．１００７／ｓ１０５５５−００７−９０６４−０（２００７年）<br class="style-scope patent-text">
 ・タコーネリ（Ｔａｃｏｎｅｌｌｉ）ら、Ｃａｎｃｅｒ  Ｃｅｌｌ  ６：３４７−６０頁（２００４）<br class="style-scope patent-text">
 ・ターナー（Ｔｕｒｎｅｒ）ら、Ｈｕｍａｎ  Ｐａｔｈｏｌ．２８（６）：７４０−７４４頁（１９９７年）<br class="style-scope patent-text">
 ・ベナブルスＪＰ（Ｖｅｎａｂｌｅｓ  ＪＰ）、ＢｉｏＥｓｓａｙｓ  ２８：３７８−３８６頁（２００６年）<br class="style-scope patent-text">
 ・ベルミレン（Ｖｅｒｍｙｌｅｎ）ら、Ｅｕｒ．Ｒｅｓｐｉｒ．Ｊ．１４：８０６−８１１頁（１９９９年）<br class="style-scope patent-text">
 ・ウィルトン（Ｗｉｌｔｏｎ）およびフレッチャー（Ｆｌｅｔｃｈｅｒ）、Ｃｕｒｒ  Ｇｅｎｅ  Ｔｈｅｒ．、５（５）：４６７−８３頁（２００５年）<br class="style-scope patent-text">
 ・ウィンゴ（Ｗｉｎｇｏ）ら、Ｂｉｏｃｈｅｍｉｃａｌ  ａｎｄ  Ｂｉｏｐｈｙｓｉｃａｌ  Ｒｅｓｅａｒｃｈ  Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ  ２８８：６６６−６６９頁（２００１年）<br class="style-scope patent-text">
 ・ワン（Ｗｏｎｇ）ら、Ｅｘｐ  Ｍｏｌ  Ｐａｔｈｏｌ  ７５：１２４−１３０頁（２００３年）<br class="style-scope patent-text">
 ・ウィコッフ（Ｗｙｋｏｆｆ）ら、Ｃａｎｃｅｒ  Ｒｅｓ  ６０：７０７５−７０８３頁（２０００年）<br class="style-scope patent-text">
 ・ウィコッフ（Ｗｙｋｏｆｆ）ら、Ａｍ．Ｊ．Ｐａｔｈｏｌ．１５８（３）：１０１１−１０１９頁（２００１年）<br class="style-scope patent-text">
 ・シンＹ（Ｘｉｎｇ  Ｙ．）Ｆｒｏｎｔ  Ｂｉｏｓｃｉ．、１２：４０３４−４１頁（２００７年）<br class="style-scope patent-text">
 ・ザトビコバ（Ｚａｔｏｖｉｃｏｖａ）ら、Ｊ  Ｉｍｍｕｎｏｌ  Ｍｅｔｈｏｄｓ  ２８２：１１７−１３４頁（２００３年）<br class="style-scope patent-text">
 ・ザバダ（Ｚａｖａｄａ）ら、Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ  ５４：２６８−２７４頁（１９９３年）<br class="style-scope patent-text">
 ・ザバダ（Ｚａｖａｄａ）ら、Ｂｒ．Ｊ．Ｃａｎｃｅｒ  ８２（１１）：１８０８−１８１３頁（２０００年）<br class="style-scope patent-text">
略語<br class="style-scope patent-text">
  以下の略語が本明細書中に使用される：<br class="style-scope patent-text">
</span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000002" he="229" wi="142" file="0005866328.tif" img-format="tif" img-content="drawing" width="568" height="916" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000003" he="248" wi="137" file="0005866328.tif" img-format="tif" img-content="drawing" width="548" height="992" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000004" he="221" wi="138" file="0005866328.tif" img-format="tif" img-content="drawing" width="552" height="884" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
細胞株<br class="style-scope patent-text">
<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000005" he="126" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="504" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
ヌクレオチドおよびアミノ酸の記号<br class="style-scope patent-text">
  以下の記号は、本明細書においてヌクレオチドを表すために使用される：<br class="style-scope patent-text">
<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000006" he="178" wi="96" file="0005866328.tif" img-format="tif" img-content="drawing" width="384" height="712" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
  ２０の主要アミノ酸があり、それらの各々は、３つの隣接ヌクレオチド（トリプレットコードまたはコドン）の異なる配列により特定され、特定の順序で一緒に結合して特徴的なタンパク質を形成する。例えば、以下の図１に示される前記アミノ酸を同定するために、３文字または１文字の通則が、本明細書に使用される：<br class="style-scope patent-text">
<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000007" he="219" wi="90" file="0005866328.tif" img-format="tif" img-content="drawing" width="360" height="876" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
Anderson et al., Oncogene 25: 61-69 (2006) <br class="style-scope patent-text"> Alvarez-Perez et al., MAGMA 18: 293-301 (2005) <br class="style-scope patent-text"> Bartosova et al., J. MoI. Pathol. 197: 314-321 (2002) <br class="style-scope patent-text"> -Beasley et al., Cancer Res. 61 (13): 5262-5267 (2001) <br class="style-scope patent-text"> Cecchi et al., J Med Chem 48: 4834-41 (2005). <br class="style-scope patent-text"> -Chegwidden et al., EXS 90: 343-363 (2000) <br class="style-scope patent-text"> • Krastina et al., Int. J Cancer 105: 873-881 (2003) <br class="style-scope patent-text"> -Dorai et al., Eur. J Cancer 41: 2935-2947 (2005) <br class="style-scope patent-text"> Garcia-Branco, Curr Opin Mol Ther. 7 (5): 476-82 (2005) <br class="style-scope patent-text"> Giatromanolaki et al., Cancer Res. 61 (21): 7992-7998 (2001) <br class="style-scope patent-text"> Gothie et al., J Biol Chem 275: 6922-6927 (2000) <br class="style-scope patent-text"> Gut et al., Gastroenterology 123: 1889-1903 (2002). <br class="style-scope patent-text"> -Harris AL. , Nature Rev Cancer 2: 38-47 (2002). <br class="style-scope patent-text"> He et al., Oncogene 25: 192-2202 (2006) <br class="style-scope patent-text"> Hockel and Vaupel, Semin. Oncol. 28 (2 Addendum 8): 36-41 (2001) <br class="style-scope patent-text"> -Ivanov et al. Pathol. 158 (3): 905-919 (2001) <br class="style-scope patent-text">・ Kaluz et al., Cancer Res 62: 4469-4477 (2002). <br class="style-scope patent-text"> Kivela et al., World J Gastroenterol 11: 155-163 (2005) <br class="style-scope patent-text"> Koukourakis et al., Clin. Cancer Res. 7 (11): 3399-3403 (2001) <br class="style-scope patent-text"> Liao et al., Am. J. et al. Pathol. 145 (3): 598-609 (1994) <br class="style-scope patent-text"> -Liao et al., Cancer Res. 57: 2827-2831 (1997) <br class="style-scope patent-text"> Lieskovska et al., Neoplasma 46: 17-24 (1999). <br class="style-scope patent-text"> Matlin et al., Nat Rev Mol Cell Biol 6: 386-398 (2005) <br class="style-scope patent-text"> Morgan et al., Am J Physiol-Cell Physiol 293 (2): C738-C748 (2007) <br class="style-scope patent-text"> Olive et al., Cancer Res 61: 8924-8929 (2001) <br class="style-scope patent-text">・ Opavsky et al., Genomics 33 (3): 480-487 (1996). <br class="style-scope patent-text"> Ortova-Gut, Gastroenterology 123: 1889-1903 (2002) <br class="style-scope patent-text"> Pajares et al., Lancet Oncol. , 8 (4): 349-57 (2007) <br class="style-scope patent-text"> Pastorek et al., Oncogene 9: 2877-2888 (1994) <br class="style-scope patent-text"> -Pastorekova and Pastorek, <figure-callout id="9" label="Chapter" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Chapter</a></figure-callout> 9, Carbon Anhydrase: Its Inhibitors and Activators [Edited by Spuran et al .; CRC Press (London, etc.) 2004] <br class="style-scope patent-text"> Pastorekova et al., Virology 187: 620-626 (1992) <br class="style-scope patent-text"> -Pastorekova et al., Gastroenterology 112: 398-408 (1997) <br class="style-scope patent-text"> Pastrekova et al., J Enz Inhib Med Chem 19: 199-229 (2004) <br class="style-scope patent-text"> Potter and Harris, Br J Cancer 89: 2-7 (2003) <br class="style-scope patent-text"> Robertson et al., Cancer Res 64: 6160-6165 (2004) <br class="style-scope patent-text"> Robinson and Stringer, J Cell Sci 114: 853-865 (2001) <br class="style-scope patent-text"> Romero-Ramirez et al., Cancer Res 64: 5943-5947 (2004) <br class="style-scope patent-text"> Roy et al., Nucl Acid Res 33: 5026-5033 (2005) <br class="style-scope patent-text"> Saario et al., Am J Pathol 153: 279-285 (1998). <br class="style-scope patent-text"> • Scotheim and Nees, Int J Biochem Cell Biol. , 39 (7-8): 1432-49 (2007) <br class="style-scope patent-text"> -Srebrow and Cornbright, J Cell Sci. 119 (Part 13): 2635-41 (2006). <br class="style-scope patent-text"> Supran and Scozza Fava, J.A. Enzyme Inhib. 15 (6): 597-610 (2000) <br class="style-scope patent-text"> Svastova et al., Exp Cell Res 290: 332-345 (2003) <br class="style-scope patent-text"> Svastova et al., FEBS Letters 577: 439-445 (2004) <br class="style-scope patent-text">・ Sweetach et al., Cancer Metastases Rev, DOI 10.1007 / s10555-007-9064-0 (2007) <br class="style-scope patent-text"> Taconelli et al., Cancer Cell 6: 347-60 (2004). <br class="style-scope patent-text"> Turner et al., Human Pathol. 28 (6): 740-744 (1997) <br class="style-scope patent-text">・ Venables JP, BioEssays 28: 378-386 (2006) <br class="style-scope patent-text"> Vermylen et al., Eur. Respir. J. et al. 14: 806-811 (1999) <br class="style-scope patent-text"> Wilton and Fletcher, Curr Gene Ther. 5 (5): 467-83 (2005) <br class="style-scope patent-text"> Wingo et al., Biochemical and Biophysical Research Communications 288: 666-669 (2001) <br class="style-scope patent-text"> Wong et al. Exp Mol Pathol 75: 124-130 (2003) <br class="style-scope patent-text"> Wykoff et al., Cancer Res 60: 7075-7083 (2000) <br class="style-scope patent-text"> Wykoff et al., Am. J. et al. Pathol. 158 (3): 1011-1019 (2001) <br class="style-scope patent-text"> Xing Y. Front Biosci. 12: 4034-41 (2007) <br class="style-scope patent-text"> Zatovicova et al., J Immunol Methods 282: 117-134 (2003) <br class="style-scope patent-text"> -Zavada et al., Int. J. et al. Cancer 54: 268-274 (1993) <br class="style-scope patent-text"> -Zavada et al., Br. J. et al. Cancer 82 (11): 1808-1813 (2000) <br class="style-scope patent-text"> Abbreviations The following abbreviations are used herein: <br class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000002" he="229" wi="142" file="0005866328.tif" img-format="tif" img-content="drawing" width="568" height="916" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000003" he="248" wi="137" file="0005866328.tif" img-format="tif" img-content="drawing" width="548" height="992" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000004" he="221" wi="138" file="0005866328.tif" img-format="tif" img-content="drawing" width="552" height="884" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> Cell line <br class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000005" he="126" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="504" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> Nucleotide and amino acid symbols The following symbols are used herein to represent nucleotides: <br class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000006" he="178" wi="96" file="0005866328.tif" img-format="tif" img-content="drawing" width="384" height="712" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> There are 20 major amino acids, each of which is specified by a different sequence of three adjacent nucleotides (triplet code or codon) and joined together in a specific order to form a characteristic protein. For example, to identify the amino acids shown in FIG. 1 below, a three letter or one letter convention is used herein: <br class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000007" he="219" wi="90" file="0005866328.tif" img-format="tif" img-content="drawing" width="360" height="876" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> 
      <p class="style-scope patent-text"></p>
    </tech-solution>
  </summary-of-invention>
  
  <description-of-drawings class="style-scope patent-text">
    <p num="0049" class="style-scope patent-text">
      <figref num="1A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＣＡ ＩＸのスプライシング変異体の同定および推定構造：マウスＣａｒ９遺伝子（ＧｅｎＢａｎｋ番号ＡＹ０４９０７７）のゲノム構造。</span>Identification and putative structure of a splicing variant of mouse CA IX: Genomic structure of mouse Car9 gene (GenBank number AY049077).</span>
      </figref>
      <figref num="1B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＣＡ ＩＸのスプライシング変異体の同定および推定構造：マウス胃腸管系組織におけるＣａｒ９スプライシング変異体のＲＴ−ＰＣＲ［実施例に用いられるプライマーの配列に関しては下記表２を参照］。</span>Identification and putative structure of splicing variant of mouse CA IX: RT-PCR of Car9 splicing variant in mouse gastrointestinal tissue [see Table 2 below for primer sequences used in Examples].</span>
      </figref>
      <figref num="1C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＣＡ ＩＸのスプライシング変異体の同定および推定構造：ＦＬ転写体およびＡＳ転写体の別々の増幅。</span>Identification and putative structure of splicing variants of mouse CA IX: separate amplification of FL and AS transcripts.</span>
      </figref>
      <figref num="1D" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＣＡ ＩＸのスプライシング変異体の同定および推定構造：ＦＬアミノ酸配列［配列番号７３］とＡＳアミノ酸配列［配列番号１０７］の比較。</span>Identification and predicted structure of a splicing variant of mouse CA IX: Comparison of FL amino acid sequence [SEQ ID NO: 73] and AS amino acid sequence [SEQ ID NO: 107].</span>
      </figref>
      <figref num="1E" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＣＡ ＩＸのスプライシング変異体の同定および推定構造：マウスＡＳ ＣＡ ＩＸタンパク質の推定された構造。</span>Identification and predicted structure of a splicing variant of mouse CA IX: putative structure of mouse AS CA IX protein.</span>
      </figref>
      <figref num="2A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＡＳ ＣＡ ＩＸの免疫ブロット分析および局在化。マウスＡＳ ｃＤＮＡを含むｐＳＧ５Ｃ−ＡＳプラスミドは、ＮＩＨ３Ｔ３細胞およびＭＤＣＫ細胞にそれぞれ形質移入された：マウスＣＡ ＩＸに対してポリクローナル血清を用いるＡＳ形質移入細胞の免疫ブロットが、単一のＡＳ関連バンドを示す。</span>Immunoblot analysis and localization of mouse AS CA IX. PSG5C-AS plasmid containing mouse AS cDNA was transfected into NIH3T3 cells and MDCK cells, respectively: immunoblot of AS-transfected cells using polyclonal serum against mouse CA IX shows a single AS-related band .</span>
      </figref>
      <figref num="2B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">マウスＡＳ ＣＡ ＩＸの免疫ブロット分析および局在化。マウスＡＳ ｃＤＮＡを含むｐＳＧ５Ｃ−ＡＳプラスミドは、ＮＩＨ３Ｔ３細胞およびＭＤＣＫ細胞にそれぞれ形質移入された：形質移入体の免疫蛍光分析が、マウスＡＳタンパク質の細胞内局在を示す。</span>Immunoblot analysis and localization of mouse AS CA IX. The pSG5C-AS plasmid containing mouse AS cDNA was transfected into NIH3T3 cells and MDCK cells, respectively: immunofluorescence analysis of the transfectants shows the intracellular localization of the mouse AS protein.</span>
      </figref>
      <figref num="3A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＣＡ ＩＸのスプライシング変異体の同定および推定された構造：ヒトＣＡ９遺伝子（ＧｅｎＢａｎｋ番号Ｚ５４３４９）のゲノム構造の略図。プライマー位置は、矢印により示される[実施例に用いられるプライマーの配列に関しては表２を参照]。選択的スプライシングにより排除されたエクソンは、暗灰色にある。</span>Identification and predicted structure of a splicing variant of human CA IX: schematic representation of the genomic structure of the human CA9 gene (GenBank number Z54349). Primer positions are indicated by arrows [see Table 2 for primer sequences used in the Examples]. Exons excluded by alternative splicing are dark gray.</span>
      </figref>
      <figref num="3B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＣＡ ＩＸのスプライシング変異体の同定および推定された構造：スプライシング変異体間を識別しないｈ１Ｓ−ｈ６Ａプライマー［配列番号９５および９６］を用いたヒト胃腸におけるＣＡ９のＲＴ−ＰＣＲ分析。</span>Identification and predicted structure of a splicing variant of human CA IX: RT-PCR analysis of CA9 in human gastrointestinal tract using h1S-h6A primers [SEQ ID NOs: 95 and 96] that do not discriminate between splicing variants.</span>
      </figref>
      <figref num="3C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＣＡ ＩＸのスプライシング変異体の同定および推定された構造：ｈ６Ｓ−ｈ１１Ａプライマー［配列番号９７および９８］を用いたヒト組織におけるＦＬとＡＳ双方の転写体の増幅。</span>Identification and predicted structure of a splicing variant of human CA IX: Amplification of both FL and AS transcripts in human tissues using the h6S-h11A primer [SEQ ID NOs: 97 and 98].</span>
      </figref>
      <figref num="3D" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＣＡ ＩＸのスプライシング変異体の同定および推定された構造：ヒトＦＬおよびＡＳ ＣＡ９  ｃＤＮＡから推測されたアミノ酸配列［配列番号２および１０９］の比較。シグナルペプチド（ＳＰ）はイタリックで書かれ、プロテオグリカン様ドメイン（ＰＧ）は太字であり、炭酸脱水酵素ドメイン（ＣＡ）は実線で囲み、アミノ酸（ａａ）４１５で開始する膜貫通領域（ＴＭ）は破線で囲ってある。点線はＡＳで欠失したアミノ酸残基を表す。触媒亜鉛に結合するヒスチジンおよびＳ−Ｓ結合の形成に関与するシステインは、単独に破線で囲ってある。</span>Identification and deduced structure of splicing variants of human CA IX: comparison of amino acid sequences deduced from human FL and AS CA9 cDNA [SEQ ID NOs: 2 and 109]. The signal peptide (SP) is written in italics, the proteoglycan-like domain (PG) is bold, the carbonic anhydrase domain (CA) is surrounded by a solid line, and the transmembrane region (TM) starting at amino acid (aa) 415 is a dashed line It is surrounded by. The dotted line represents the amino acid residue deleted in AS. The histidine that binds to the catalytic zinc and the cysteine that is involved in the formation of the S—S bond are enclosed in dashed lines alone.</span>
      </figref>
      <figref num="3E" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＣＡ ＩＸのスプライシング変異体の同定および推定された構造：ヒトＦＬおよびＡＳ ＣＡ ＩＸタンパク質の推定された構造。</span>Identification and deduced structure of splicing variants of human CA IX: deduced structure of human FL and AS CA IX proteins.</span>
      </figref>
      <figref num="4A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">スプライシング変異体、すなわちＦＬに関してはｈ７Ｓ−ｈ８Ａ［配列番号９９および１００］およびＡＳに関してはｈ７Ｓ−ｈ１０／７Ａ［配列番号９９および１０１］の個々の増幅のために設計されたプライマーを用いた（図３を参照）ヒトＡＳ ＣＡ９のＲＴ−ＰＣＲ分析による、ヒト腫瘍細胞株およびヒト組織におけるＡＳ ＣＡ ＩＸ変異体の発現。ベータ−アクチンを標品として用いた（図４Ｂおよび４Ｃにおいて同じ）：酸素正常状態（Ｎ）および低酸素状態（Ｈ）に４８時間露出させた細胞からｃＤＮＡを単離した。この結果は、ＡＳ発現が安定しており、低酸素状態に依存しないことを示している。</span>Splicing variants were used, ie primers designed for individual amplification of h7S-h8A [SEQ ID NO: 99 and 100] for FL and h7S-h10 / 7A [SEQ ID NO: 99 and 101] for AS (FIG. 3) Expression of AS CA IX variants in human tumor cell lines and human tissues by RT-PCR analysis of human AS CA9. Beta-actin was used as a standard (same in FIGS. 4B and 4C): cDNA was isolated from cells exposed to normoxia (N) and hypoxia (H) for 48 hours. This result indicates that AS expression is stable and does not depend on hypoxia.</span>
      </figref>
      <figref num="4B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">低密度および高密度で７２時間インキュベートした細胞からｃＤＮＡを単離した。この結果は、ＡＳ発現が安定しており、密度に依存しないことを示している。</span>CDNA was isolated from cells incubated at low and high density for 72 hours. This result indicates that AS expression is stable and independent of density.</span>
      </figref>
      <figref num="4C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">正常および腫瘍ヒト組織からｃＤＮＡを単離した。この結果は、ＡＳ発現が安定しており、腫瘍表現型に依存しないことを示している。</span>CDNA was isolated from normal and tumor human tissues. This result indicates that AS expression is stable and independent of tumor phenotype.</span>
      </figref>
      <figref num="5A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＡＳ ＣＡ ＩＸの局在化およびオリゴマー化を示す図。ＣＡ ＩＸ陰性ＭＤＣＫ細胞およびＦＬ ＣＡ ＩＸの天然の低酸素状態により誘導された発現を有するＨｅＬａ細胞に、ｐＳＧ５Ｃプラスミド内のＡＳＣＡ９ ｃＤＮＡを持続的に形質移入した：ＡＳ形質移入（ＡＳ）、ＦＬ形質移入（ＦＬ）および対照細胞（モック）の免疫蛍光分析を、ＡＳおよびＦＬタンパク質の双方を認識するＭ７５ ｍａｂを用いて実施した。</span>Figure 2 shows the localization and oligomerization of human AS CA IX. HeLa cells with CA IX negative MDCK cells and FL CA IX natural hypoxia-induced expression were persistently transfected with ASCA9 cDNA in the pSG5C plasmid: AS transfection (AS), FL transfection Immunofluorescence analysis of (FL) and control cells (mock) was performed using an M75 mab that recognizes both AS and FL proteins.</span>
      </figref>
      <figref num="5B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＡＳ ＣＡ ＩＸの局在化およびオリゴマー化を示す図。ＣＡ ＩＸ陰性ＭＤＣＫ細胞およびＦＬ ＣＡ ＩＸの天然の低酸素状態により誘導された発現を有するＨｅＬａ細胞に、ｐＳＧ５Ｃプラスミド内のＡＳＣＡ９ ｃＤＮＡを持続的に形質移入した：ＨｅＬａ−ＡＳ細胞および対照ＨｅＬａ細胞からのタンパク質抽出物および培地の免疫ブロット分析。ＡＳ ＣＡ ＩＸ変異体は、ＡＳ形質細胞の抽出物ならびに培地中のＭ７５ ｍａｂにより検出された。</span>Figure 2 shows the localization and oligomerization of human AS CA IX. HeLa cells with CA IX negative MDCK cells and FL CA IX natural hypoxia-induced expression were persistently transfected with ASCA9 cDNA in the pSG5C plasmid: from HeLa-AS cells and control HeLa cells Immunoblot analysis of protein extracts and media. The AS CA IX mutant was detected by an extract of AS plasma cells as well as M75 mab in the medium.</span>
      </figref>
      <figref num="6A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">オリゴマーを形成するＦＬおよびＡＳスプライシング変異体の能力：非還元性ＳＤＳ−ＰＡＧＥおよびＭ７５による免疫ブロットにより、ＡＳがオリゴマーを形成できないことを示した。</span>Ability of FL and AS splicing variants to form oligomers: Immunoblot with non-reducing SDS-PAGE and M75 showed that AS was unable to form oligomers.</span>
      </figref>
      <figref num="6B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">オリゴマーを形成するＦＬおよびＡＳスプライシング変異体の能力：ＭＡｂＶ／１０（ＡＳは認識しないが、ＦＬを認識する）またはＭ７５（双方の変異体を認識する）で抽出されたＨｅＬａ−ＡＳ抽出物からの免疫沈降によるオリゴマー中のスプライシング変異体の検出。沈降されたオリゴマーの成分は、ペルオキシダーゼ標識Ｍ７５を用いて可視化した。</span>Ability of FL and AS splicing variants to form oligomers: from HeLa-AS extracts extracted with MAbV / 10 (not recognizing AS but recognizing FL) or M75 (recognizing both variants) Detection of splicing variants in oligomers by immunoprecipitation. The precipitated oligomeric components were visualized using peroxidase-labeled M75.</span>
      </figref>
      <figref num="7A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">酸性化、阻害剤結合およびスフェロイド形成に対する過剰発現ＡＳ変異体の効果：ＡＳ形質移入ＨｅＬａ細胞および関連するモック形質移入対照を、それぞれ酸素正常状態および低酸素状態で４８時間インキュベートし、細胞外ｐＨを、実験の終了直後に培地中で測定した。データは、低酸素状態の細胞対酸素正常状態の細胞で測定されたｐＨ値間の差異（ΔｐＨ）として表され、標準偏差を含む。結果は、ＡＳの発現が、低酸素状態でＦＬ ＣＡ ＩＸタンパク質により媒介される酸性化を減少させることを示す。</span>Effect of overexpressed AS mutants on acidification, inhibitor binding and spheroid formation: AS transfected HeLa cells and associated mock transfection controls were incubated for 48 hours in normoxia and hypoxia, respectively, and the extracellular pH was Measured in the medium immediately after the end of the experiment. Data is expressed as the difference (ΔpH) between pH values measured in hypoxic versus normoxic cells and includes standard deviations. The results show that AS expression decreases acidification mediated by FL CA IX protein in hypoxia.</span>
      </figref>
      <figref num="7B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">酸性化、阻害剤結合およびスフェロイド形成に対する過剰発現ＡＳ変異体の効果：ヒトＦＬ ＣＡ ＩＸタンパク質を構成的に発現するＭＤＣＫ−ＣＡ ＩＸ形質移入細胞を、ＭＤＣＫ−ＡＳ形質移入体からの調整培地を添加した分泌ＡＳ変異体の不在下（対照）または存在下、蛍光ＣＡ阻害剤（ＦＩＴＣ−ＣＡ Ｉ）により４８時間処理した図である。調整培地を、新鮮な培地と混合した。ＦＩＴＣ−ＣＡ Ｉは低酸素状態の細胞にのみ結合し、ＡＳタンパク質の存在下でかなり減少した。</span>Effect of overexpressed AS variants on acidification, inhibitor binding and spheroid formation: MDCK-CA IX transfected cells constitutively expressing human FL CA IX protein, conditioned medium from MDCK-AS transfectants added FIG. 5 shows a treatment with a fluorescent CA inhibitor (FITC-CA I) for 48 hours in the absence (control) or presence of a secreted AS mutant. Conditioned medium was mixed with fresh medium. FITC-CA I bound only to hypoxic cells and was significantly reduced in the presence of AS protein.</span>
      </figref>
      <figref num="7C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">酸性化、阻害剤結合およびスフェロイド形成に対する過剰発現ＡＳ変異体の効果：同じ実験を、ＭＤＣＫ−ＡＳ細胞からの調整培地の半分（１／２ＡＳ）または三分の一（１／３ＡＳ）のいずれかで繰り返し実施した。ＦＩＴＣ−ＣＡ Ｉと対応する蛍光との結合は、シオン（Ｓｃｉｏｎ）画像ソフトウェアを用いて獲得された画像から評価した。データは、ＡＳの不在下、ＦＩＴＣ−ＣＡ Ｉと共にインキュベートされた低酸素状態のＭＤＣＫ−ＣＡ ＩＸ細胞により示された陽性対照のパーセンテージとして表示された。その結果、ＡＳがＣＡ ＩＸに対するＦＩＴＣ−ＣＡ Ｉの結合を減少させることが確認された。</span>Effect of overexpressed AS mutants on acidification, inhibitor binding and spheroid formation: the same experiment was done either in half (1/2 AS) or one third (1/3 AS) of conditioned medium from MDCK-AS cells Repeatedly. The binding of FITC-CAI to the corresponding fluorescence was evaluated from images acquired using Scion image software. Data were expressed as a percentage of the positive control exhibited by hypoxic MDCK-CA IX cells incubated with FITC-CA I in the absence of AS. As a result, it was confirmed that AS decreased the binding of FITC-CA I to CA IX.</span>
      </figref>
      <figref num="7D" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">酸性化、阻害剤結合およびスフェロイド形成に対する過剰発現ＡＳ変異体の効果：対照のモック形質移入ＨｅＬａ細胞およびＡＳ形質移入ＨｅＬａ細胞それぞれから増殖させたスフェロイドの顕微鏡画像。対照のＨｅＬａ細胞は、低酸素状態誘導の機能性ＦＬ ＣＡ ＩＸタンパク質を発現し、コンパクトコア(compact core)を形成するスフェロイドを生じる。低酸素誘導のＦＬ ＣＡ ＩＸおよび構成的に発現したＡＳ双方を含むＨｅＬａ−ＡＳ細胞は、ルースコア(loose core)を含むが、これは恐らくＦＬの機能がＡＳにより損なわれるため、低酸素コア細胞の生存減少に至ったためと思われる。</span>Effect of overexpressed AS mutants on acidification, inhibitor binding and spheroid formation: microscopic images of spheroids grown from control mock-transfected and AS-transfected HeLa cells, respectively. Control HeLa cells express hypoxia-inducible functional FL CA IX protein and produce spheroids that form a compact core. HeLa-AS cells containing both hypoxia-induced FL CA IX and constitutively expressed AS contain a loose core, which is presumably because the function of FL is impaired by AS. This seems to be due to the decrease in survival.</span>
      </figref>
      <figref num="8A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図８Ａ〜Ｃは、本明細書に記載される、単離されたＭＮ ｃＤＮＡ［配列番号１］クローンのヌクレオチド配列である。また、ｃＤＮＡによりコードされた推定アミノ酸配列［配列番号２］も示している。</span>8A-C are the nucleotide sequences of the isolated MN cDNA [SEQ ID NO: 1] clones described herein. Also shown is the deduced amino acid sequence [SEQ ID NO: 2] encoded by the cDNA.</span>
      </figref>
      <figref num="8B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図８Ａ〜Ｃは、本明細書に記載される、単離されたＭＮ ｃＤＮＡ［配列番号１］クローンのヌクレオチド配列である。また、ｃＤＮＡによりコードされた推定アミノ酸配列［配列番号２］も示している。</span>8A-C are the nucleotide sequences of the isolated MN cDNA [SEQ ID NO: 1] clones described herein. Also shown is the deduced amino acid sequence [SEQ ID NO: 2] encoded by the cDNA.</span>
      </figref>
      <figref num="8C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図８Ａ〜Ｃは、本明細書に記載される、単離されたＭＮ ｃＤＮＡ［配列番号１］クローンのヌクレオチド配列である。また、ｃＤＮＡによりコードされた推定アミノ酸配列［配列番号２］も示している。</span>8A-C are the nucleotide sequences of the isolated MN cDNA [SEQ ID NO: 1] clones described herein. Also shown is the deduced amino acid sequence [SEQ ID NO: 2] encoded by the cDNA.</span>
      </figref>
      <figref num="9A" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="9B" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="9C" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="9D" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="9E" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="9F" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９Ａ〜Ｆは、ＭＮ［配列番号３］の１０，８９８ｂｐの完全ゲノム配列。塩基数は以下のとおりである：２６５４のＡ；２７３９のＣ；２６４５のＧ；および２８５９のＴ。１１のエクソンは、一般に大文字で示されるが、エクソン１は、ＲＮアーゼ保護アッセイにより測定されたように３５０７位で開始されると考えられている。</span>9A-F are 10,898 bp complete genome sequences of MN [SEQ ID NO: 3]. The number of bases is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. Eleven exons are generally shown in capital letters, but <figure-callout id="1" label="exon" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 1 is thought to start at position 3507 as measured by the RNase protection assay.</span>
      </figref>
      <figref num="10" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ヒトＭＮ遺伝子［配列番号２４］の提案されたプロモーターに関するヌクレオチド配列。このヌクレオチドは、ＲＮアーゼ保護アッセイにしたがって転写開始部位から番号が付けられる。調節要素として可能性のあるものを上線で示している。転写開始部位は、星印（ＲＮアーゼ保護）および対応するヌクレオチド上に点（ＲＡＣＥ）で示される。第一のエクソンの配列は、星印のもとで開始する。ＭＮ４プロモーター断片のＦＴＰ分析により、コード鎖および非コード鎖双方で保護された５つの領域（Ｉ〜Ｖ）、および非コード鎖は保護されないが、コード鎖において保護された２つの領域（ＶＩおよびＶＩＩ）が明らかとなった。</span>Nucleotide sequence for the proposed promoter of the human MN gene [SEQ ID NO: 24]. This nucleotide is numbered from the transcription start site according to the RNase protection assay. Possible adjustment elements are indicated by overlines. The transcription start site is indicated by an asterisk (RNase protection) and a dot (RACE) on the corresponding nucleotide. The first exon sequence starts with an asterisk. By FTP analysis of the MN4 promoter fragment, five regions (IV) protected by both the coding and non-coding strands, and two regions protected by the coding strand (VI and VII), while the non-coding strand is not protected. ) Became clear.</span>
      </figref>
    </p>
  </description-of-drawings>
  <description-of-embodiments class="style-scope patent-text">
    <p num="0050" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｐＨおよび細胞接着を調節する調節機構の一部として、ＭＮ／ＣＡ ＩＸタンパク質は腫瘍形成において機能的に関係がある。ＭＮ／ＣＡ ＩＸは、ＨＩＦ−１経路を経て主として低酸素状態で誘導される；ＨＩＦ−１はまた、ＭＮ／ＣＡ ＩＸ発現の増加を生じ得るＰＩ３Ｋ経路を経て伝達された高細胞密度など、種々の細胞外シグナルおよび発癌性変化により酸素正常状態でも発現する可能性がある。ＨＩＦ−１とＰＩ３Ｋ双方の経路が、ＨＩＦ−１タンパク質レベルを増加させ、その増加が、ＭＮ／ＣＡ ＩＸレベルの増加に移し変えられる可能性がある。
</span>
&nbsp;&nbsp;As part of a regulatory mechanism that regulates pH and cell adhesion, the MN / CA IX protein is functionally involved in tumorigenesis. MN / CA IX is induced mainly under hypoxia via the HIF-1 pathway; HIF-1 also has a variety of high cell densities transmitted via the PI3K pathway that can result in increased MN / CA IX expression. May be expressed even in normoxia due to extracellular signals and carcinogenic changes. It is possible that both HIF-1 and PI3K pathways increase HIF-1 protein levels and that increase is translated into an increase in MN / CA IX levels.
</span>
    </p>
    <p num="0051" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  下記の実施例に示されるように、本発明者は、高酵素活性およびｐＨを調節する能力により低酸素誘導されるＣＡ ＩＸタンパク質をコードする完全長（ＦＬ）ＣＡ９転写体に加えて、量の少ない構成的に産生された選択的にスプライスされた（ＡＳ）ＣＡ９転写体もあることを見出した。下記の実施例２に示されるように、ヒトＣＡ９ ｍＲＮＡの選択的スプライシング変異体は、エクソン８および９を含まず、低酸素状態とは無関係に腫瘍細胞に発現する。また、この変異体は、完全長転写体の不在下で正常組織において検出可能であり、したがって、低酸素状態関連および癌関連ＣＡ９発現の検出に基づく予後診断において偽陽性データが生じ得る。スプライシング変異体は、触媒ドメインのＣ末端部分を欠く切断ＣＡ ＩＸタンパク質をコードし、触媒活性の減少を示し、細胞内に局在するか、または分泌する。過剰発現される場合、変異体は、完全長ＣＡ ＩＸタンパク質が低酸素状態の細胞内ｐＨを酸性化する能力、および炭酸脱水酵素阻害剤に結合する能力を減少させる。実施例４および５において、ヒトＡＳ ＣＡ ＩＸ変異体が、細胞膜に限らず、過剰発現の際にＦＬタンパク質の機能を阻害することを示す実験を記載している。実施例５において、スプライシング変異体ｃＤＮＡを形質移入したＨｅＬａ細胞は、コンパクトなコアを形成しないスフェロイドを生じることから、ＨｅＬａ細胞は、低酸素ストレスに適合できないことを示唆している。このＡＳ能力は、細胞が、苛酷なアシドーシスを受けず、過度のｐＨ調節を必要としない場合、特に軽度の低酸素条件下で関連があり得る。
</span>
&nbsp;&nbsp;As shown in the examples below, in addition to the full-length (FL) CA9 transcript encoding CA IX protein that is hypoxia-induced by high enzyme activity and the ability to regulate pH, We have also found that there are few constitutively produced alternatively spliced (AS) CA9 transcripts. As shown in Example 2 below, an alternative splicing variant of human CA9 mRNA does not contain <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9 and is expressed in tumor cells independent of hypoxia. This mutant can also be detected in normal tissues in the absence of full-length transcripts, and thus can produce false positive data in prognosis based on detection of hypoxia-related and cancer-related CA9 expression. Splicing variants encode truncated CA IX proteins that lack the C-terminal portion of the catalytic domain, exhibit reduced catalytic activity, and are localized or secreted intracellularly. When overexpressed, the variant reduces the ability of the full-length CA IX protein to acidify hypoxic intracellular pH and bind to a carbonic anhydrase inhibitor. Examples 4 and 5 describe experiments that show that human ASCA IX mutants inhibit FL protein function during overexpression, not limited to cell membranes. In Example 5, HeLa cells transfected with the splicing mutant cDNA give rise to spheroids that do not form a compact core, suggesting that HeLa cells cannot adapt to hypoxic stress. This AS ability may be relevant, especially under mild hypoxic conditions, when the cells are not subject to severe acidosis and do not require excessive pH adjustment.
</span>
    </p>
    <p num="0052" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡ ＩＸのＡＳ変異体の低酸素および腫瘍に無関係な産生は、ＣＡ ＩＸの診断態様、予後診断態様および治療態様に関して多くの関係がある。完全長ＣＡ９ ｍＲＮＡ（機能的ＣＡ ＩＸタンパク質をコードする）の将来の診断／予後診断試験において、選択的にスプライスされた変異体の同時検出を回避するために設計されたプローブ／プライマーを設計することができ、癌治療は、例えば、他の治療法の中でもアンチセンスおよびＲＮＡ干渉療法に用いられるオリゴヌクレオチドの設計により、ＣＡ９選択的スプライシングに基づくことができる。
</span>
&nbsp;&nbsp;Hypoxia and tumor-independent production of AS mutants of CA IX have many implications for the diagnostic, prognostic and therapeutic aspects of CA IX. Design probes / primers designed to avoid simultaneous detection of alternatively spliced variants in future diagnostic / prognostic tests of full-length CA9 mRNA (encoding functional CA IX protein) Cancer treatment can be based on CA9 alternative splicing, for example, by designing oligonucleotides used for antisense and RNA interference therapy, among other therapies.
</span>
    </p>
    <p num="0053" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
前新生物／新生物疾患<br class="style-scope patent-text">
  本発明の診断方法／予後診断方法および治療方法の対象である前新生物疾患／新生物疾患（および患部組織）は、ＭＮ／ＣＡ ＩＸの異常発現に関連するものである。本明細書に用いられる「前新生物組織／新生物組織」はまた、体液中の前新生物細胞／新生物細胞を含むことができる。前記前新生物疾患／新生物疾患は、乳房、尿路、膀胱、腎臓、卵巣、子宮、子宮頚部、子宮内膜、扁平上皮細胞、腺扁平上皮細胞、膣、外陰部、前立腺、肝臓、肺、皮膚、甲状腺、膵臓、精巣、脳、頭頚部、中胚葉、肉腫、胃、脾臓、胃腸管、食道、および大腸の前新生物疾患／新生物疾患からなる群から選択されるのが好ましい。
</span>Preneoplastic / neoplastic disease The preneoplastic / neoplastic disease (and affected tissue) that is the subject of the diagnostic / prognostic and therapeutic methods of the present invention is associated with abnormal expression of MN / CA IX. is there. As used herein, “preneoplastic tissue / neoplastic tissue” can also include preneoplastic cells / neoplastic cells in body fluids. The preneoplastic / neoplastic diseases are breast, urinary tract, bladder, kidney, ovary, uterus, cervix, endometrium, squamous cell, adenosquamous cell, vagina, vulva, prostate, liver, lung Preferably selected from the group consisting of preneoplastic / neoplastic diseases of the skin, thyroid, pancreas, testis, brain, head and neck, mesoderm, sarcoma, stomach, spleen, gastrointestinal tract, esophagus, and colon.</span>
    </p>
    <p num="0054" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
酸素正常状態および低酸素状態<br class="style-scope patent-text">
  本明細書に用いられる「酸素正常状態」とは、哺乳動物の特定組織に関して生理的酸素張力レベルの正常範囲内にある特定の哺乳動物組織中の酸素張力レベルとして定義される。本明細書に用いられる「低酸素状態」とは、特定の組織または細胞中のＨＩＦ−１αを安定化させるために必要な酸素張力レベルとして定義される。実験的に誘導された低酸素状態は、一般的に２％以下であって、酸欠状態（酸欠状態は致死的となり得る０％のｐＯ<sub class="style-scope patent-text">２</sub>）以上のｐＯ<sub class="style-scope patent-text">２</sub>の範囲内にある。低酸素状態に関係する本明細書に記載された実施例では、代表的な低酸素状態である２％ｐＯ<sub class="style-scope patent-text">２</sub>で実施された。しかしながら、当業者は、「低酸素状態」として理解され、同様の実験結果を生じる他の酸素張力レベルを考えることもあろう。例えば、ウィコッフ（Ｗｙｋｏｆｆ）ら［Ｃａｎｃｅｒ  Ｒｅｓｅａｒｃｈ、６０：７０７５−７０８３頁（２０００年）］は、代表的な低酸素状態として０．１％ｐＯ<sub class="style-scope patent-text">２</sub>の条件を用いてＣＡ９のＨＩＦ−１α−従属発現を誘導した。トームズ（Ｔｏｍｅｓ）らは、０．３％、０．５％および２．５％ｐＯ<sub class="style-scope patent-text">２</sub>の代表的なインビトロ低酸素状態下、ＨｅＬａ細胞またはヒト乳房線維芽細胞におけるＨＩＦ−１αの安定化およびＣＡ９発現の程度が変わることを立証している［トームズ（Ｔｏｍｅｓ）ら、Ｂｒ．Ｃａｎｃｅｒ  Ｒｅｓ．Ｔｒｅａｔ．８１（１）：６１−６９頁（２００３年）］。あるいは、カルツ（Ｋａｌｕｚ）らは、ＣＡ９の実験的誘導に関して０．５％ｐＯ<sub class="style-scope patent-text">２</sub>の代表的な低酸素状態を用いており［カルツ（Ｋａｌｕｚ）ら、Ｃａｎｃｅｒ  Ｒｅｓ．、６３：９１７−９２２頁（２００３年）］、０．１〜１％ｐＯ<sub class="style-scope patent-text">２</sub>を低酸素状態の「実験的に誘導された範囲」として言及している［Ｃａｎｃｅｒ  Ｒｅｓｅａｒｃｈ、６２：４４６９−４４７７頁（２００２年）］。
</span>Normoxia and hypoxia As used herein, normoxia is defined as the oxygen tension level in a particular mammalian tissue that is within the normal range of physiological oxygen tension levels for that particular tissue in the mammal. Is done. As used herein, “hypoxia” is defined as the level of oxygen tension required to stabilize HIF-1α in a particular tissue or cell. Experimentally induced hypoxia is typically 2% or less and is in the range of pO <sub class="style-scope patent-text">2</sub> above the oxygen deficiency (the oxygen deficiency is 0% pO <sub class="style-scope patent-text">2 which</sub> can be lethal). Examples described herein relating to hypoxia were performed at 2% pO <sub class="style-scope patent-text">2</sub> , which is a typical hypoxia. However, one of ordinary skill in the art will consider other oxygen tension levels that are understood as “hypoxic conditions” and produce similar experimental results. For example, Wykoff et al. [Cancer Research, 60: 7075-7083 (2000)] describes HIF-1α-dependent expression of CA9 using 0.1% pO <sub class="style-scope patent-text">2</sub> as a typical hypoxia. Induced. Tomes et al. Stabilized HIF-1α and CA9 in HeLa cells or human breast fibroblasts under representative in vitro hypoxic conditions of 0.3%, 0.5% and 2.5% pO <sub class="style-scope patent-text">2.</sub> It has been demonstrated that the degree of expression changes [Tomes et al., Br. Cancer Res. Treat. 81 (1): 61-69 (2003)]. Alternatively, Kaluz et al. Have used a typical hypoxic state of 0.5% pO <sub class="style-scope patent-text">2</sub> for experimental induction of CA9 [Kaluz et al., Cancer Res. 63: 917-922 (2003)], referring to 0.1-1% pO <sub class="style-scope patent-text">2</sub> as the “experimentally derived range” of hypoxia [Cancer Research, 62: 4469-4477. (2002)].</span>
    </p>
    <p num="0055" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  上記文献のトームズ（Ｔｏｍｅｓ）らにより示されるように、２％以上のｐＯ<sub class="style-scope patent-text">２</sub>の酸素張力レベルもまた低酸素状態であり得る。当業者は、ＨＩＦ−１α安定化の特定に基づいて、ある状態が本明細書に定義された低酸素状態であるかどうかを特定することができるであろう。特定の組織または細胞における低酸素状態の代表的な範囲は、例えば、約３％から約０．０５％ｐＯ<sub class="style-scope patent-text">２</sub>の間、約２％から約０．１％ｐＯ<sub class="style-scope patent-text">２</sub>の間、約１％から約０．１％ｐＯ<sub class="style-scope patent-text">２</sub>の間、および約０．５％から約０．１％ｐＯ<sub class="style-scope patent-text">２</sub>の間であり得る。
</span>As shown by Tomes et al. In the above document, oxygen tension levels of 2% or more of pO <sub class="style-scope patent-text">2</sub> can also be hypoxic. One skilled in the art will be able to identify whether a condition is a hypoxic condition as defined herein based on the identification of HIF-1α stabilization. Typical ranges of hypoxia in a particular tissue or cell are, for example, between about 3% to about 0.05% pO <sub class="style-scope patent-text">2</sub> , between about 2% to about 0.1% pO <sub class="style-scope patent-text">2</sub> , from about 1% between about 0.1% pO <sub class="style-scope patent-text">2,</sub> and from about 0.5% may be between about 0.1% pO <sub class="style-scope patent-text">2.</sub> </span>
    </p>
    <p num="0056" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ遺伝子およびタンパク質<br class="style-scope patent-text">
  本明細書における用語「ＣＡ ＩＸ」および「ＭＮ／ＣＡ９」は、ＭＮに関する同義語と考えられている。Ｇ２５０抗原は、ＭＮタンパク質／ポリペプチドを称するものと考える。
</span>MN Genes and Proteins The terms “CA IX” and “MN / CA9” herein are considered synonyms for MN. The G250 antigen is considered to refer to the MN protein / polypeptide.</span>
    </p>
    <p num="0057" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの国際公開第９３／１８１５２号パンフレットおよび／または国際公開第９５／３４６５０号パンフレットは、本明細書の図８に示されるＭＮ ｃＤＮＡ配列［配列番号１］、また図８に示されるＭＮアミノ酸配列［配列番号２］、および本明細書の図９に示されるＭＮゲノム配列［配列番号３］について開示している。ＭＮ遺伝子は、１１のエクソンおよび１０のイントロンで構成される。
</span>
&nbsp;&nbsp;Zavada et al., WO 93/18152 and / or WO 95/34650, are the MN cDNA sequence shown in FIG. 8 of the present specification [SEQ ID NO: 1] and shown in FIG. The MN amino acid sequence [SEQ ID NO: 2] and the MN genomic sequence [SEQ ID NO: 3] shown in FIG. 9 herein are disclosed. The MN gene is composed of 11 exons and 10 introns.
</span>
    </p>
    <p num="0058" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図８に示されたＭＮ ｃＤＮＡのＯＲＦは、計算値４９．７ｋｄの分子量を有する４５９のアミノ酸タンパク質に関するコード化能力を有する。ＭＮタンパク質の総アミノ酸組成物はかなり酸性であり、４．３のｐＩを有することが推定される。二次元電気泳動後の免疫ブロット法によるＣＧＬ３からの天然ＭＮタンパク質の分析は、コンピュータ推定と一致して、ＭＮは、４．７から６．３のｐＩ範囲を有する幾つかの等電点形態で存在する酸性タンパク質であることを示している。
</span>
&nbsp;&nbsp;The ORF of the MN cDNA shown in FIG. 8 has a coding capacity for a 459 amino acid protein with a calculated molecular weight of 49.7 kd. It is estimated that the total amino acid composition of the MN protein is fairly acidic and has a pI of 4.3. Analysis of native MN protein from CGL3 by immunoblotting after two-dimensional electrophoresis is consistent with computer estimation that MN is in several isoelectric forms with a pI range of 4.7 to 6.3. It shows that it is an acidic protein that exists.
</span>
    </p>
    <p num="0059" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図８に示されるＭＮタンパク質の最初の３７のアミノ酸は、推定上のＭＮシグナルペプチド［配列番号４］である。ＭＮタンパク質は、細胞外ドメイン［図８のアミノ酸（ａａ）３８〜４１４；配列番号５］、膜貫通ドメイン［ａａ４１５〜４３４；配列番号６］および細胞内ドメイン［ａａ４３５〜４５９；配列番号７］を有する。細胞外ドメインは、プロテオグリカン様ドメイン［ａａ５３〜１１１；配列番号８］および炭酸脱水酵素（ＣＡ）ドメイン［ａａ１３５〜３９１；配列番号９］を含む。
</span>
&nbsp;&nbsp;The first 37 amino acids of the MN protein shown in FIG. 8 is the putative MN signal peptide [SEQ ID NO: 4]. The MN protein comprises an extracellular domain [amino acids (aa) 38 to 414 in FIG. 8; SEQ ID NO: 5], a transmembrane domain [aa 415 to 434; SEQ ID NO: 6] and an intracellular domain [aa 435 to 459; SEQ ID NO: 7]. Have. The extracellular domain includes a proteoglycan-like domain [aa 53-111; SEQ ID NO: 8] and a carbonic anhydrase (CA) domain [aa 135-391; SEQ ID NO: 9].
</span>
    </p>
    <p num="0060" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡドメインは、アンカーに依存しない誘導に必須であるが、一方、ＴＭアンカーおよびＩＣテールは、その生物学的効果にとって不必要である。ＭＮタンパク質はまた、形質移入された細胞内で細胞膜ラッフリングさせることができ、固体支持体への結合に関与すると思われる。このデータは、細胞増殖の調節、接着および細胞間伝達におけるＭＮの関与を示している。
</span>
&nbsp;&nbsp;The CA domain is essential for anchor-independent induction, while the TM anchor and IC tail are unnecessary for its biological effects. The MN protein can also be cell membrane ruffled in transfected cells and appears to be involved in binding to a solid support. This data indicates the involvement of MN in the regulation of cell proliferation, adhesion and intercellular communication.
</span>
    </p>
    <p num="0061" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ遺伝子−クローニングおよび配列決定<br class="style-scope patent-text">
  図８Ａ〜Ｃに、完全長ＭＮ ｃＤＮＡクローンに関するヌクレオチド配列［配列番号１］を提供する。図９Ａ〜Ｆに、完全ＭＮゲノム配列［配列番号３］を提供する。提案されたＭＮプロモーターに関するヌクレオチド配列［配列番号２４］は、図９Ａ〜Ｆのｎｔｓ３００１から３５４０、および図１０に示される。
</span>MN Gene-Cloning and Sequencing FIG. 8A-C provides the nucleotide sequence [SEQ ID NO: 1] for the full-length MN cDNA clone. 9A-F provides the complete MN genomic sequence [SEQ ID NO: 3]. The nucleotide sequence [SEQ ID NO: 24] for the proposed MN promoter is shown in nts 3001 to 3540 of FIGS.</span>
    </p>
    <p num="0062" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  当然のことながら、遺伝子コードの縮退のため、すなわち、１つ以上のコドンが１つのアミノ酸をコードし［例えば、コドンＴＴＡ、ＴＴＧ、ＣＴＴ、ＣＴＣ、ＣＴＡおよびＣＴＧの各々が、アミノ酸のロイシン（ｌｅｕ）をコードする］、例えば、１つのコドンが別のコドンで置換される配列番号１および３におけるヌクレオチド配列の変更は、本発明による実質的に等しいタンパク質またはポリペプチドを生じるであろう。ＭＮ ｃＤＮＡのヌクレオチド配列および相補的核酸配列におけるこのような変更は全て、本発明の範囲内に含まれる。
</span>
&nbsp;&nbsp;Of course, due to the degeneracy of the genetic code, ie, one or more codons encode one amino acid [eg, each of the codons TTA, TTG, CTT, CTC, CTA and CTG is the amino acid leucine (leu. For example, alteration of the nucleotide sequence in SEQ ID NOs: 1 and 3 in which one codon is replaced with another codon will result in a substantially equal protein or polypeptide according to the invention. All such changes in the nucleotide sequence and complementary nucleic acid sequence of the MN cDNA are included within the scope of the present invention.
</span>
    </p>
    <p num="0063" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、当然のことながら、本明細書に記載され、図８、９および１０に示されるヌクレオチド配列は、本明細書で単離され、記載されたｃＤＮＡ、ゲノムおよびプロモーターヌクレオチド配列の正確な構造のみを表している。実質的に同様のまたは相同的ＭＮタンパク質およびポリペプチド、例えば、同様のエピトープを有するものをコードするために、僅かに修飾されたヌクレオチド配列が見出されるか、または当業界に知られた技法により修飾できることが予想され、このようなヌクレオチド配列およびタンパク質／ポリペプチドは、本発明の目的にとって等価物であると考えられる。
</span>
&nbsp;&nbsp;Furthermore, it will be appreciated that the nucleotide sequences described herein and shown in FIGS. 8, 9 and 10 are only the exact structure of the cDNA, genomic and promoter nucleotide sequences isolated and described herein. Represents. Slightly modified nucleotide sequences are found or modified by techniques known in the art to encode substantially similar or homologous MN proteins and polypeptides, such as those having similar epitopes. It is expected that such nucleotide sequences and proteins / polypeptides are considered equivalent for the purposes of the present invention.
</span>
    </p>
    <p num="0064" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質／ポリペプチドに相同的または実質的に相同的なタンパク質／ポリペプチドをコードする合成核酸配列、ならびにストリンジェント条件下、前記代表的配列［配列番号１、３および２４］にハイブリダイズする核酸配列、または遺伝子コードの縮退がなかったら、ストリンジェントなハイブリダイゼーション条件下、前記ｃＤＮＡヌクレオチド配列にハイブリダイズする核酸配列などの、等価コドンを有するＤＮＡまたはＲＮＡは、本発明の範囲内であると考えられる。本明細書に示された核酸配列の修飾および変更は、代表的なＭＮ配列およびその断片と実質的に同じである配列を生じると考えられる。
</span>
&nbsp;&nbsp;Synthetic nucleic acid sequences that encode proteins / polypeptides that are homologous or substantially homologous to MN proteins / polypeptides, and nucleic acids that hybridize to the representative sequences [SEQ ID NOs: 1, 3, and 24] under stringent conditions DNA or RNA having an equivalent codon, such as a nucleic acid sequence that hybridizes to the cDNA nucleotide sequence under stringent hybridization conditions, is considered within the scope of the present invention if there is no sequence or degeneracy of the genetic code. It is done. Modifications and alterations of the nucleic acid sequences presented herein are believed to result in sequences that are substantially the same as the representative MN sequences and fragments thereof.
</span>
    </p>
    <p num="0065" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  少なくとも８０〜９０％、好ましくは少なくとも９０％の相同性を有する極めて密接に関連するｎｔ配列だけが、ストリンジェント条件下、互いにハイブリダイズすると考えられる。図８に示されたＭＮ ｃＤＮＡ配列とヒト炭酸脱水酵素ＩＩ（ＣＡ ＩＩ）の対応するｃＤＮＡの配列比較により、２５以上のヌクレオチドを有するＣＡ ＩＩ ｃＤＮＡ配列のセグメントが、ストリンジェントなハイブリダイゼーション条件下、ＭＮ ｃＤＮＡにハイブリダイズすることまたは逆を可能にする上で十分に長いと考えられる２つの配列間で同一の延伸部分がないことが示された。
</span>
&nbsp;&nbsp;Only very closely related nt sequences with at least 80-90%, preferably at least 90% homology are considered to hybridize to each other under stringent conditions. A sequence comparison of the MN cDNA sequence shown in FIG. 8 and the corresponding cDNA of human carbonic anhydrase II (CA II) shows that a segment of the CA II cDNA sequence having 25 or more nucleotides is under stringent hybridization conditions. It was shown that there were no identical stretches between the two sequences that would be long enough to allow hybridization to the MN cDNA or vice versa.
</span>
    </p>
    <p num="0066" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書におけるストリンジェントなハイブリダイゼーション条件は、ストリンジェントであるとして当該技術分野で理解される標準的なハイブリダイゼーション条件に合致すると考えられる。例えば、当然のことながら一般に、ストリンジェント条件は、５０℃から７０℃の温度で０．０２Ｍから０．１５ＭのＮａＣｌにより提供されるような、比較的低塩条件および／または高温条件を包む。２０℃〜５５℃の温度で０．１５Ｍ〜０．９Ｍ塩のような低ストリンジェント条件は、温度上昇とともにハイブリッド二重鎖を不安定にさせるのに役立つホルムアミド量を増加させて加えることによって、よりストリンジェントにさせることができる。
</span>
&nbsp;&nbsp;Stringent hybridization conditions herein are considered to be consistent with standard hybridization conditions understood in the art as being stringent. For example, it will be appreciated that generally stringent conditions encompass relatively low salt conditions and / or high temperature conditions, such as that provided by 0.02 M to 0.15 M NaCl at a temperature of 50 ° C to 70 ° C. Low stringent conditions such as 0.15 M to 0.9 M salt at a temperature of 20 ° C. to 55 ° C. are added by increasing the amount of formamide that helps to destabilize the hybrid duplex with increasing temperature. It can be made more stringent.
</span>
    </p>
    <p num="0067" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  代表的なストリンジェントなハイブリダイゼーション条件は、サムブルック（Ｓａｍｂｒｏｏｋ）らのＭｏｌｅｃｕｌａｒ  Ｃｌｏｎｉｎｇ：Ａ  Ｌａｂｏｒａｔｏｒｙ  Ｍａｎｕａｌ、１．９１頁および９．４７−９．５１頁（第二版、コールドスプリングハーバー・ラボラトリープレス（Ｃｏｌｄ  Ｓｐｒｉｎｇ  Ｈａｒｂｏｒ  Ｌａｂｏｒａｔｏｒｙ  Ｐｒｅｓｓ）；コールドスプリングハーバー、ニューヨーク州；１９８９年）；マニアチス（Ｍａｎｉａｔｉｓ）ら、Ｍｏｌｅｃｕｌａｒ  Ｃｌｏｎｉｎｇ：Ａ  Ｌａｂｏｒａｔｏｒｙ  Ｍａｎｕａｌ、３８７−３８９頁（コールドスプリングハーバー・ラボラトリー（Ｃｏｌｄ  Ｓｐｒｉｎｇ  Ｈａｒｂｏｒ  Ｌａｂｏｒａｔｏｒｙ）；コールドスプリングハーバー、ニューヨーク州；１９８２年）；ツチヤ（Ｔｓｕｃｈｉｙａ）ら、Ｏｒａｌ  Ｓｕｒｇｅｒｙ，Ｏｒａｌ  Ｍｅｄｉｃｉｎｅ，Ｏｒａｌ  Ｐａｔｈｏｌｏｇｙ、７１（６）：７２１−７２５頁（１９９１年６月）；および米国特許第５，９８９，８３８号明細書、米国特許第５，９７２，３５３号明細書、米国特許第５，９８１，７１１号明細書、ならびに米国特許第６，０５１，２２６号明細書に記載されている。
</span>
&nbsp;&nbsp;Representative stringent hybridization conditions are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, pages 1.91 and 9.47-9.51 (second edition, Cold Spring Harbor Laboratory Press ( Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY; 1989); Maniatis et al., Molecular Cloning: A Laboratory Manual, 387-389 (Cold Spring Harbor Laboratory; Cold Spring Spring; Cold Spring Spring; Harbor, New York; 19 2 years); Tsuchiya et al., Oral Surgary, Oral Medicine, Oral Pathology, 71 (6): 721-725 (June 1991); and US Pat. No. 5,989,838, US Pat. No. 5,972,353, US Pat. No. 5,981,711 and US Pat. No. 6,051,226.
</span>
    </p>
    <p num="0068" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮゲノム配列（配列番号３）を含むプラスミド−Ａ４ａクローンならびにＸＥ１およびＸＥ３サブクローンは、１９９５年６月６日、アメリカン・タイプ・カルチャー・コレクション（ＡＴＣＣ）に、それぞれＡＴＣＣ寄託番号９７１９９、９７２００、および９７１９８として寄託された。
</span>
&nbsp;&nbsp;Plasmid-A4a clones containing the MN genomic sequence (SEQ ID NO: 3) and XE1 and XE3 subclones were obtained from the American Type Culture Collection (ATCC) on June 6, 1995, ATCC deposit numbers 97199, 97200, and Deposited as 97198.
</span>
    </p>
    <p num="0069" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
完全ＭＮゲノム領域のエクソン−イントロン構造<br class="style-scope patent-text">
  オーバーラップクローンの完全配列は、１０，８９８ｂｐ（配列番号３）を含む。ヒトＭＮ遺伝子は、１１のエクソンならびに２つの上流反復要素および６つのイントロンＡｌｕ反復要素を含んでなる。エクソンは全て、４４５ｂｐである第１エクソンを除いて２７ｂｐから１９１ｂｐの範囲と小型である。イントロンのサイズは、８９ｂｐから１４００ｂｐの範囲である。ＣＡドメインは、エクソン２〜８によりコードされ、一方、エクソン１、１０および１１は、それぞれＭＮ／ＣＡ ＩＸタンパク質のプロテオグリカン様ドメイン、膜貫通アンカーおよび細胞質テールに相当する。下表１は、ＡＧ−ＧＴモチーフを含むコンセンサススプライス配列に合致するスプライスドナーおよびアクセプター配列を掲げている［マウント（Ｍｏｕｎｔ）、Ｎｕｃｌｅｉｃ  Ａｃｉｄｓ  Ｒｅｓ．１０：４５９−４７２頁（１９８２年）］。<br class="style-scope patent-text">
<tables num="1" class="style-scope patent-text"> </tables></span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000008" he="212" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="848" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> 
Exon-intron structure of the complete MN genomic region The complete sequence of the overlapping clone contains 10,898 bp (SEQ ID NO: 3). The human MN gene comprises 11 exons and 2 upstream repeat elements and 6 intron Alu repeat elements. All exons are small, ranging from 27 bp to 191 bp, with the exception of the first exon, which is 445 bp. Intron sizes range from 89 bp to 1400 bp. The CA domain is encoded by exons 2-8, while <figure-callout id="1" label="exons" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="11" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout></a></figure-callout> 1, 10 and 11 correspond to the proteoglycan-like domain, transmembrane anchor and cytoplasmic tail of the MN / CA IX protein, respectively. Table 1 below lists splice donor and acceptor sequences that match a consensus splice sequence containing the AG-GT motif [Mount, Nucleic Acids Res. 10: 459-472 (1982)]. <br class="style-scope patent-text"> <tables num="1" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000008" he="212" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="848" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> </tables> 
    <p class="style-scope patent-text"></p>
    <p num="0070" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ遺伝子転写開始部位および終結部位のマッピング<br class="style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの国際公開第９５／３４６５０号パンフレットには、ＭＮ遺伝子転写開始部位および終結部位をマッピングする方法が記載されている。ＲＮアーゼ保護アッセイを、ＭＮ遺伝子の５'末端の精密マッピングに使用した。プローブは、均一に標識された４７０ヌクレオチドコピーＲＮＡ（ｎｔ−２０５から＋２６５）［配列番号６６］であり、そのプローブをＭＮを発現するＨｅＬａ細胞およびＣＧＬ３細胞からの全ＲＮＡにハイブリダイズさせ、配列決定ゲル上で分析した。その分析は、ＭＮ遺伝子転写が複数部位で開始し、最も長いＭＮ転写物の５'末端は、ＲＡＣＥにより以前特徴づけられたものよりも３０ｎｔ長いことを示した。
</span>Mapping of MN Gene Transcription Start and Termination Sites Zavada et al., WO 95/34650, describes a method for mapping MN gene transcription start and termination sites. The RNase protection assay was used for fine mapping of the 5 ′ end of the MN gene. The probe is a uniformly labeled 470 nucleotide copy RNA (nt-205 to +265) [SEQ ID NO: 66], which hybridizes to total RNA from HeLa and CGL3 cells expressing MN and sequenced. Analyzed on gel. The analysis showed that MN gene transcription started at multiple sites and the 5 ′ end of the longest MN transcript was 30 nt longer than that previously characterized by RACE.</span>
    </p>
    <p num="0071" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
マウスＣａｒ９ｃＤＮＡ<br class="style-scope patent-text">
  マウスＣＡ ＩＸをコードするｃＤＮＡおよび遺伝子のクローニングおよび特徴づけは、以前に記載されている［オルトバ−ガット（Ｏｒｔｏｖａ−Ｇｕｔ）ら、Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ、１２３：１８８９−１９０３頁（２００２年）］。マウスＣａｒ９ｃＤＮＡ断片を、ヒトｃＤＮＡ由来のプライマーおよびＣ５７ ＢＬ／６Ｊマウスの胃から単離されたテンプレートＲＮＡを用いてＲＴ  ＰＣＲにより単離した。完全長ｃＤＮＡは、５'／３'双方の方向においてｃＤＮＡ末端の高速増幅により得られた。完全長ｃＤＮＡは、４９ｂｐの５'非翻訳領域、１３１１ｂｐのオープンリーディングフレームおよび６２２ｐの３'非翻訳配列からなる１９８２ｂｐを包含する（登録番号ＡＪ２４５８５７；配列番号７１のもとでＥＭＢＬデータベースに寄託された）。
</span>Mouse Car9 cDNA <br class="style-scope patent-text"> Cloning and characterization of the cDNA and gene encoding mouse CA IX has been described previously [Ortova-Gut et al., Gastroenterology, 123: 1889-1903 (2002)]. The mouse Car9 cDNA fragment was isolated by RT PCR using primers derived from human cDNA and template RNA isolated from the stomach of C57 BL / 6J mice. Full length cDNA was obtained by rapid amplification of the cDNA ends in both 5 ′ / 3 ′ directions. The full-length cDNA includes 1982 bp consisting of 49 bp of 5 ′ untranslated region, 1311 bp of open reading frame and 622 p of 3 ′ untranslated sequence (Accession number AJ245857; deposited in the EMBL database under SEQ ID NO: 71). ).</span>
    </p>
    <p num="0072" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｃａｒ９ ｃＤＮＡは、４７．３ｋＤａの理論的分子量を有する４３７のアミノ酸タンパク質（登録番号ＣＡＣ８０９７５（Ｑ８ＶＤＥ４）；配列番号７３としてＥＭＢＬデータベースに寄託された）のコード能を有する。マウスタンパク質は、そのヒト相同体と６９．５％の配列同一性を示し、同様の推定されたドメイン配列を有する［オパブスキー（Ｏｐａｖｓｋｙ）ら、（１９９６年）］。アミノ酸（ａａ）１〜３１（配列番号７４）は、シグナルペプチドに相当する。成熟タンパク質（ａａ３２〜３８９）（配列番号７５）のＮ末端細胞外領域は、プロテオグリカン様領域（ａａ４８〜１０７）（配列番号７６）、および炭酸脱水酵素ドメイン（ａａ１１２〜３６９）（配列番号７７）からなる。Ｃ末端領域（ａａ３９０〜４３７）（配列番号７８）は、膜貫通アンカー（ａａ３９０〜４１１）（配列番号７９）および短細胞質テール（ａａ４１２〜４３７）（配列番号８０）からなる。マウスＣＡ ＩＸとヒトＣＡ ＩＸとの間の配列相違の大部分は、プロテオグリカン様（ＰＧ）領域内に見られたが、一方、ＣＡドメインは最も高度に保存されていることが明らかとなった。しかしながら、酵素活性部位に関与する５つの重要なアミノ酸（Ｈｉｓ<sup class="style-scope patent-text">９４</sup>、Ｈｉｓ<sup class="style-scope patent-text">９６</sup>、Ｇｌｕ<sup class="style-scope patent-text">１０６</sup>、Ｈｉｓ<sup class="style-scope patent-text">１１９</sup>、Ｔｈｒ<sup class="style-scope patent-text">１９９</sup>）のうち、ヒトＣＡ ＩＸでは全てが保存されるが、マウスのイソ酵素では１つが変化する（Ｔｈｒ<sup class="style-scope patent-text">１９９</sup>→Ｓｅｒ）。その置換にもかかわらず、スルホンアミドアガロースに結合されたマウスＣＡ ＩＸは、酵素活性を有し得ることが示唆される。
</span>The Car9 cDNA has the coding ability of a 437 amino acid protein (registration number CAC80975 (Q8VDE4); deposited in the EMBL database as SEQ ID NO: 73) with a theoretical molecular weight of 47.3 kDa. The mouse protein shows 69.5% sequence identity with its human homolog and has a similar deduced domain sequence [Opavsky et al. (1996)]. Amino acids (aa) 1-31 (SEQ ID NO: 74) correspond to signal peptides. The N-terminal extracellular region of the mature protein (aa32-389) (SEQ ID NO: 75) is derived from the proteoglycan-like region (aa48-107) (SEQ ID NO: 76) and the carbonic anhydrase domain (aa112-369) (SEQ ID NO: 77). Become. The C-terminal region (aa390-437) (SEQ ID NO: 78) consists of a transmembrane anchor (aa390-411) (SEQ ID NO: 79) and a short cytoplasmic tail (aa412-437) (SEQ ID NO: 80). Most of the sequence differences between mouse CA IX and human CA IX were found within the proteoglycan-like (PG) region, while the CA domain was found to be the most highly conserved. However, of the five important amino acids involved in the enzyme active site (His <sup class="style-scope patent-text">94</sup> , His <sup class="style-scope patent-text">96</sup> , Glu <sup class="style-scope patent-text">106</sup> , His <sup class="style-scope patent-text">119</sup> , Thr <sup class="style-scope patent-text">199</sup> ), all are conserved in human CA IX, but one in mouse isoenzymes. Change (Thr <sup class="style-scope patent-text">199</sup> → Ser). Despite the substitution, it is suggested that mouse CA IX conjugated to sulfonamide agarose may have enzymatic activity.</span>
    </p>
    <p num="0073" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｃａｒ９ ｃＤＮＡの利用により、マウス組織におけるＣａｒ９ ｍＲＮＡの発現パターンの分析を可能にした。ＣＡドメインをコードする領域の３'部分を検出するために設計された１７０ｂｐのリボプローブによりリボヌクレアーゼ保護アッセイ（ＲＮＰ）を実施した。ヒトおよびラットの組織における分布に基づいて予想されたとおり、最高レベルのＣａｒ９ ｍＲＮＡが、マウスの胃に検出された。中等度レベルのＣａｒ９ ｍＲＮＡは、小腸および大腸に見られたが、一方、腎臓および脳では、極めて弱い発現を示した。肝臓および脾臓は陰性であった。注目すべきことに、ＲＮＰシグナルはまた、胎仔日齢Ｅ１８．５におけるマウス胎仔に存在したが、Ｅ１０．５における胎仔幹細胞には存在しなかった。これは、マウス胃腸管の発育におけるＣＡ ＩＸに関する役割を示唆し得る。
</span>
&nbsp;&nbsp;Utilization of Car9 cDNA enabled analysis of the expression pattern of Car9 mRNA in mouse tissues. A ribonuclease protection assay (RNP) was performed with a 170 bp riboprobe designed to detect the 3 ′ portion of the region encoding the CA domain. As expected based on distribution in human and rat tissues, the highest levels of Car9 mRNA were detected in the mouse stomach. Moderate levels of Car9 mRNA were found in the small and large intestines, whereas they showed very weak expression in the kidney and brain. Liver and spleen were negative. Of note, the RNP signal was also present in the mouse fetus at fetal age E18.5 but not in the fetal stem cells at E10.5. This may suggest a role for CA IX in the development of the mouse gastrointestinal tract.
</span>
    </p>
    <p num="0074" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
マウスＣａｒ９遺伝子の編成<br class="style-scope patent-text">
  Ｃａｒ９遺伝子を単離し、その編成を特定するために、完全長Ｃａｒ９ ｃＤＮＡを、ｐＢＡＣ１０８Ｌにおけるマウス胎仔幹細胞１２９／Ｏｌａゲノムライブラリーのスクリーニングに用いた。マウス野生型ゲノムＤＮＡの制限マッピングおよびサザンブロット解析により確認されたように、完全Ｃａｒ９ゲノム配列を含む１つのＢＡＣＭ−３５５（Ｇ１３）クローンが得られた。このクローンから誘導された３つのオーバーラップゲノム断片を、ｐブルースクリプトＩＩ ＫＳにサブクローン化した。
</span>Organization of the mouse Car9 gene In order to isolate and identify the organization of the Car9 gene, the full-length Car9 cDNA was used to screen a mouse fetal stem cell 129 / Ola genomic library in pBAC108L. One BACM-355 (G13) clone containing the complete Car9 genomic sequence was obtained, as confirmed by restriction mapping of mouse wild type genomic DNA and Southern blot analysis. Three overlapping genomic fragments derived from this clone were subcloned into pBluescript II KS.</span>
    </p>
    <p num="0075" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ゲノム配列（ＧｅｎＢａｎｋ登録番号ＡＹ０４９０７７；配列番号７２）の分析により、Ｃａｒ９遺伝子は、６．７ｋｂのマウスゲノムを含み、１１のエクソンおよび１０のイントロンからなることが明らかとなった。イントロンの分布およびエクソン対タンパク質ドメインの関係は、ヒトのものと同様である［オパブスキー（Ｏｐａｖｓｋｙ）ら、（１９９６年）］。サザンハイブリダイゼーションパターンにより、Ｃａｒ９が単一コピー遺伝子であることが示された。５．９ｋｂを包含し、プロモーター領域およびエクソン１〜６にわたる大腸菌（ＥｃｏＲｉ）−ＨｉｎｄＩＩＩ断片を、標的ベクターの構築に用いた。
</span>
&nbsp;&nbsp;Analysis of the genomic sequence (GenBank accession number AY049077; SEQ ID NO: 72) revealed that the Car9 gene contains a 6.7 kb mouse genome and consists of 11 exons and 10 introns. The distribution of introns and exon-to-protein domain relationships are similar to those of humans [Opavsky et al. (1996)]. Southern hybridization pattern indicated that Car9 is a single copy gene. An E. coli (EcoRi) -HindIII fragment encompassing the 5.9 kb, spanning the promoter region and exons 1-6 was used for the construction of the target vector.
</span>
    </p>
    <p num="0076" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮタンパク質および／またはポリペプチド<br class="style-scope patent-text">
  語句「ＭＮタンパク質および／またはポリペプチド」（ＭＮタンパク質／ポリペプチド）とは、ＭＮ遺伝子またはその断片によりコードされるタンパク質および／またはポリペプチドを意味するとして本明細書に定義される。本発明による代表的な好ましいＭＮタンパク質は、図８に示される推定アミノ酸配列を有する。好ましいＭＮタンパク質／ポリペプチドは、図８に示されたＭＮタンパク質と実質的に相同性を有するタンパク質および／またはポリペプチドである。例えば、そのような実質的に相同なＭＮタンパク質／ポリペプチドは、本発明のＭＮ特異的抗体、好ましくはＭＡｂ Ｍ７５、Ｖ／１０、ＭＮ１２、ＭＮ９およびＭＮ７またはそれらの等価体と反応性であるものである。Ｍ７５ ｍａｂを分泌するＶＵ−Ｍ７５ハイブリドーマは、１９９２年９月１７日、ＨＢ１１１２８としてＡＴＣＣに寄託された。
</span>MN protein and / or polypeptide The phrase “MN protein and / or polypeptide” (MN protein / polypeptide) is used herein to mean a protein and / or polypeptide encoded by a MN gene or fragment thereof. Defined. An exemplary preferred MN protein according to the present invention has the deduced amino acid sequence shown in FIG. Preferred MN proteins / polypeptides are proteins and / or polypeptides that are substantially homologous to the MN protein shown in FIG. For example, such substantially homologous MN proteins / polypeptides are reactive with the MN-specific antibodies of the invention, preferably MAbs M75, V / 10, MN12, MN9 and MN7 or their equivalents It is. A VU-M75 hybridoma secreting M75 mab was deposited with the ATCC as HB11128 on September 17, 1992.</span>
    </p>
    <p num="0077" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「ポリペプチド」または「ペプチド」は、ペプチド結合により共有結合したアミノ酸の鎖であり、本明細書において５０以下のアミノ酸からなると考えられている。「タンパク質」は、本明細書において５０以上のアミノ酸からなるポリペプチドであると定義される。用語のポリペプチドは、用語のペプチドおよびオリゴペプチドを包含する。本明細書に用いられる「ＡＳのＭＮ／ＣＡ ＩＸ」、「ＡＳのＣＡ ＩＸ」または「ＡＳのＭＮ」とは、ＡＳ型のＭＮ／ＣＡ９ ｍＲＮＡによりコードされたタンパク質および／またはポリペプチドのことである。
</span>
&nbsp;&nbsp;A “polypeptide” or “peptide” is a chain of amino acids covalently linked by peptide bonds and is herein considered to consist of 50 or fewer amino acids. A “protein” is defined herein as a polypeptide of 50 or more amino acids. The term polypeptide encompasses the terms peptides and oligopeptides. As used herein, “AS MN / CA IX”, “AS CA IX” or “AS MN” refers to a protein and / or polypeptide encoded by an AS-type MN / CA9 mRNA. is there.
</span>
    </p>
    <p num="0078" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質は、幾つかの興味深い特徴：細胞膜局在性、ＨｅＬａ細胞における細胞密度依存的な発現、ＨｅＬａ×線維芽細胞体細胞ハイブリッドの腫瘍形成表現型との関連性、および数ある組織の中で、多くのヒト癌における発現を示す。ＭＮタンパク質は、一般に対応する正常な組織には認められないが、腫瘍組織切片では直接見ることができる（正常な胃粘膜および胆嚢組織のような上記の例外）。ＭＮはまた、形成異常および／または悪性疾患を示す組織検体の形態学的には正常に見える領域に時に発現する。まとめると、これらの特徴は、細胞増殖、分化および／または悪性転換の調節におけるＭＮの関与を示している。
</span>
&nbsp;&nbsp;The MN protein has several interesting features: cell membrane localization, cell density-dependent expression in HeLa cells, association with the tumorigenic phenotype of HeLa x fibroblast somatic cell hybrids, and in a number of tissues Shows expression in many human cancers. MN protein is generally not found in corresponding normal tissue, but can be seen directly in tumor tissue sections (the above exceptions such as normal gastric mucosa and gallbladder tissue). MN is also sometimes expressed in morphologically normal areas of tissue specimens that exhibit dysplasia and / or malignancy. Taken together, these features indicate the involvement of MN in the regulation of cell proliferation, differentiation and / or malignant transformation.
</span>
    </p>
    <p num="0079" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  インビボで新生物細胞により産生されるタンパク質またはポリペプチドは、細胞培養における腫瘍細胞により、または形質転換細胞により産生されるタンパク質またはポリペプチドとは、配列が変化し得ることを認識できる。したがって、限定はしないが、アミノ酸置換、伸長、欠失、切断およびそれらの組合せなど、アミノ酸配列を変化させたＭＮタンパク質および／またはポリペプチドは、本発明の範囲内に入る。体液中に存在するタンパク質は、タンパク質分解プロセスなどの分解プロセスに供されることもまた認識することができ；したがって、著しく切断されているＭＮタンパク質およびＭＮポリペプチドが、血清などの体液中に認められる。語句「ＭＮ抗原」は、本明細書では、ＭＮタンパク質および／またはポリペプチドを包含するものとして使用される。
</span>
&nbsp;&nbsp;It can be appreciated that proteins or polypeptides produced by neoplastic cells in vivo can change sequence from those produced by tumor cells in cell culture or by transformed cells. Accordingly, MN proteins and / or polypeptides with altered amino acid sequences such as, but not limited to, amino acid substitutions, extensions, deletions, truncations and combinations thereof are within the scope of the invention. It can also be recognized that proteins present in bodily fluids are subjected to degradation processes such as proteolytic processes; thus, highly cleaved MN proteins and MN polypeptides are found in bodily fluids such as serum. It is done. The phrase “MN antigen” is used herein to encompass MN proteins and / or polypeptides.
</span>
    </p>
    <p num="0080" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質およびポリペプチドのアミノ酸配列は、遺伝子操作により修飾され得ることがさらに認識されるであろう。１つ以上のアミノ酸を欠失させまたは置換することができる。そのようなアミノ酸の変化は、タンパク質またはポリペプチドの生物学的活性における測定可能な変化は生じさせず、本発明の範囲内にあるタンパク質またはポリペプチド、ならびにＭＮ突然変異タンパク質を生じ得る。
</span>
&nbsp;&nbsp;It will further be appreciated that the amino acid sequences of MN proteins and polypeptides can be modified by genetic engineering. One or more amino acids can be deleted or substituted. Such amino acid changes do not cause measurable changes in the biological activity of the protein or polypeptide, and may result in proteins or polypeptides within the scope of the invention, as well as MN muteins.
</span>
    </p>
    <p num="0081" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明のＭＮタンパク質およびポリペプチドは、本発明による種々の方法、例えば、組換え的、合成的、あるいは生物学的に、すなわちより長いタンパク質およびポリペプチドを酵素的および／または化学的に開裂させることにより、調製することができる。ＭＮタンパク質を調製するための好ましい方法は、組換え手法によるものである。
</span>
&nbsp;&nbsp;The MN proteins and polypeptides of the present invention can be subjected to various methods according to the present invention, for example, recombinantly, synthetically, or biologically, i.e., enzymatically and / or chemically cleave longer proteins and polypeptides. Can be prepared. A preferred method for preparing MN protein is by recombinant techniques.
</span>
    </p>
    <p num="0082" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮタンパク質およびポリペプチドの組換え製造<br class="style-scope patent-text">
  ＭＮタンパク質、例えば、図８に示されたようなＭＮタンパク質またはその断片を調製するための代表的な方法は、ＭＮ ｃＤＮＡの完全長または適切な断片を、適切な発現ベクター内に挿入することであると考えられる。ザバダ（Ｚａｖａｄａ）らの国際公開第９３／１８１５２号パンフレットには、ベクターｐＧＥＸ−３Ｘ（ファルマシア（Pharmacia）社）の部分的ｃＤＮＡを用いて融合タンパク質ＧＥＸ−３Ｘ−ＭＮ（現在はＧＳＴ−ＭＮと称される）の製造について記載されている。ＸＬ１−ブルー細胞に由来する非グリコシル化ＧＳＴ−ＭＮ（ＭＮ融合タンパク質ＭＮグルタチオンＳ−トランスフェラーゼ）。
</span>Recombinant production of MN proteins and polypeptides Representative methods for preparing MN proteins, eg, MN proteins or fragments thereof as shown in FIG. 8, include the full length or appropriate fragments of MN cDNA, This is considered to be inserted into an appropriate expression vector. Zavada et al., WO 93/18152, uses a partial cDNA of the vector pGEX-3X (Pharmacia) to name the fusion protein GEX-3X-MN (now called GST-MN). )) Is described. Non-glycosylated GST-MN (MN fusion protein MN glutathione S-transferase) derived from XL1-blue cells.</span>
    </p>
    <p num="0083" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｖａｄａ）らの国際公開第９５／３４６５０号パンフレットには、昆虫細胞から発現されたグリコシル化ＭＮタンパク質および発現プラスミドｐＥｔ−２２ｂ［ノバジェン（Novagen）社（米国ウィスコンシン州マジソン所在）］を用いて大腸菌（Ｅ．ｃｏｌｉ）から発現された非グリコシル化ＭＮタンパク質双方の組換え製造が記載されている。組換えバキュロウィルス発現ベクターは、昆虫細胞を感染させるために使用された。グリコシル化ＭＮ２０−１９タンパク質は、バキュロウィルス感染ｓｆ９細胞［クロンテック（Clontech）社（米国カリフォルニア州パロアルト所在）］において組換え的に製造された。
</span>
&nbsp;&nbsp;Zavada et al., WO 95/34650, uses glycosylated MN protein expressed from insect cells and the expression plasmid pEt-22b [Novagen (Madison, Wis., USA)]. Recombinant production of both non-glycosylated MN proteins expressed from E. coli has been described. A recombinant baculovirus expression vector was used to infect insect cells. Glycosylated MN20-19 protein was produced recombinantly in baculovirus infected sf9 cells [Clontech (Palo Alto, Calif.)].
</span>
    </p>
    <p num="0084" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ特異的抗体の調製<br class="style-scope patent-text">
  用語の「抗体」は、抗体全体のみならず抗体の生物学的活性断片、好ましくは抗原結合性領域を含む断片を含むように本明細書に定義されている。ＭＮタンパク質および別の組織特異抗原に特異的である二重特異性抗体が、抗体の定義にさらに含まれる。
</span>Preparation of MN-specific antibodies The term “antibody” is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments comprising an antigen binding region. Bispecific antibodies that are specific for the MN protein and another tissue specific antigen are further included in the definition of antibodies.</span>
    </p>
    <p num="0085" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明の方法に従った有用な抗体は、従来の方法論および／または遺伝子工学により調製することができる。抗体断片は、好ましくは、超可変領域等の、軽鎖および／または重鎖（Ｖ<sub class="style-scope patent-text">Ｈ</sub>およびＶ<sub class="style-scope patent-text">Ｌ</sub>）の可変領域、さらにより好ましくは、Ｖ<sub class="style-scope patent-text">Ｈ</sub>およびＶ<sub class="style-scope patent-text">Ｌ</sub>双方の領域から遺伝子操作することができる。例えば、本明細書に用いられる用語の「抗体」は、他の可能性の中でも「一価抗体」；共有結合であろうと非共有結合であろうともＦａｂ'およびＦ（ａｂ）<sub class="style-scope patent-text">２</sub>断片を含むＦａｂタンパク質；軽鎖または重鎖単独、好ましくは、可変重鎖領域および可変軽鎖領域（Ｖ<sub class="style-scope patent-text">Ｈ</sub>およびＶ<sub class="style-scope patent-text">Ｌ</sub>領域）、より好ましくは、超可変領域［あるいは、Ｖ<sub class="style-scope patent-text">Ｈ</sub>およびＶ<sub class="style-scope patent-text">Ｌ</sub>領域の相補性決定領域（ＣＤＲ）として知られている］を含み；１つ以上の抗原に結合できる「ハイブリッド」抗体；定常領域−可変領域のキメラ、異なる起源の重鎖および軽鎖を有する「複合」免疫グロブリン；特異性の改善および標準的な組換え技法、またオリゴヌクレオチド特異的変異誘発技法により調製された他の特徴を有する「改変」抗体などのポリクローナル抗体ならびにモノクローナル抗体および生物学的に活性なそれらの断片を含む［ダルバディー−マクファリアンド（Ｄａｌｂａｄｉｅ−ＭａｃＦａｒｌａｎｄ））ら、「Ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ−ｄｉｒｅｃｔｅｄ  ｍｕｔａｇｅｎｅｓｉｓ  ａｓ  ａ  ｇｅｎｅｒａｌ  ａｎｄ  ｐｏｗｅｒｆｕｌ  ｍｅｔｈｏｄ  ｆｏｒ  ｓｔｕｄｉｅｓ  ｏｆ  ｐｒｏｔｅｉｎ  ｆｕｎｃｔｉｏｎ」、ＰＮＡＳ  ＵＳＡ  ７９：６４０９頁（１９８２年）］。
</span>Useful antibodies according to the methods of the invention can be prepared by conventional methodologies and / or genetic engineering. Antibody fragments are preferably genetically engineered from the variable region of the light and / or heavy chain (V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> ), such as the hypervariable region, and even more preferably from both the V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> regions. it can. For example, the term “antibody” as used herein includes, among other possibilities, “monovalent antibodies”; Fab ′ and F (ab) <sub class="style-scope patent-text">2</sub> fragments, whether covalent or non-covalent. Fab protein; light chain or heavy chain alone, preferably variable heavy chain region and variable light chain region (V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> region), more preferably hypervariable region [or complementarity of V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> regions A “hybrid” antibody that can bind to one or more antigens; a constant region-variable region chimera, a “complex” immunoglobulin having heavy and light chains of different origin Polyclonal antibodies such as “modified” antibodies with improved specificity and other characteristics prepared by standard recombination techniques, as well as oligonucleotide-specific mutagenesis techniques, and monochrome Null antibodies and biologically active fragments thereof [Dalbadie-MacFarland et al., "Oligonuclide-directed mutagenesis as a general method in A stu- dent of the United States 79," 6409 (1982)].</span>
    </p>
    <p num="0086" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  多数の使用に関して、特に医薬品用、またはインビボ追跡用の使用に関して、部分的またはより好ましくは、完全なヒト化抗体および／または生物学的に活性な抗体断片が、特に最も適切であることが見出され得る。このようなヒト化抗体／抗体断片は、当業界に周知の方法により調製することができる。
</span>
&nbsp;&nbsp;For many uses, especially for pharmaceutical or in vivo tracking uses, partially or more preferably fully humanized antibodies and / or biologically active antibody fragments have been found to be particularly suitable. Can be issued. Such humanized antibodies / antibody fragments can be prepared by methods well known in the art.
</span>
    </p>
    <p num="0087" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮタンパク質／ポリペプチドを同定するために本発明に従った有用な抗体は、従来の様式、例えば、西洋わさびペルオキシダーゼ（ＨＲＰ）などの酵素、蛍光化合物、または多くの他の標識があるが、中でも<sup class="style-scope patent-text">１２５</sup>Ｉなどの放射性同位元素により標識化することができる。本発明による好ましい標識は<sup class="style-scope patent-text">１２５</sup>Ｉであり、抗体を標識する好ましい方法は、クロラミン−Ｔの使用によるものである［ハンター，Ｗ．Ｍ．（Ｈｕｎｔｅｒ，Ｗ．Ｍ．）、Ｈａｎｄｂｏｏｋ  ｏｆ  Ｅｘｐｅｒｉｍｅｎｔａｌ  Ｉｍｍｕｎｏｌｏｇｙ１４．１−１４．４０頁における「Ｒａｄｉｏｉｍｍｕｎｏａｓｓａｙ」（Ｄ．Ｗ．ウェア（Ｄ．Ｗ．Ｗｅｉｒ）編集；ブラックウェル（Ｂｌａｃｋｗｅｌｌ）、オックスフォード／ロンドン／エジンバラ／メルボルン；１９７８年）］。他の代表的な標識としては、例えば、多くの他の可能性があるが、中でもアロフィコシアニンおよびフィコエリトリンを挙げることができる。
</span>Antibodies useful in accordance with the present invention to identify MN proteins / polypeptides are in a conventional manner, for example, enzymes such as horseradish peroxidase (HRP), fluorescent compounds, or many other labels, among others It can be labeled with a radioisotope such as <sup class="style-scope patent-text">125</sup> I. The preferred label according to the invention is <sup class="style-scope patent-text">125</sup> I and the preferred method for labeling antibodies is by the use of chloramine-T [Hunter, W., et al. M.M. (Hunter, W.M.), Handbook of Experimental Immunology 14.1-14.40, “Radioimmunoassay” (DW Weir edited by Blackwell, Oxford / London / Edinburgh) / Melbourne; 1978)]. Other representative labels include, for example, many other possibilities, among others allophycocyanin and phycoerythrin.</span>
    </p>
    <p num="0088" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ザバダ（Ｚａｂａｄａ）らの国際公開第９３／１８１５２号パンフレットおよび国際公開第９５／３４６５０号パンフレットには、ＭＮ特異的抗体を製造するための詳細な方法、およびＭ７５、ＭＮ７、ＭＮ９、ならびにＭＮ１２モノクローナル抗体として代表的なＭＮ特異的抗体を調製するための詳細なステップが記載されている。
</span>
&nbsp;&nbsp;Zabada et al., WO 93/18152 and WO 95/34650, describe detailed methods for producing MN-specific antibodies, and M75, MN7, MN9, and MN12 monoclonal antibodies. Detailed steps for preparing representative MN-specific antibodies are described.
</span>
    </p>
    <p num="0089" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
エピトープ<br class="style-scope patent-text">
  エピトープを含むペプチドに対するＭＡｂの親和性は、文脈において、例えば、そのペプチドが、短い配列（４〜６のａａ）であるかどうか、またはこのような短ペプチドが、片側または両側に、より長いａａ配列によってフランクされているかどうか、またはエピトープに関する試験において、そのペプチドが溶液中にあるか、または表面に固定されているかどうかによって決まる。したがって、ＭＮ特異的ＭＡｂに関して本明細書に記載された代表的なエピトープは、これらＭＡｂの使用の文脈において変わり得ることが当業者によって予想されるであろう。
</span>Epitope The affinity of a MAb for a peptide containing an epitope is, in context, for example, whether the peptide is a short sequence (4-6 aa) or if such a short peptide is longer on one or both sides. It depends on whether it is flanked by aa sequences or whether the peptide is in solution or immobilized on the surface in testing for epitopes. Thus, it will be expected by those skilled in the art that the representative epitopes described herein for MN-specific MAbs can vary in the context of the use of these MAbs.</span>
    </p>
    <p num="0090" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  用語の「ＭＮタンパク質／ポリペプチドのエピトープに相当する」は、ある場合において、天然タンパク質またはポリペプチドのアミノ酸配列の変更が、抗原性であり、新生物疾患に対する防御免疫および／または抗腫瘍形成効果を付与し得る実用的な可能性を含むことが理解されるであろう。可能な配列変更としては、限定はしないが、アミノ酸置換、伸長、欠失、切断、内挿およびそれらの組合せが挙げられる。このような変更を含むタンパク質またはポリペプチドが免疫原性であり、このようなポリペプチドまたはタンパク質によって誘発された抗体が、ワクチンとして投与された場合に防御免疫および／または抗腫瘍形成活性を提供するのに十分な程度に、天然ＭＮタンパク質およびポリペプチドと交差反応するという条件で、このような変更は本発明の考慮された範囲内に入る。
</span>
&nbsp;&nbsp;The term “corresponds to an epitope of a MN protein / polypeptide” in some cases is that the alteration of the amino acid sequence of the native protein or polypeptide is antigenic and has a protective immunity and / or anti-tumorigenic effect against neoplastic disease It will be understood that it includes practical possibilities that can be given. Possible sequence alterations include, but are not limited to, amino acid substitutions, extensions, deletions, truncations, interpolations and combinations thereof. Proteins or polypeptides containing such alterations are immunogenic, and antibodies elicited by such polypeptides or proteins provide protective immunity and / or anti-tumorigenic activity when administered as a vaccine Such modifications fall within the contemplated scope of the invention, provided that they cross-react with native MN proteins and polypeptides to a sufficient extent.
</span>
    </p>
    <p num="0091" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＰＧドメインおよび隣接領域における免疫優性エピトープ<br class="style-scope patent-text">
  上記のとおり、完全長ＣＡ ＩＸの細胞外ドメインは、ＰＧおよびＣＡドメインならびに幾つかのスペーサーあるいはヒンジ領域を含んでなる。ＣＡ ＩＸの免疫優性エピトープは、主として約ａａ５３〜１１１（配列番号８）または約ａａ５２〜１２５（配列番号８１）におけるＰＧ領域にあり、好ましくはここでは約ａａ５２〜１２５（配列番号８１）にあると考えられる。ＣＡ ＩＸの免疫優性エピトープは、ＰＧ領域に隣接する領域に位置し得る。例えば、ａａ３６〜５１（配列番号２１）に関するエピトープは、免疫優性エピトープであると考えられるであろう。
</span>Immunodominant epitopes in the PG domain and adjacent regions As described above, the extracellular domain of full-length CA IX comprises the PG and CA domains and several spacer or hinge regions. The immunodominant epitope of CA IX is mainly in the PG region at about aa 53-111 (SEQ ID NO: 8) or about aa 52-125 (SEQ ID NO: 81), preferably here at about aa 52-125 (SEQ ID NO: 81) Conceivable. The immunodominant epitope of CA IX can be located in a region adjacent to the PG region. For example, the epitope for aa 36-51 (SEQ ID NO: 21) would be considered an immunodominant epitope.</span>
    </p>
    <p num="0092" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  主要なＣＡ ＩＸの免疫優性エピトープは、Ｍ７５ ｍａｂに対するものである。Ｍ７５モノクローナル抗体は、ＣＡ ＩＸのＮ末端プロテオグリカン様（ＰＧ）領域における免疫優性エピトープに特異的であると考えられる。アミノ酸配列の整列により、ＭＮ／ＣＡ ＩＸタンパク質ＰＧ領域（ａａ５３〜１１１）［配列番号８］とヒトアグリカン（ａａ７８１〜８３９）［配列番号１０］との間でかなりの相同性が示される。Ｍ７５のエピトープは、ＣＡ ＩＸのＮ末端ＰＧ領域において４回等しく反復されているアミノ酸配列ＰＧＥＥＤＬＰ（配列番号１１）として同定されている［Ｚａｖａｄａ（ザバダ）ら（２０００年）］。代表的な免疫優性エピトープでもあり、Ｍ７５ ｍａｂも結合し得る密接に関連するエピトープとして、例えば、推定ＣＡ ＩＸアミノ酸配列を示す図８Ａ〜８Ｃのアミノ酸（ａａ）６１〜９６（配列番号１２）に見ることができる免疫優性の６回タンデム反復が挙げられる。ＰＧドメイン内の免疫優性のタンデム反復エピトープの変異としては、ＧＥＥＤＬＰ（配列番号１３）（ａａ６１〜６６、ａａ７９〜８４、ａａ８５〜９０およびａａ９１〜９６）、ＥＥＤＬ（配列番号１４）（ａａ６２〜６５、ａａ８０〜８３、ａａ８６〜８９、ａａ９２〜９５）、ＥＥＤＬＰ（配列番号１５）（ａａ６２〜６６、ａａ８０〜８４、ａａ８６〜９０、ａａ９２〜９６）、ＥＤＬＰＳＥ（配列番号１６）（ａａ６３〜６８）、ＥＥＤＬＰＳＥ（配列番号１７）（ａａ６２〜６８）、ＤＬＰＧＥＥ（配列番号１８）（ａａ８２〜８７、ａａ８８〜９８）、ＥＥＤＬＰＳ（配列番号１９）（ａａ６２〜６７）およびＧＥＤＤＰＬ（配列番号２０）（ａａ５５〜６０）が挙げられる。他の免疫優性エピトープとしては、例えば、ａａ６８〜９１（配列番号２２）が挙げられるであろう。
</span>
&nbsp;&nbsp;The major CA IX immunodominant epitope is for the M75 mab. The M75 monoclonal antibody appears to be specific for an immunodominant epitope in the N-terminal proteoglycan-like (PG) region of CA IX. Amino acid sequence alignments show considerable homology between the MN / CA IX protein PG region (aa 53-111) [SEQ ID NO: 8] and human aggrecan (aa 781-839) [SEQ ID NO: 10]. The epitope for M75 has been identified as the amino acid sequence PGEEDLP (SEQ ID NO: 11) that is repeated four times equally in the N-terminal PG region of CA IX [Zavada et al. (2000)]. As closely related epitopes that are also representative immunodominant epitopes and can also bind M75 mab, see for example amino acids (aa) 61-96 (SEQ ID NO: 12) in FIGS. 8A-8C showing the putative CA IX amino acid sequence. 6 tandem repeats of immunodominance that can be mentioned. Mutations of the immunodominant tandem repeat epitope within the PG domain include GEEDLP (SEQ ID NO: 13) (aa 61-66, aa 79-84, aa 85-90 and aa 91-96), EEDL (SEQ ID NO: 14) (aa 62-65, aa 80-83, aa 86-89, aa 92-95), EEDLP (SEQ ID NO: 15) (aa 62-66, aa 80-84, aa 86-90, aa 92-96), EDLPSE (SEQ ID NO: 16) (aa 63-68), EEDLPSE (SEQ ID NO: 17) (aa 62-68), DLPGEE (SEQ ID NO: 18) (aa 82-87, aa 88-98), EEDLPS (SEQ ID NO: 19) (aa 62-67) and GEDDPL (SEQ ID NO: 20) (aa 55-60) Is mentioned. Other immunodominant epitopes may include, for example, aa68-91 (SEQ ID NO: 22).
</span>
    </p>
    <p num="0093" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  モノクローナル抗体ＭＮ９およびＭＮ１２は、それぞれＮ末端ＰＧ領域の配列番号１９〜２０内の免疫優性エピトープに特異的であると考えられる。ＭＮ７モノクローナル抗体は、図８Ａ〜８Ｃのａａ１２７〜１４７（配列番号２３）においてＰＧ領域に隣接する免疫優性エピトープに特異的であり得る。
</span>
&nbsp;&nbsp;Monoclonal antibodies MN9 and MN12 are believed to be specific for immunodominant epitopes within SEQ ID NOs: 19-20, respectively, of the N-terminal PG region. The MN7 monoclonal antibody can be specific for an immunodominant epitope adjacent to the PG region in aa127-147 (SEQ ID NO: 23) of FIGS.
</span>
    </p>
    <p num="0094" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡドメイン（配列番号９）内で好ましいと考えられるエピトープは、約ａａ２７９〜２９１（配列番号６７）に由来する。細胞内ドメイン（ＩＣドメイン）（配列番号７）内で好ましいと考えられるエピトープは、約ａａ４３５〜４５０（配列番号６８）に由来する。
</span>
&nbsp;&nbsp;An epitope considered to be preferred within the CA domain (SEQ ID NO: 9) is derived from about aa 279-291 (SEQ ID NO: 67). An epitope considered to be preferred within the intracellular domain (IC domain) (SEQ ID NO: 7) is derived from about aa435-450 (SEQ ID NO: 68).
</span>
    </p>
    <p num="0095" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  配列番号６９（図８Ａ〜８Ｃのａａ１６６〜３９７）は、ＣＡドメインの重要な抗原性成分であると考えられる。ＣＡドメイン内には幾つかの抗原性部位がある。ＣＡドメインに特異的になるように、ＣＡ ＩＸ欠失マウスにおいて調製された４つの群のＣＡ ＩＸ特異的モノクローナル抗体があり；これらの群のうちの３つの群は配列番号６９に対するものである。抗原性部位は、アミノ酸１３５〜１６６（配列番号８４）にもまた部分的に位置し得る。ＭＮタンパク質の炭酸脱水酵素ドメインに特異的に結合する代表的な好ましいＭＮ特異的抗体は、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０ Ｍａｂである。
</span>
&nbsp;&nbsp;SEQ ID NO: 69 (aa 166-397 in FIGS. 8A-8C) is believed to be an important antigenic component of the CA domain. There are several antigenic sites within the CA domain. There are four groups of CA IX specific monoclonal antibodies prepared in CA IX deficient mice to be specific for the CA domain; three of these groups are directed to SEQ ID NO: 69. The antigenic site may also be located partially at amino acids 135-166 (SEQ ID NO: 84). A representative preferred MN-specific antibody that specifically binds to the carbonic anhydrase domain of the MN protein is produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP in Ghent, Belgium under accession number LMBP6009CB. V / 10 Mab.
</span>
    </p>
    <p num="0096" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
アッセイ<br class="style-scope patent-text">
組織中のＡＳおよびＦＬのＭＮ／ＣＡ ＩＸ発現に関するスクリーンのためのアッセイ<br class="style-scope patent-text">
  この方法は、もしあれば、前新生物疾患／新生物疾患と診断された患者から採取したサンプルに存在するＡＳおよび／またはＦＬのＭＮ／ＣＡ９遺伝子発現産物に関するスクリーニングを含むことができ；ＭＮ／ＣＡ９遺伝子発現産物は、ＭＮタンパク質、ＭＮポリペプチド、ＭＮタンパク質またはＭＮポリペプチドをコードするｍＲＮＡ、ＭＮタンパク質またはＭＮポリペプチドをコードするｍＲＮＡに相当するＡＳまたはＦＬ型のｃＤＮＡであり得る。
</span>Assay for Screening for AS and FL MN / CA IX Expression in Tissue This method is a method for measuring AS and / or presence in samples taken from patients diagnosed with preneoplastic / neoplastic disease, if any. Or screening for FL MN / CA9 gene expression products; MN / CA9 gene expression products may include MN protein, MN polypeptide, MN protein or mRNA encoding MN polypeptide, MN protein or MN polypeptide. It may be AS or FL type cDNA corresponding to the encoded mRNA.</span>
    </p>
    <p num="0097" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  多数のフォーマットを、本発明の方法による使用に適応させることができる。ＡＳおよび／またはＦＬのＭＮ ｍＲＮＡの検出および定量化は、例えば、ＰＣＲ、ＲＴ−ＰＣＲ、リアルタイムＰＣＲまたは定量的リアルタイムＲＴ−ＰＣＲなどの核酸増幅法により実施することができるか、またはマイクロアレイチップの使用により実施することができる。ＡＳおよび／またはＦＬのＭＮタンパク質またはＭＮポリペプチドの検出および定量化は、当該技術分野で一般に公知のアッセイは他にもあるが、中でもウェスタンブロット、酵素結合免疫吸着アッセイ、放射免疫アッセイ、競合免疫アッセイ、デュアル抗体サンドイッチアッセイ、免疫組織化学染色アッセイ、凝集アッセイ、蛍光免疫アッセイ、免疫電子顕微鏡および免疫金を用いる走査型顕微鏡により実施することができる。このようなアッセイにおけるＭＮ ＡＳおよび／またはＦＬ遺伝子発現産物の検出は、当該技術分野で公知の従来法により適応させることができる。
</span>
&nbsp;&nbsp;A number of formats can be adapted for use with the method of the present invention. Detection and quantification of AS and / or FL MN mRNA can be performed, for example, by nucleic acid amplification methods such as PCR, RT-PCR, real-time PCR or quantitative real-time RT-PCR, or use of a microarray chip Can be implemented. Detection and quantification of AS and / or FL MN protein or MN polypeptide is amongst other assays generally known in the art, among others, Western blot, enzyme-linked immunosorbent assay, radioimmunoassay, competitive immunity Assays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, fluorescent immunoassays, immunoelectron microscopes and scanning microscopes using immunogold can be performed. Detection of MN AS and / or FL gene expression products in such assays can be adapted by conventional methods known in the art.
</span>
    </p>
    <p num="0098" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
核酸プローブおよび／またはプライマー<br class="style-scope patent-text">
  本発明の核酸プローブおよび／またはプライマーは、図８に示されたＭＮ ｃＤＮＡ配列［配列番号１］または図９Ａ〜Ｆの完全ゲノム配列［配列番号３］等の他のＭＮ遺伝子配列に、相補的または実質的に相補的である配列を含むものである。語句の「実質的に相補的」は、当該技術分野で十分に理解され、したがって標準的なハイブリダイゼーション条件の文脈において用いられる意味を有するように本明細書に定義される。ハイブリダイゼーション条件のストリンジェンシーは、相補性の精度を制御するために調整することができる。２つの核酸は、例えば、それらがストリンジェントなハイブリダイゼーション条件下で互いにハイブリダイズする場合、互いに実質的に相補的である。上記に示したように、少なくとも８０〜９０％、好ましくは少なくとも９０％の相同性を有する極めて密接に関連するｎｔ配列だけが、ストリンジェントな条件下で互いにハイブリダイズすると考えられる。
</span>Nucleic acid probes and / or primers The nucleic acid probes and / or primers of the present invention can be used for other MNs such as the MN cDNA sequence shown in FIG. 8 [SEQ ID NO: 1] or the complete genomic sequence of FIGS. A gene sequence includes a sequence that is complementary or substantially complementary. The phrase “substantially complementary” is defined herein to have the meaning that is well understood in the art and thus used in the context of standard hybridization conditions. The stringency of hybridization conditions can be adjusted to control the accuracy of complementarity. Two nucleic acids are substantially complementary to each other, for example, if they hybridize to each other under stringent hybridization conditions. As indicated above, only very closely related nt sequences with at least 80-90%, preferably at least 90% homology are considered to hybridize to each other under stringent conditions.</span>
    </p>
    <p num="0099" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明に使用される特に好ましいプローブおよび／またはプライマーは、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡ発現と、選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡ発現とを識別するプローブおよび／またはプライマーである。最近の多数の論文は、癌における選択的スプライシングに関する一般情報、および癌関連遺伝子により発現されたｍＲＮＡ変異体を検出するために使用された特定のプローブおよび／またはプライマーの設計に関する特定の情報を提供しており、そこからプローブおよび／またはプライマーが、ＡＳおよび／またはＦＬ ＣＡ９ ｍＲＮＡ変異体を検出するために設計され得る［例えば、マトリン（Ｍａｔｌｉｎ）ら、Ｎａｔ  Ｒｅｖ  Ｍｏｌ  Ｃｅｌｌ  Ｂｉｏｌ．６：３８６−３９８頁（２００５年）；ベナブルスＪＰ（Ｖｅｎａｂｌｅｓ  ＪＰ）、ＢｉｏＥｓｓａｙｓ、２８：３７８−３８６頁（２００６年）；スコセイム（Ｓｃｏｔｈｅｉｍ）およびネス（Ｎｅｅｓ）、Ｉｎｔ  Ｊ  Ｂｉｏｃｈｅｍ  Ｃｅｌｌ  Ｂｉｏｌ．、３９（７−８）：１４３２−１４４９頁（２００７年）；スレブロウ（Ｓｒｅｂｒｏｗ）およびコーンブリット（Ｋｏｒｎｂｌｉｈｔｔ）、Ｊ  Ｃｅｌｌ  Ｓｃｉ．、１１９（第１３部）：２６３５−２６４１頁（２００６年）；ゴーシー（Ｇｏｔｈｉｅ）ら、Ｊ  Ｂｉｏｌ  Ｃｈｅｍ．２７５：６９２２−６９２７頁（２０００年）；ロビンソン（Ｒｏｂｉｎｓｏｎ）ら、Ｊ  Ｃｅｌｌ  Ｓｃｉ．、１１４：８５３−８６５頁（２００１年）；フー（Ｈｅ）ら、Ｏｎｃｏｇｅｎｅ、２５：２１９２−２２０２頁（２００６年）；ロイ（Ｒｏｙ）ら、Ｎｕｃｌｅｉｃ  ａｃｉｄｓ  Ｒｅｓ．、３３（１６）：５０２６−５０３３頁（２００５年）；タコーネリ（Ｔａｃｏｎｅｌｌｉ）ら、Ｃａｎｃｅｒ  Ｃｅｌｌ  ６：３４７−３６０頁（２００４年）を参照］。１つの方法において、ＦＬ ＣＡ９ ｍＲＮＡだけを検出するために使用される少なくとも１種のプローブまたはプライマーが、ＡＳ ＣＡ９ ｍＲＮＡにおいて欠失された領域内から全体的にまたは部分的に誘導され、一方、ＡＳ ＣＡ９ ｍＲＮＡだけを検出するために使用される少なくとも１種のプローブまたはプライマーは、選択的スプライシングで生じたジャンクションから誘導されるであろう。例えば、ヒトＦＬのＭＮ／ＣＡ９特異的プローブ／プライマーは、ヒトＭＮ／ＣＡ９遺伝子のエクソン８またはエクソン９に対して十分な特異性を有し、特異的に結合することが好ましく、またはヒトＭＮ／ＣＡ９遺伝子のエクソン７と８のスプライスジャンクション、エクソン８と９のスプライスジャンクション、エクソン９と１０のスプライスジャンクションに対して十分な特異性を有し、好ましくは特異的に結合する核酸を含みうる；あるいは、任意のこれらの配列に対して十分な特異性を有し、好ましくは特異的に結合するのに十分に相同的な核酸を含みうる。同様にヒトＡＳのＭＮ／ＣＡ９特異的プローブ／プライマーは、ヒトＭＮ／ＣＡ９遺伝子のエクソン７および１０のスプライスジャンクションに対して十分な特異性を有し、好ましくは特異的に結合する核酸を含みうる；あるいは、そのスプライスジャンクション位に対して十分な特異性を有し、好ましくは特異的に結合するための十分に相同的な核酸を含みうる。あるいは、プローブおよび／またはプライマーは、ＦＬおよびＡＳ双方のＣＡ９ ｍＲＮＡ、ならびに例えば、ゲル上で長さにより識別されたＦＬおよびＡＳ型のｍＲＮＡ産物を検出するために使用できるであろう。
</span>
&nbsp;&nbsp;Particularly preferred probes and / or primers used in the present invention are probes and / or primers that discriminate between full-length [FL] MN / CA9 mRNA expression and alternatively spliced [AS] MN / CA9 mRNA expression. It is. Numerous recent papers provide general information on alternative splicing in cancer and specific information on the design of specific probes and / or primers used to detect mRNA variants expressed by cancer-related genes From which probes and / or primers can be designed to detect AS and / or FL CA9 mRNA variants [see, eg, Matlin et al., Nat Rev Mol Cell Biol. 6: 386-398 (2005); Venables JP, BioEssays, 28: 378-386 (2006); Scotheim and Nees, Int J Biochem Cell Biol. 39 (7-8): 1432-1449 (2007); Srebrow and Kornblitt, J Cell Sci. 119 (Part 13): 2635-2641 (2006); Gothie et al., J Biol Chem. 275: 6922-6927 (2000); Robinson et al., J Cell Sci. 114: 853-865 (2001); He et al., Oncogene, 25: 2192-2202 (2006); Roy et al., Nucleic acids Res. 33 (16): 5026-5033 (2005); Taconelli et al., Cancer Cell 6: 347-360 (2004)]. In one method, at least one probe or primer used to detect only FL CA9 mRNA is derived, in whole or in part, from within the deleted region in AS CA9 mRNA, while AS At least one probe or primer used to detect only CA9 mRNA will be derived from a junction resulting from alternative splicing. For example, a human FL MN / CA9-specific probe / primer has sufficient specificity for and preferably specifically binds to <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 or <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 of the human MN / CA9 gene, or human MN / CA9 May include nucleic acids that have sufficient specificity for, preferably specifically bind to, the splice junctions of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8 of the CA9 gene, the splice junctions of <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, and the splice junctions of <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10; or May comprise nucleic acids with sufficient specificity for any of these sequences, preferably sufficiently homologous to specifically bind. Similarly, a human AS MN / CA9 specific probe / primer has sufficient specificity for <figure-callout id="7" label="exon" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout></a></figure-callout> 7 and 10 splice junctions of the human MN / CA9 gene, and may preferably include a nucleic acid that specifically binds. Alternatively, it may comprise a nucleic acid with sufficient specificity for the splice junction, preferably sufficiently homologous for specific binding. Alternatively, probes and / or primers could be used to detect both FL and AS CA9 mRNA, and for example, FL and AS type mRNA products identified by length on a gel.
</span>
    </p>
    <p num="0100" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ選択的スプライシング変異体に基づく癌治療<br class="style-scope patent-text">
  多くの論文において、癌関連遺伝子の選択的スプライシング変異体に基づく癌治療が検討されており、他にも治療法があるが、中でもアンチセンスおよびＲＮＡ干渉療法に使用されるオリゴヌクレオチドの設計に関する戦略が提供されている［例えば、ガルシア−ブランコ（Ｇａｒｃｉａ−Ｂｌａｎｃｏ）、Ｃｕｒｒ  Ｏｐｉｎ  Ｍｏｌ  Ｔｈｅｒ．、７（５）：４７６−４８２頁（２００５年）；ウィルトン（Ｗｉｌｔｏｎ）およびフレッチャー（Ｆｌｅｔｃｈｅｒ）、Ｃｕｒｒ  Ｇｅｎｅ  Ｔｈｅｒ．、５（５）：４６７−４８３頁（２００５年）；パジャレス（Ｐａｊａｒｅｓ）ら、Ｌａｎｃｅｌ  Ｏｎｃｏｌ．、８（４）：３４９−３５７頁（２００７年）；シンＹ．（Ｘｉｎｇ  Ｙ．）、Ｆｒｏｎｔ  Ｂｉｏｓｃｉ．、１２：４０３４−４０４１頁（２００７年）］。例えば、当業者は、それぞれ配列番号１および１０８の核酸配列からヒトＡＳ ＣＡ９ ｍＲＮＡには特異的ではないが、ヒトＦＬ ＣＡ９ ｍＲＮＡに特異的な適切なアンチセンス核酸配列、好ましくはアンチセンスオリゴヌクレオチドを特定することができるであろう。
</span>Cancer Treatment Based on MN-Alternative Splicing Variants Many papers have examined cancer treatments based on alternative splicing variants of cancer-related genes, and there are other therapies, among them antisense and RNA interference therapy Strategies are provided for the design of oligonucleotides used in [eg Garcia-Branco, Curr Opin Mol Ther. 7 (5): 476-482 (2005); Wilton and Fletcher, Curr Gene Ther. 5 (5): 467-483 (2005); Pajares et al., Lancel Oncol. 8 (4): 349-357 (2007); (Xing Y.), Front Biosci. 12: 4034-4041 (2007)]. For example, one of ordinary skill in the art would obtain an appropriate antisense nucleic acid sequence, preferably an antisense oligonucleotide, specific for human FL CA9 mRNA, but not specific for human AS CA9 mRNA from the nucleic acid sequences of SEQ ID NOs: 1 and 108, respectively. Could be identified.</span>
    </p>
    <p num="0101" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＳ型のＣＡ９ ｍＲＮＡにより発現されたＡＳのＭＮ／ＣＡ ＩＸ全体に加えて、単離されたＡＳのＭＮ／ＣＡ ＩＸタンパク質またはポリペプチド断片が、ＦＬのＭＮ／ＣＡ ＩＸ活性を阻害する能力を有し得ることを当業者は予想するであろう。したがって、ＦＬのＭＮ／ＣＡ ＩＸの活性を阻害するＡＳのＭＮ／ＣＡ ＩＸ由来の任意のタンパク質またはポリペプチドは、本発明の治療法の範囲内で考慮されている。
</span>
&nbsp;&nbsp;In addition to the entire AS MN / CA IX expressed by AS-type CA9 mRNA, the isolated AS MN / CA IX protein or polypeptide fragment has the ability to inhibit FL MN / CA IX activity. One skilled in the art would expect that this could be the case. Accordingly, any protein or polypeptide derived from AS MN / CA IX that inhibits the activity of FL MN / CA IX is contemplated within the therapeutic methods of the invention.
</span>
    </p>
    <p num="0102" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ  ＲＮＡ干渉（ＭＮ  ＲＮＡｉ）<br class="style-scope patent-text">
  ＭＮ遺伝子の発現阻害は、例えば、ＭＮ遺伝子の発現に対するＲＮＡ干渉効果を適用することによって実施することができる。ＲＮＡ干渉は、近年報告されたようにＲＮＡを用いることによって遺伝子発現を阻害するための方法である［エルバシア（Ｅｌｂａｓｈｉｒ）ら、Ｎａｔｕｒｅ、４１１：４９４−４９８頁（２００１年）］。さらに詳細には、ＭＮ遺伝子の発現は、ＭＮ遺伝子の特定のｍＲＮＡスプライス変異体（ＦＬスプライス変異体など）の発現に対してＲＮＡ干渉効果を示す１種類以上のオリゴヌクレオチドを用いることによって阻害することができる。
</span>MN RNA interference (MN RNAi) <br class="style-scope patent-text"> Inhibition of the expression of the MN gene can be carried out, for example, by applying an RNA interference effect on the expression of the MN gene. RNA interference is a method for inhibiting gene expression by using RNA as reported recently [Elbashir et al., Nature, 411: 494-498 (2001)]. More specifically, the expression of the MN gene is inhibited by using one or more oligonucleotides that exhibit an RNA interference effect on the expression of specific mRNA splice variants (such as FL splice variants) of the MN gene. Can do.</span>
    </p>
    <p num="0103" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＭＮ遺伝子のｍＲＮＡスプライス変異体の発現阻害は、細胞にｃＤＮＡの断片を含むベクターまたはその相補的ＲＮＡを形質移入することにより実施することができる。したがって、前記オリゴヌクレオチドを含んでなるＭＮスプライス変異体を阻害する薬剤もまた、本発明の範囲内に含まれる。ＭＮ ｍＲＮＡスプライス変異体を阻害する薬剤は、１種のオリゴヌクレオチドを含むことができるか、または２種以上のオリゴヌクレオチドを含むことができる。ＲＮＡ干渉効果を示す前記オリゴヌクレオチドは、ＭＮ遺伝子発現系を用いてＦＬ ｍＲＮＡ変異体の発現を特異的にサイレンシングするオリゴヌクレオチドを選択することによって、ＭＮ遺伝子のＡＳおよび／またはＦＬ ｍＲＮＡ変異体のヌクレオチド配列に基づいて設計されるオリゴヌクレオチドから得ることができる。
</span>
&nbsp;&nbsp;Inhibition of the expression of the mRNA splice variant of the MN gene can be carried out by transfecting cells with a vector containing a cDNA fragment or its complementary RNA. Accordingly, agents that inhibit MN splice variants comprising said oligonucleotides are also included within the scope of the present invention. An agent that inhibits a MN mRNA splice variant can include one oligonucleotide or can include two or more oligonucleotides. Said oligonucleotide exhibiting RNA interference effect can be obtained by selecting AS and / or FL mRNA variant of MN gene by selecting an oligonucleotide that specifically silences the expression of FL mRNA variant using MN gene expression system. It can be obtained from oligonucleotides designed on the basis of nucleotide sequences.
</span>
    </p>
    <p num="0104" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ＭＮ遺伝子治療ベクター<br class="style-scope patent-text">
  オリゴヌクレオチドを用いてＦＬ ＭＮ／ＣＡ ＩＸの発現を阻害するために、遺伝子治療の使用により標的細胞にオリゴヌクレオチドを導入することが可能である。遺伝子治療は、既知の方法を用いることによって実施することができる。例えば、注入により直接オリゴヌクレオチドを投与する工程を有してなる非ウィルス性形質移入、またはウィルスベクターを用いる形質移入のいずれかを用いることができる。非ウィルス性形質移入に関する好ましい方法は、オリゴヌクレオチドを含むリポソームなどのリン脂質小胞を投与することを含む方法、ならびに注入により直接オリゴヌクレオチドを投与することを含む方法がある。形質移入に使用される好ましいベクターは、ウィルスベクター、より好ましくは、レトロウィルスベクター、アデノウィルスベクター、アデノ関連ウィルスベクターおよびワクシニアウィルスベクターなどのＤＮＡウィルスベクター、またはＲＮＡウィルスベクターである。
</span>In order to inhibit the expression of FL MN / CA IX using MN gene therapy vector oligonucleotides, it is possible to introduce the oligonucleotides into target cells through the use of gene therapy. Gene therapy can be performed by using a known method. For example, either non-viral transfection comprising administering the oligonucleotide directly by injection or transfection using a viral vector can be used. Preferred methods for non-viral transfection include methods that involve administering phospholipid vesicles, such as liposomes containing oligonucleotides, as well as methods that involve administering oligonucleotides directly by injection. Preferred vectors used for transfection are viral vectors, more preferably DNA virus vectors such as retrovirus vectors, adenovirus vectors, adeno-associated virus vectors and vaccinia virus vectors, or RNA virus vectors.</span>
    </p>
    <p num="0105" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
材料および方法<br class="style-scope patent-text">
細胞培養、組織および抗体<br class="style-scope patent-text">
  マウスＮＩＨ  ３Ｔ３線維芽細胞、イヌＭＤＣＫ上皮細胞、腎癌由来のヒト腫瘍細胞株ＣＡＫＩ−１およびＡＣＨＮ、ならびに子宮頚部癌由来のＣａｓｋｉ、ＳｉＨａ、ＨｅＬａ、およびＣ３３ａ系を、３７℃、５％ＣＯ<sub class="style-scope patent-text">２</sub>で加湿下、１０％ＦＣＳ（バイオウィタカー（BioWhittaker）社（ベルギー国ベルビエ所在））および４０μｇ／ｍｌのゲンタマイシン（レック社（スロベニア国所在）で補足されたＤＭＥＭ中で培養した。低酸素処理は、３７℃、２％Ｏ<sub class="style-scope patent-text">２</sub>、５％ＣＯ<sub class="style-scope patent-text">２</sub>、１０％Ｈ<sub class="style-scope patent-text">２</sub>および８３％Ｎ<sub class="style-scope patent-text">２</sub>中、嫌気性ワークステーション（ラスキンテクノロジーズ（Ruskin Technologies）社（英国ブリジェンド所在））内で実施した。
</span>Materials and Methods Cell cultures, tissues and antibodies Mouse NIH 3T3 fibroblasts, canine MDCK epithelial cells, human tumor cell lines CAKI-1 and ACHN from renal cancer, and Caski, SiHa, HeLa, and C33a systems from cervical cancer In DMEM supplemented with 10% FCS (BioWhittaker (Berbier, Belgium)) and 40 μg / ml gentamicin (Leck (Slovenia)) under humidification at 37 ° C., 5% CO <sub class="style-scope patent-text">2</sub> Hypoxic treatment was performed at 37 ° C., 2% O <sub class="style-scope patent-text">2</sub> , 5% CO <sub class="style-scope patent-text">2</sub> , 10% H <sub class="style-scope patent-text">2,</sub> and 83% N <sub class="style-scope patent-text">2</sub> anaerobic workstation (Ruskin Technologies, Inc., Bridgend, UK). ).</span>
    </p>
    <p num="0106" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＨｅＬａ細胞のスフェロイドを、３７℃で３日間、組織培養皿のふたに懸滴させた培地２０μｌ当り４００の細胞から予め形成した。生じた細胞凝集体を、非接着表面のペトリ皿に移し、３日目ごとに培地を交換しながらさらに１１日間懸濁液中で培養した。このスフェロイドを、ニコンＥ４００顕微鏡で調べて、ニコンクールピクス９９０カメラで撮影した。
</span>
&nbsp;&nbsp;HeLa cell spheroids were pre-formed from 400 cells per 20 μl of medium suspended in a tissue culture dish lid at 37 ° C. for 3 days. The resulting cell aggregates were transferred to a non-adherent surface Petri dish and cultured in suspension for a further 11 days with medium changes every 3 days. The spheroids were examined with a Nikon E400 microscope and photographed with a Nikon Coolpix 990 camera.
</span>
    </p>
    <p num="0107" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒト組織は、以前に記載された（キベラ（Ｋｉｖｅｌａ）ら、２００５年）採取物から選択された。マウス組織は、子宮頚部転移により殺処理されたＢＡＬＢ／ｃマウスから切開された。この組織を、ＲＮＡ単離および／またはタンパク質抽出に使用するまで−８０℃で保存した。
</span>
&nbsp;&nbsp;Human tissue was selected from a previously described harvest (Kivela et al., 2005). Mouse tissue was dissected from BALB / c mice that were sacrificed by cervical metastasis. The tissue was stored at −80 ° C. until used for RNA isolation and / or protein extraction.
</span>
    </p>
    <p num="0108" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒトＭＮ／ＣＡ ＩＸタンパク質に特異的なＭ７５およびＶ／１０マウスＭＡｂは、以前に同定されている（パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、１９９３年、ザトビコバ（Ｚａｔｏｖｉｃｏｖａ）ら、２００３年）。二次抗マウスペルオキシダーゼ複合化抗体および西洋わさびペルオキシダーゼと複合化した抗ウサギ抗体は、セバファーマ（Sevapharma）社（チェコ共和国プラハ所在）から入手した。抗マウスＦＩＴＣ複合化抗体は、ベクターラボラトリーズ（Vector Laboratories）社（米国カリフォルニア州バーリンガム所在）から入手した。Ａｌｅｘａ４８８複合化抗ウサギ二次抗体は、アドバンスト・ターゲッティング・システムズ（Advanced Targeting Systems）社（米国カリフォルニア州サンディエゴ所在）から入手した。
</span>
&nbsp;&nbsp;M75 and V / 10 mouse MAbs specific for the human MN / CA IX protein have been previously identified (Pasterekova et al., 1993, Zatovicova et al., 2003). Secondary anti-mouse peroxidase conjugated antibody and anti-rabbit antibody conjugated with horseradish peroxidase were obtained from Sevapharma (Prague, Czech Republic). Anti-mouse FITC-conjugated antibody was obtained from Vector Laboratories (Burlingham, Calif.). Alexa488 conjugated anti-rabbit secondary antibody was obtained from Advanced Targeting Systems (San Diego, Calif.).
</span>
    </p>
    <p num="0109" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
免疫蛍光法<br class="style-scope patent-text">
  免疫蛍光法を、以前に記載されたとおりに実施した（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）。カバーガラス上で増殖させた細胞を氷冷ＰＢＳで２回すすぎ、冷メタノールにより−２０℃で５分間固定した。このカバーグラスを、１％ＢＳＡを含むＰＢＳにより３７℃で３０分間インキュベートし、次いで１：１０００に希釈されたｍＣＡ ＩＸに対しＭ７５ ｍａｂまたはウサギポリクローナル血清を含む非希釈ハイブリドーマ培地と共にインキュベートした。マウスＣＡ ＩＸタンパク質に対する抗体は、他でも記載されている（ガット（Ｇｕｔ）ら、２００２年）。一次抗体とのインキュベーションを、３７℃での加湿チャンバ内で１時間実施した。このカバーグラスを、０．０２％のツイーン２０を含むＰＢＳで１０分間３回洗浄し、次にＰＢＳ中０．５％ＢＳＡ中、１：３００に希釈されたフルオレセイン複合化抗マウス二次抗体で処理するか、またはＰＢＳ中０．５％ＢＳＡ中、１：１０００に希釈された抗ウサギＡｌｅｘａ４８８複合化二次抗体で処理した。ＰＢＳで１０分間、３回すすいだ後、このカバーグラスを装着媒体（カルビオケム（Calbiochem）社（米国マサチューセッツ州ケンブリッジ所在））と共に顕微鏡スライド上に乗せ、次にニコン社のＥ４００顕微鏡で調べてニコンクールピクス９９０カメラで撮影した。
</span>Immunofluorescence Immunofluorescence was performed as previously described (Svastova et al., 2004). Cells grown on cover slips were rinsed twice with ice-cold PBS and fixed with cold methanol at −20 ° C. for 5 minutes. The coverglass was incubated with PBS containing 1% BSA for 30 minutes at 37 ° C. and then incubated with undiluted hybridoma medium containing M75 mab or rabbit polyclonal serum against mCA IX diluted 1: 1000. Antibodies against mouse CA IX protein have been described elsewhere (Gut et al., 2002). Incubation with primary antibody was performed in a humidified chamber at 37 ° C. for 1 hour. The cover glass was washed 3 times for 10 minutes with PBS containing 0.02% Tween 20, and then with fluorescein conjugated anti-mouse secondary antibody diluted 1: 300 in 0.5% BSA in PBS. Treated with anti-rabbit Alexa 488 conjugated secondary antibody diluted 1: 1000 in 0.5% BSA in PBS. After rinsing three times with PBS for 10 minutes, the cover glass is placed on a microscope slide with a mounting medium (Calbiochem (Cambridge, Mass., USA)), then examined with a Nikon E400 microscope and a Nikon Coolpix. Taken with a 990 camera.</span>
    </p>
    <p num="0110" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
発現プラスミド<br class="style-scope patent-text">
  マウススプライシング変異体をコードする真核生物発現プラスミドｐＳＧ５Ｃ−ｍＡＳを、マウスＣＡ９ ｃＤＮＡを含むｐＳＧ５Ｃ−Ｃａｒ９プラスミドから逆ＰＣＲにより作出した。順方向プライマーは、エクソン９（ｍ９Ｓ、５'−ＴＣＣＡＴＧＴＧＡＡＴＴＣＣＴＧＣＴＴＣＡＣＴＧ−３'）［配列番号１０２］の開始点に対して設計され、逆方向プライマーは、エクソン６（ｍ６Ａ、５'−ＣＴＴＣＣＴＣＣＧＡＧＡＴＴＴＣＴＴＣＣＡＡＡＴ−３'）［配列番号１０３］の終止点に特異的であった。同様に、ヒトスプライシング変異体をコードする真核生物発現プラスミドｐＳＧ５Ｃ−ＡＳを、エクソン１０および７に対するプライマーを用いて完全長ヒトＣＡ９ ｃＤＮＡ（ＧｅｎＢａｎｋ番号Ｘ６６８３９）を含むｐＳＧ５Ｃ−ＭＮ／ＣＡ９発現プラスミド（パストレク（Ｐａｓｔｏｒｅｋ）ら、１９９４年）から逆ＰＣＲにより作出した。順方向プライマー（ｈ１０Ｓ、５'−ＧＴＧＡＣＡＴＣＣＴＡＧＣＣＣＴＧＧＴＴＴＴＴ−３'）［配列番号１０４］は、エクソン１０の開始点に特異的であり、逆方向プライマー（ｈ７Ａ、５'−ＣＴＧＣＴＴＡＧＣＡＣＴＣＡＧＣＡＴＣＡＣＴＧ−３'）［配列番号１０５］は、エクソン７の終止点に特異的であった。同じｈ７Ａおよびｈ１０Ｓプライマーを、シグナルペプチドなしの完全長ＣＡ ＩＸタンパク質をコードする一次プラスミド構成物ｐＧＥＸ−３Ｘ−ＣＡ９から、ヒトＣＡ ＩＸタンパク質のＧＳＴ融合スプライス変異体をコードする細菌発現ベクターｐＧＥＸ−３Ｘ−ＡＳの調製に使用した。ＰＣＲ増幅は、Ｐｈｕｓｉｏｎポリメラーゼ（フィンザイムス（Finnzymes）社（フィンランド国エスポー所在））を用いて実施した。ＰＣＲ反応は、９８℃で３０秒間の最初の変性、９８℃で１０秒間３２サイクルの変性、６４℃で３０秒間のアニーリング、７２℃で１分４０秒間の伸長、最後に７２℃で５分間の伸長で構成された。ＰＣＲ産物をゲル精製し、Ｔ４ポリヌクレオチドキナーゼで処理し、Ｔ４ ＤＮＡリガーゼ（インビトロジェン社（米国カリフォルニア州カールスバッド所在））とライゲーションさせた。全ての構成物を塩基配列決定法により検証した。ヒトＣＡ ＩＸの細胞外部分を含むＧＳＴ−ＰＧＣＡ融合タンパク質をコードする構成物は、以前に記載されている（ザトビコバ（Ｚａｔｏｖｉｃｏｖａ）ら、２００３年）。下表２に、実施例に使用されたプライマーの配列を提供する。<br class="style-scope patent-text">
<tables num="2" class="style-scope patent-text"> </tables></span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000009" he="176" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="704" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> 
Expression Plasmid The eukaryotic expression plasmid pSG5C-mAS encoding the mouse splicing variant was generated by inverse PCR from the pSG5C-Car9 plasmid containing the mouse CA9 cDNA. The forward primer is designed against the starting point of exon 9 (m9S, 5′-TCCATGTGAATTCCTGCTTCACTG-3 ′) [SEQ ID NO: 102], and the reverse primer is exon 6 (m6A, 5′-CTTCCTCCGAATTTCTCTCAAAT-3 ′) Specific to the end of [SEQ ID NO: 103]. Similarly, the eukaryotic expression plasmid pSG5C-AS encoding the human splicing variant was transformed into a pSG5C-MN / CA9 expression plasmid (Pastrek) containing full-length human CA9 cDNA (GenBank number X66839) using primers for <figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 10 and 7. (Pastorek et al., 1994). The forward primer (h10S, 5′-GTGACATCCCTAGCCCTGGTTTTTT-3 ′) [SEQ ID NO: 104] is specific for the start of <figure-callout id="10" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 10 and the reverse primer (h7A, 5′-CTGCTTAGCACTCAGCCATCACTTG-3 ′) [SEQ ID NO: 105 ] Was specific to the end point of <figure-callout id="7" label="exon" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 7. The same h7A and h10S primers were transferred from the primary plasmid construct pGEX-3X-CA9 encoding the full-length CA IX protein without a signal peptide to the bacterial expression vector pGEX-3X- encoding the GST fusion splice variant of the human CA IX protein. Used in the preparation of AS. PCR amplification was performed using Phusion polymerase (Finnzymes, Inc., Espoo, Finland). The PCR reaction consisted of an initial denaturation at 98 ° C for 30 seconds, 32 cycles of denaturation at 98 ° C for 10 seconds, annealing at 64 ° C for 30 seconds, extension at 72 ° C for 1 minute 40 seconds, and finally at 72 ° C for 5 minutes. Composed of elongation. The PCR product was gel purified, treated with T4 polynucleotide kinase, and ligated with T4 DNA ligase (Invitrogen, Carlsbad, Calif.). All constructs were verified by sequencing. A construct encoding a GST-PGCA fusion protein containing the extracellular portion of human CA IX has been previously described (Zatovicova et al., 2003). Table 2 below provides the primer sequences used in the examples. <br class="style-scope patent-text"> <tables num="2" class="style-scope patent-text"> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000009" he="176" wi="159" file="0005866328.tif" img-format="tif" img-content="drawing" width="636" height="704" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> </tables> 
    <p class="style-scope patent-text"></p>
    <p num="0111" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
形質移入<br class="style-scope patent-text">
  細胞を６０ｍｍのペトリ皿にプレーティングし、翌日およそ７０％の密度に達した。形質移入は、ヒトおよびマウスのＣＡ ＩＸのスプライシング変異体をコードするそれぞれ２μｇのｐＳＧ５Ｃ−ｈＡＳプラスミドおよびｐＳＧ５Ｃ−ｍＡＳプラスミド、２００ｎｇのｐＳＶ２ｎｅｏプラスミドと共に実施した。形質移入は、ヒトおよびマウスのＣＡ ＩＸのスプライシング変異体をコードするそれぞれ２μｇのｐＳＧ５Ｃ−ｈＡＳプラスミドおよびｐＳＧ５Ｃ−ｍＡＳプラスミド、２００ｎｇのｐＳＶ２ｎｅｏプラスミドと共に、Ｇｅｎｅ  Ｐｏｒｔｅｒ  ＩＩ形質移入剤（ゲンランティス（Genlantis）社（米国カリフォルニア州サンディエゴ所在））を用いて実施した。ＨｅＬａ細胞に関しては９００μｇ／ｍｌの濃度で、ＭＤＣＫ細胞に関しては５００μｇ／ｍｌの濃度でＧ４１８（インビトロジェン社製）を用いて、形質移入細胞を選別に供した。耐性コロニーをクローン化し、免疫ブロット法によりスプライシング変異体の発現を試験し、増殖させた。
</span>Transfected cells were plated in 60 mm petri dishes and reached a density of approximately 70% the next day. Transfections were performed with 2 μg of pSG5C-hAS plasmid and pSG5C-mAS plasmid, 200 ng of pSV2neo plasmid encoding human and mouse CA IX splicing variants, respectively. Transfection was performed with Gene Porter II transfection agent (Genlantis) (with 2 μg pSG5C-hAS plasmid and pSG5C-mAS plasmid, 200 ng pSV2neo plasmid encoding human and mouse CA IX splicing variants, respectively) (San Diego, California, USA))). Transfected cells were subjected to sorting using G418 (Invitrogen) at a concentration of 900 μg / ml for HeLa cells and 500 μg / ml for MDCK cells. Resistant colonies were cloned and tested for splice variant expression by immunoblotting and expanded.</span>
    </p>
    <p num="0112" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
蛍光ＣＡ阻害剤の結合<br class="style-scope patent-text">
  蛍光ＣＡ阻害剤（ＦＩＴＣ−ＣＡ Ｉ）は、ホモスルファニルアミドとフルオレセインイソチオシアネートとの反応により得られ、ＣＡ ＩＸに対して２４ｎＭのＫ<sub class="style-scope patent-text">ｉ</sub>値を示した（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年、セッチ（Ｃｅｃｃｈｉ）ら、２００５年）。この阻害剤を１００ｍＭの濃度で２０％のＤＭＳＯを有するＰＢＳ中に溶解し、細胞への添加直前に培地中で最終的に１ｍＭ濃度に希釈した。ＭＤＣＫ−ＣＡ ＩＸ細胞（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）を、ヒトＡＳ変異体を分泌するＭＤＣＫ−ＡＳ形質移入体から馴化培地を含めた培地に、３．５ｃｍの皿当り４×１０<sup class="style-scope patent-text">５</sup>細胞の密度でプレーティングした。対照細胞を、分泌ＡＳの不在下でインキュベートした。２４時間のインキュベーション後、同じ新鮮な培地を補充し、ＦＩＴＣ−ＣＡ Ｉを細胞に添加し、細胞を低酸素ワークステーションに移し、さらに４８時間結合させた。平行して酸素正常状態中でサンプルをインキュベートした。最後に細胞をＰＢＳで５回洗浄し、ニコンＥ４００エピ蛍光顕微鏡により検視した。蛍光強度は、Ｓｃｉｏｎ  Ｉｍａｇｅ  Ｂｅｔａ４．０２ソフトウェア（シオン社（Scion Corporation）（米国メリーランド州フレデリック所在））を用いて獲得した画像から評価し、相対的ＦＩＴＣ−ＣＡ Ｉ結合をパーセントで表した。
</span>Binding fluorescent CA inhibitor fluorescence CA inhibitor (FITC-CA I) are obtained by reaction of a homo sulfanilamide and fluorescein isothiocyanate, it showed a <sub class="style-scope patent-text">K i</sub> value of 24nM against CA IX (Subasutoba (Svastova) 2004, Cecchi et al., 2005). This inhibitor was dissolved in PBS with 20% DMSO at a concentration of 100 mM and finally diluted to 1 mM concentration in the medium just prior to addition to the cells. MDCK-CA IX cells (Svastova et al., 2004) were transferred from MDCK-AS transfectants secreting human AS mutants to medium containing conditioned medium at 4 × 10 <sup class="style-scope patent-text">5</sup> cells per 3.5 cm dish. The density was plated. Control cells were incubated in the absence of secreted AS. After 24 hours of incubation, the same fresh medium was replenished, FITC-CA I was added to the cells, the cells were transferred to a hypoxic workstation and allowed to bind for an additional 48 hours. Samples were incubated in parallel in normoxia. Finally, the cells were washed 5 times with PBS and examined with a Nikon E400 epifluorescence microscope. Fluorescence intensity was evaluated from images acquired using Scion Image Beta 4.02 software (Scion Corporation, Frederick, MD, USA) and relative FITC-CAI binding was expressed as a percentage.</span>
    </p>
    <p num="0113" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
タンパク質の抽出<br class="style-scope patent-text">
  タンパク質は、以前記載されたとおり（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）、ＲＩＰＡ緩衝液により、細胞単層または組織ホモジネートから抽出した。タンパク質は、プロテアーゼ阻害剤のＣｏｍｐｌｅｔｅ  ｍｉｎｉ（ロッシュ・アプライドサイエンス（Roche Applied Science）社（ドイツ国マンハイム所在））を含むＲＩＰＡ緩衝液（ＰＢＳ中、１％トリトンＸ−１００、０．１％デオキシコール酸ナトリウム、１ｍＭのフェニルメチルスルホニルフルオリド）により、細胞単層または組織ホモジネートから、氷上で３０分間、抽出した。抽出物は、１３０００ｒｐｍで１５分間、遠心分離し、総タンパク質濃度を、製造元の指示に従って、ＢＣＡアッセイ（ピアス（Pierce）社（米国イリノイ州ロックフォード所在））によって特定した。総タンパク質の抽出物（３０〜５０μｇを含むアリコート）を、２−メルカプトエタノール有り（還元条件）、または２−メルカプトエタノールなし（非還元条件）で、ラムリ（Laemmli）のサンプル緩衝液中、１０％および８％のＳＤＳ−ＰＡＧＥにおいて分離した。
</span>Protein Extraction Protein was extracted from cell monolayers or tissue homogenates with RIPA buffer as previously described (Svastova et al., 2004). The protein is a RIPA buffer (1% Triton X-100, 0.1% deoxycholic acid in PBS) containing the protease inhibitor Complete mini (Roche Applied Science, Mannheim, Germany). Sodium, 1 mM phenylmethylsulfonyl fluoride) was extracted from cell monolayers or tissue homogenates on ice for 30 minutes. Extracts were centrifuged for 15 minutes at 13000 rpm and total protein concentration was determined by BCA assay (Pierce, Rockford, Ill., USA) according to manufacturer's instructions. Extract of total protein (aliquot containing 30-50 μg) with 10% in Laemmli sample buffer with or without 2-mercaptoethanol (reducing conditions) or without 2-mercaptoethanol (non-reducing conditions) And 8% SDS-PAGE.</span>
    </p>
    <p num="0114" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
免疫沈降および免疫ブロット法<br class="style-scope patent-text">
  低酸素状態下および正常酸素状態下で２４時間、ＦＣＳなしでインキュベートしたＡＳ−形質移入細胞の培地から、細胞外ヒトＡＳの検出用サンプルを調製した。培地の１／４（５００μｌ）を１０倍に濃縮し、ＳＤＳ−ＰＡＧＥで分離した。免疫沈降用に、１ｍｌのハイブリドーマ培地中のＣＡ ＩＸ特異的ＭＡｂｓを、タンパク質−Ａセファロースの５０％懸濁液（ファルマシア（Pharmacia）社（スウェーデン国ウプサラ所在））２５μｌに、室温で２時間結合させた。細胞抽出物（２００μｌ）を、タンパク質−Ａセファロースの５０％懸濁液２０μｌで予備クリアしてから、結合したＭＡｂに加えた。タンパク質−Ａセファロース上に採取した免疫複合体を洗浄し、沸騰させ、以前記載されたとおり（ザトビコバ（Ｚａｔｏｖｉｃｏｖａ）ら、２００３年）、ＳＤＳ−ＰＡＧＥおよび免疫ブロット法に供した。タンパク質を、ＳＤＳ−ＰＡＧＥにおいて分離し、ポリビニリデンフルオリド（ＰＶＤＦ）膜（Ｉｍｍｏｂｉｌｏｎ（商標）−Ｐ、ミリポア（Ｍｉｌｌｉｐｏｒｅ）社（米国マサチューセッツ州ビレリカ所在））上にブロットした。この膜を、０．２％Ｎｏｎｉｄｅｔ  Ｐ−４０を含むＰＢＳ中、５％無脂肪乳を含むブロック緩衝液で１時間処理し、次いで、ブロック緩衝液（１：２に希釈したハイブリドーマ培地中のＭ７５モノクローナル抗体または１：１０００に希釈したウサギ抗マウスＣＡ ＩＸポリクローナル抗体）中に希釈した一次抗体と共に１時間インキュベートした。処理後、膜を、０．２％のＮｏｎｉｄｅｔ  Ｐ−４０を有するＰＢＳ中、４５分間完全に洗浄し、ブロック緩衝液中で１：７５００および１：５０００に希釈した、西洋わさびペルオキシダーゼに結合させたブタ抗マウスまたは抗ウサギ二次抗体（セバファーマ（Sevapharma）社製）と共に１時間インキュベートした。膜を、０．２％のＮｏｎｉｄｅｔ  Ｐ−４０（シグマ（Ｓｉｇｍａ）社（米国ミズーリ州セントルイス所在））を含むＰＢＳ中で洗浄し、ＥＣＬ検出系により展開した。
</span>Immunoprecipitation and immunoblotting Samples for detection of extracellular human AS were prepared from the culture medium of AS-transfected cells incubated without FCS for 24 hours under hypoxia and normoxia. 1/4 (500 μl) of the medium was concentrated 10 times and separated by SDS-PAGE. For immunoprecipitation, CA IX specific MAbs in 1 ml of hybridoma medium were bound to 25 μl of a 50% protein-A Sepharose suspension (Pharmacia, Uppsala, Sweden) for 2 hours at room temperature. It was. Cell extracts (200 μl) were precleared with 20 μl of a 50% suspension of protein-A sepharose and then added to the bound MAb. Immune complexes harvested on protein-A sepharose were washed, boiled and subjected to SDS-PAGE and immunoblotting as previously described (Zatovicova et al., 2003). Proteins were separated in SDS-PAGE and blotted onto polyvinylidene fluoride (PVDF) membranes (Immobilon ™ -P, Millipore, Billerica, Mass., USA). This membrane was treated with block buffer containing 5% non-fat milk in PBS containing 0.2% Nonidet P-40 for 1 hour and then blocked with buffer (M75 in hybridoma medium diluted 1: 2). Monoclonal antibody or rabbit anti-mouse CA IX polyclonal antibody diluted 1: 1000) and incubated with primary antibody for 1 hour. After treatment, membranes were washed thoroughly for 45 minutes in PBS with 0.2% Nonidet P-40 and bound to horseradish peroxidase diluted 1: 7500 and 1: 5000 in block buffer. Incubated with porcine anti-mouse or anti-rabbit secondary antibody (Sevapharma) for 1 hour. Membranes were washed in PBS containing 0.2% Nonidet P-40 (Sigma, St. Louis, MO) and developed with an ECL detection system.</span>
    </p>
    <p num="0115" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  膜タンパク質および膜直下タンパク質の単離およびオリゴマーの分析のため、細胞をＰＢＳで洗浄し、ＲＩＰＡ抽出緩衝液と共に３０秒間、氷上でインキュベートした。タンパク質を有するＲＩＰＡ緩衝液を吸引し、細胞に新鮮なＲＩＰＡ緩衝液を加えた。次いで、残りのタンパク質を氷上で１５分間抽出した。ＣＡ ＩＸ特異的なＭＡｂ  Ｖ／１０（ＦＬを認識するが、ＡＳは認識しない）またはＭ７５（双方の変異体を認識する）を用いて先ずオリゴマーをＨｅＬａ−ＡＳ抽出物から免疫沈降させた。沈降させたオリゴマーの成分を、還元性ＳＤＳ−ＰＡＧＥ中に溶解し、ブロットし、ペルオキシダーゼ標識したＭ７５を用いて可視化した。
</span>
&nbsp;&nbsp;Cells were washed with PBS and incubated with RIPA extraction buffer for 30 seconds on ice for isolation of membrane proteins and proteins directly under the membrane and analysis of oligomers. RIPA buffer with protein was aspirated and fresh RIPA buffer was added to the cells. The remaining protein was then extracted on ice for 15 minutes. Oligomers were first immunoprecipitated from HeLa-AS extracts using CA IX specific MAb V / 10 (recognizes FL but not AS) or M75 (recognizes both variants). Precipitated oligomeric components were dissolved in reducing SDS-PAGE, blotted, and visualized using peroxidase-labeled M75.
</span>
    </p>
    <p num="0116" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
逆転写ＰＣＲ<br class="style-scope patent-text">
  ＩｎｓｔａＰｕｒｅ試薬（ユーロジェンテック（Eurogentec）社（ベルギー国セライング所在）を用いて、総ＲＮＡを、細胞または組織から単離した。ランダムヘプタマープライマー（４００ｎｇ／μｌ）を用い、Ｍ−ＭｕＬＶ逆転写酵素（フィンザイムス（Finnzymes）社（フィンランド国オイ所在））により、逆転写を実施した。５μｇの総ＲＮＡとランダムプライマー（４００ｎｇ／μｌ）の混合物を７０℃で１０分間加熱し、氷上で速やかに冷却し、６ｍＭのＭｇＣｌ<sub class="style-scope patent-text">２</sub>、４０ｍＭのＫＣｌ、１ｍＭのＤＴＴ、０．１ｍｇ／ｍｌのＢＳＡおよび５０ｍＭのトリス−ＨＣｌ、ｐＨ８．３を含む逆転写酵素緩衝液を添加した。最終容量２４μｌの混合物に、さらに２００ＵのＭ−ＭｕＬＶ逆転写酵素を添加し、４２℃で１時間インキュベートし、７０℃で１５分間加熱し、使用するまで−８０℃で保存した。
</span>Reverse transcription PCR <br class="style-scope patent-text"> Total RNA was isolated from cells or tissues using InstaPure reagent (Eurogentec, Seraing, Belgium) M-MuLV reverse transcriptase using random heptamer primers (400 ng / μl). (Finzymes (Oy, Finland)) Reverse transcription was performed by heating a mixture of 5 μg of total RNA and random primer (400 ng / μl) at 70 ° C. for 10 minutes and quickly cooling on ice. , Reverse transcriptase buffer containing 6 mM MgCl <sub class="style-scope patent-text">2</sub> , 40 mM KCl, 1 mM DTT, 0.1 mg / ml BSA and 50 mM Tris-HCl, pH 8.3 was added to the final volume of 24 μl Add 200 U M-MuLV reverse transcriptase and incubate at 42 ° C. for 1 hour, Heated for 15 min at 0 ° C., and stored at -80 ° C. until use.</span>
    </p>
    <p num="0117" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  表２（上記）に掲載したプライマーと共に、Ｄｙｎａｚｙｍｅ  ＥＸＴポリメラーゼ（フィンザイムス（Finnzymes）社製）によってＰＣＲを実施した。得られたＰＣＲ断片を、１．５％アガロースゲル上で処理した。ＰＣＲのプロトコルは、以下のように構成された：９４℃で３分間の後、以下を３０サイクル：９４℃で３０秒間の変性、４０秒間のアニーリング（温度はプライマーセットに依る）、７２℃で４０秒間の伸長、引き続き、７２℃で５分間の最終伸長。このＰＣＲ産物を精製し、アプライドバイオシステムズ（Applied Biosystems）社（米国フォスターシティー所在）のＡＢＩ ３１００による自動シークエンサーを用いて配列決定した。
</span>
&nbsp;&nbsp;PCR was performed with Dynazyme EXT polymerase (Finnzymes) with the primers listed in Table 2 (above). The resulting PCR fragment was processed on a 1.5% agarose gel. The PCR protocol was configured as follows: 94 ° C for 3 minutes followed by 30 cycles: 94 ° C for 30 seconds denaturation, 40 seconds annealing (temperature depends on primer set), 72 ° C 40 seconds extension followed by 5 minutes final extension at 72 ° C. The PCR product was purified and sequenced using an automated sequencer with ABI 3100 from Applied Biosystems (Foster City, USA).
</span>
    </p>
    <embodiments-example class="style-scope patent-text">
      <p num="0118" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下の実施例は例示のみを目的としており、本発明を限定することは決して意図していない。
</span>
&nbsp;&nbsp;The following examples are for illustrative purposes only and are in no way intended to limit the invention.
</span>
      </p>
      <p num="0119" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
実施例１<br class="style-scope patent-text">
ＣＡ ＩＸのマウススプライス変異体の同定、構造および発現<br class="style-scope patent-text">
  マウス組織におけるＣａｒ９  ｍＲＮＡの発現に関する以前の逆転写（ＲＴ）ＰＣＲデータは、エクソン１〜６の増幅に基づいていた。しかし、エクソン６〜１１にわたる領域を増幅するために、プライマーｍ６Ｓおよびｍ１１Ａを用いたＣａｒ９ ｍＲＮＡのＲＴ ＰＣＲ分析により、２つの増幅産物、すなわち、１つは予想された大きさのＰＣＲ産物、もう１つはそれよりも小さい産物の存在が判明した（図１Ａ、１Ｂ）。この小さいＰＣＲ産物の配列決定により、そのＣａｒ９特異性が証明され、それが、エクソン７および８を欠く、マウスＣａｒ９ ｍＲＮＡの選択的スプライシング（ＡＳ）変異体（配列番号１０６）であることが示された。このマウスＡＳ変異体は、分析した３つの組織、胃、小腸および結腸全てに見られた（図１Ｂ）。対応する一対のプライマー（野性型に対してはｍ８Ｓ〜ｍ１０ＡおよびＡＳに対してはｍ６／９Ｓ〜ｍ１０Ａ）を用いたＣａｒ９の野生型およびＡＳ変異体の個々のＲＴ ＰＣＲ増幅により、分析した組織において、双方の産物が同時に存在することが確認された（図１Ｃ）。
</span>Example 1 <br class="style-scope patent-text"> Identification, structure and expression of mouse splice variants of CA IX Previous reverse transcription (RT) PCR data for expression of Car9 mRNA in mouse tissues was based on amplification of exons 1-6. However, RT PCR analysis of Car9 mRNA with primers m6S and m11A to amplify the region spanning exons 6-11, showed two amplification products, one for the expected size and one for the other. One was found to have a smaller product (FIGS. 1A, 1B). Sequencing of this small PCR product demonstrates its Car9 specificity and shows that it is a alternatively spliced (AS) variant of mouse Car9 mRNA (SEQ ID NO: 106) lacking <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8. It was. This mouse AS variant was found in all three tissues analyzed, stomach, small intestine and colon (FIG. 1B). In the tissues analyzed by individual RT PCR amplification of Car9 wild type and AS mutants with a corresponding pair of primers (m8S to m10A for wild type and m6 / 9S to m10A for AS) It was confirmed that both products were present simultaneously (FIG. 1C).</span>
      </p>
      <p num="0120" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＳ変異体配列のコンピュータ解析により、推定タンパク質（配列番号１０７）は、完全長マウスＣＡ ＩＸより約６ｋＤａだけ小さく、その推定分子量は４８ｋＤａであることが示された。スプライシング変異体は、触媒（ＣＡ）ドメインのＣ末端部分および膜貫通アンカーの上流の領域を欠く一方、膜貫通ドメインおよび細胞質内ドメインは完全のままである、アミノ酸３３５〜３７９を欠失したタンパク質をコードする能力を有する（図１Ｄ、１Ｅ）。
</span>
&nbsp;&nbsp;Computer analysis of the AS mutant sequence showed that the predicted protein (SEQ ID NO: 107) was about 6 kDa smaller than the full-length mouse CA IX and its estimated molecular weight was 48 kDa. Splicing variants lack a protein lacking amino acids 335-379 that lacks the C-terminal portion of the catalytic (CA) domain and the region upstream of the transmembrane anchor, while the transmembrane and cytoplasmic domains remain intact. Has the ability to code (FIGS. 1D, 1E).
</span>
      </p>
      <p num="0121" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  マウスＡＳ ＣＡ ＩＸ変異体の細胞内局在性を調べるために、本発明者らは、ＡＳ ＣＡｒ９のｃＤＮＡをｐＳＧ５Ｃ発現プラスミド内にクローン化し、それを、永久的な形質移入細胞株の作出に用いた。ＡＳ変異体は、内因性のＣＡ ＩＸタンパク質を含まないマウスＮＩＨ３Ｔ３線維芽細胞およびイヌＭＤＣＫ上皮細胞に過剰発現した。ポリクローナル抗マウスＣＡ ＩＸ抗体を用い（ガット（Ｇｕｔ）ら、２００２年）、免疫ブロットおよび免疫蛍光により、双方の形質移入した細胞株を調べた。形質移入体の細胞抽出物中におよそ４８ｋＤａの単一バンドが検出され、コンピュータで推定されたマウスＡＳ ＣＡ ＩＸタンパク質の分子量とよく対応していた（図２Ａ）。形質移入された細胞は、明瞭な細胞質染色を示し、マウスＡＳ変異体が細胞質ゾル内に局在していることを示唆していた（図２Ｂ）。
</span>
&nbsp;&nbsp;To investigate the subcellular localization of the mouse AS CA IX variant, we cloned the AS CAr9 cDNA into the pSG5C expression plasmid and used it to create a permanently transfected cell line. It was. The AS mutant was overexpressed in mouse NIH3T3 fibroblasts and canine MDCK epithelial cells that did not contain endogenous CA IX protein. Both transfected cell lines were examined by immunoblotting and immunofluorescence using a polyclonal anti-mouse CA IX antibody (Gut et al., 2002). A single band of approximately 48 kDa was detected in the cell extract of the transfectants, which corresponded well with the molecular weight of the mouse AS CA IX protein estimated by computer (FIG. 2A). Transfected cells showed clear cytoplasmic staining, suggesting that the mouse AS mutant was localized in the cytosol (FIG. 2B).
</span>
      </p>
      <p num="0122" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
実施例２<br class="style-scope patent-text">
ＣＡ ＩＸのヒトスプライス変異体の同定および構造<br class="style-scope patent-text">
  ヒトの組織および細胞株におけるＡＳ ＣＡ９ ｍＲＮＡを探索するために、本発明者らは、ヒトＣＡ９ ｍＲＮＡの全体をカバーするプライマーセットを設計した（図３Ａ）。これらを、ヒトの胃および小腸から単離したｍＲＮＡから逆転写したｃＤＮＡテンプレート上でＲＴ−ＰＣＲにおいて用いた。エクソン１および６に対して設計されたプライマーを用いて、本発明者らは、予想されたＰＣＲ産物のみを検出した（図３Ｂ）。しかしながら、エクソン６および１１に対するプライマーにより、２つのＰＣＲアンプリコン、すなわち、大量の長い産物と、非常に少量の短い産物が生じた（図３Ｃ）。この短い方の産物の配列解析によって、これが、ヒトＣＡ９ ｍＲＮＡのＡＳ変異体に相当することが確認された。スプライシングにより、エクソン８および９の検出に至った。
</span>Example 2 <br class="style-scope patent-text"> Identification and structure of human splice variants of CA IX. To search for AS CA9 mRNA in human tissues and cell lines, we designed a primer set that covers the entire human CA9 mRNA (FIG. 3A). . These were used in RT-PCR on cDNA templates reverse transcribed from mRNA isolated from human stomach and small intestine. Using primers designed for <figure-callout id="1" label="exons" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="6" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 1 and 6, we detected only the expected PCR product (FIG. 3B). However, primers for <figure-callout id="6" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="11" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 6 and 11 yielded two PCR amplicons, a large amount of long product and a very small amount of short product (FIG. 3C). Sequence analysis of this shorter product confirmed that this corresponds to an AS variant of human CA9 mRNA. Splicing led to detection of <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9.</span>
      </p>
      <p num="0123" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンピュータで推定されたヒトＡＳ ＣＡ ＩＸタンパク質は、アミノ酸３５６〜４１２を欠いており、完全長（ＦＬ）ＣＡ ＩＸに関する４９ｋＤａの推定サイズに比較して、その推定分子量は約４３ｋＤａである。欠失により、触媒ＣＡドメインのＣ末端部分から３５のアミノ酸およびＣＡドメインと膜貫通領域との間に局在する２１のアミノ酸が除去されたが、これらには、分子間Ｓ−Ｓ結合の形成に関与すると考えられるＣｙｓ<sup class="style-scope patent-text">４０９</sup>が含まれる（図３Ｄ）。ＡＳ  ｍＲＮＡにおける１１１９ｂｐ位（ＦＬ ＣＡ９ ｍＲＮＡでは、停止コドンは、１１４２ｂｐ位にある）におけるフレームシフトで作出された停止コドンにより、ＡＳタンパク質は切断され、膜貫通ドメインも細胞質内ドメインも含んでいない（図３Ｅ）。
</span>The computerized human AS CA IX protein lacks amino acids 356-412 and has an estimated molecular weight of approximately 43 kDa compared to an estimated size of 49 kDa for full length (FL) CA IX. The deletion removed 35 amino acids from the C-terminal portion of the catalytic CA domain and 21 amino acids localized between the CA domain and the transmembrane region, which included the formation of intermolecular SS bonds. Includes Cys <sup class="style-scope patent-text">409, which</sup> is thought to be involved in (Figure 3D). The AS protein is cleaved by a stop codon created by a frameshift at position 1119 bp in AS mRNA (in FL CA9 mRNA, the stop codon is at position 1422 bp) and does not contain a transmembrane or cytoplasmic domain (Figure 3E).</span>
      </p>
      <p num="0124" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
実施例３<br class="style-scope patent-text">
腫瘍細胞株および腫瘍組織におけるヒトＡＳ ＣＡ ＩＸの発現<br class="style-scope patent-text">
  ＣＡ９ ｍＲＮＡのＦＬ変異体およびＡＳ変異体の別々の検出を促進するために、本発明者らは、それら個々の増幅を可能にするプライマーを利用した。その設計は、１つのＦＬ特異的プライマーを欠失領域内に配置し、もう１つのＡＳ特異的プライマーを選択的スプライシングで生じたジャンクションに配置することに基づいていた（図３Ａ）。
</span>Example 3 <br class="style-scope patent-text"> Expression of human AS CA IX in tumor cell lines and tumor tissues To facilitate separate detection of FL and AS variants of CA9 mRNA, we utilize primers that allow their individual amplification did. The design was based on placing one FL-specific primer within the deletion region and another AS-specific primer at the junction generated by alternative splicing (FIG. 3A).</span>
      </p>
      <p num="0125" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  先ず、本発明者らは、低酸素状態（２％）および酸素正常状態（２１％）に曝露したヒト癌細胞株におけるＡＳ変異体の存在を解析した。ＡＳ変異体は、試験した全ての細胞株で検出され、低酸素状態と酸素正常状態とで同様のレベルを示した（図４Ａ）。これは、ＦＬ ＣＡ９ ｍＲＮＡと対照的であり、ＦＬＣＡ９ ｍＲＮＡは、明らかに低酸素状態誘導的であり、いわゆる腎癌由来のＡＣＨＮ細胞および子宮頚部癌由来のＣａｓｋｉ細胞およびＳｉＨａ細胞においてかなりのレベル増加を示し、一方、ＣＡＫＩ−１細胞は、きわめて低レベルのＦＬＣＡ９を発現した（図４Ａ）。ＣＡ９遺伝子を欠くＣ３３ａ子宮頚部癌細胞においては、ＦＬＣＡ９特異的なシグナルは見られなかった（リースコブスカ（Ｌｉｅｓｋｏｖｓｋａ）ら、１９９９年）。
</span>
&nbsp;&nbsp;First, we analyzed the presence of AS mutants in human cancer cell lines exposed to hypoxia (2%) and normoxia (21%). AS mutants were detected in all cell lines tested and showed similar levels in hypoxia and normoxia (FIG. 4A). This is in contrast to FL CA9 mRNA, which is clearly hypoxic-inducible, with a significant level increase in so-called renal cancer-derived ACHN cells and cervical cancer-derived Caski cells and SiHa cells. On the other hand, CAKI-1 cells expressed very low levels of FLCA9 (FIG. 4A). No FLCA9-specific signal was seen in C33a cervical cancer cells lacking the CA9 gene (Lieskovska et al., 1999).
</span>
      </p>
      <p num="0126" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以前の研究により、細胞周囲の低酸素状態に関連したＦＬ ＣＡ ＩＸの密度誘導発現が示されている（カルツ（Ｋａｌｕｚ）ら、２００２年）。ＡＳ変異体の発現が密度依存的であるかどうかを調べるために、本発明者らは、低密度培養（１ｃｍ<sup class="style-scope patent-text">２</sup>当たり１×１０<sup class="style-scope patent-text">４</sup>細胞でプレーティング）ならびに高密度培養（１ｃｍ<sup class="style-scope patent-text">２</sup>当たり８×１０<sup class="style-scope patent-text">４</sup>細胞でプレーティング）それぞれにおいて２４時間培養したＨｅＬａ細胞およびＳｉＨａ細胞を用いた。高密度細胞は、明らかにＦＬＣＡ９ ｍＲＮＡの酸素正常状態発現を示したが、そのレベルは、低酸素状態細胞におけるレベルよりも低かった。ＡＳ変異体のレベルに関しては、低密度単層で培養した細胞と高密度単層で培養した細胞との間に顕著な違いは見られなかった（図４Ｂ）。
</span>Previous studies have shown density-induced expression of FL CA IX associated with pericellular hypoxia (Kaluz et al., 2002). In order to investigate whether the expression of AS mutants is density dependent, we have developed a low density culture (plating at 1 × 10 <sup class="style-scope patent-text">4</sup> cells per cm <sup class="style-scope patent-text">2</sup> ) as well as a high density culture (8 × per cm <sup class="style-scope patent-text">2</sup> ). HeLa cells and SiHa cells cultured for 24 hours in each were plated with 10 <sup class="style-scope patent-text">4</sup> cells). High density cells clearly showed normoxic expression of FLCA9 mRNA, but the level was lower than that in hypoxic cells. Regarding the level of AS mutant, no significant difference was seen between cells cultured in low density monolayer and cells cultured in high density monolayer (FIG. 4B).</span>
      </p>
      <p num="0127" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  最後に、本発明者らは、ヒトの胃、結腸、直腸および肝臓などの正常な組織と悪性組織におけるＡＳ発現を解析した。ＲＴ−ＰＣＲにより、試験した全ての組織においてＡＳ変異体の存在が判明した（図４Ｃ）。先行の研究と一致して、ＦＬ転写体は、正常な胃、ならびに結腸および直腸に由来する腫瘍において見られた（サーミオ（Ｓａａｒｎｉｏ）ら、１９９８年、キベラ（Ｋｉｖｅｌａ）ら、２００５年）。
</span>
&nbsp;&nbsp;Finally, we analyzed AS expression in normal and malignant tissues such as human stomach, colon, rectum and liver. RT-PCR revealed the presence of AS mutants in all tissues tested (FIG. 4C). Consistent with previous studies, FL transcripts were found in normal stomach and tumors derived from the colon and rectum (Saarnio et al., 1998, Kivela et al., 2005).
</span>
      </p>
      <p num="0128" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
実施例４<br class="style-scope patent-text">
ＣＡ ＩＸのヒトＡＳ変異体の局在性および基本的な特徴<br class="style-scope patent-text">
  ＣＡ ＩＸのＡＳ変異体の基本的な特徴付けを実施するために、本発明者らは、ヒトＡＳタンパク質の異所性発現を有する形質移入体を作出した。ＣＡ ＩＸ陰性のＭＤＣＫ細胞、ならびに高密度および低酸素状態に応じてＦＬ ＣＡ ＩＸを天然に発現するヒトＨｅＬａ子宮頚部癌細胞に、ヒトＡＳ  ｃＤＮＡを形質移入した。ＴＭ領域およびＩＣ領域のスプライシングおよびフレームシフト媒介の除去を推定したコンピュータ解析と一致して、ＡＳ ＣＡ ＩＸタンパク質は、細胞膜にとどめられず、ＭＤＣＫ細胞と酸素正常状態のＨｅＬａ細胞の双方において、細胞内局在を示した（図５Ａ）。これは、形質移入ＭＤＣＫ細胞および低酸素状態（２％のＯ<sub class="style-scope patent-text">２</sub>）に曝露した偽形質移入ＨｅＬａ細胞におけるＦＬ ＣＡ ＩＸの細胞表面局在とは明らかに対照的であった。
</span>Example 4 <br class="style-scope patent-text"> Localization and basic characteristics of the human AS variant of CA IX To perform the basic characterization of the AS variant of CA IX, we have ectopic expression of the human AS protein. Transfectants were created. Human AS cDNA was transfected into CA IX negative MDCK cells and human HeLa cervical cancer cells that naturally express FL CA IX in response to high density and hypoxia. Consistent with computer analysis that presumed splicing and frameshift-mediated removal of the TM and IC regions, ASCA IX protein is not restricted to the cell membrane and is intracellular in both MDCK and normoxic HeLa cells. Localization was shown (FIG. 5A). This was in sharp contrast to the cell surface localization of FL CA IX in transfected MDCK cells and mock-transfected HeLa cells exposed to hypoxia (2% O <sub class="style-scope patent-text">2</sub> ).</span>
      </p>
      <p num="0129" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  形質移入ＨｅＬａ−ＡＳ細胞は、免疫ブロットにおいて、ＡＳ ＣＡ ＩＸに対応するおよそ４３／４７ｋＤａの２つのバンドおよび低酸素状態により誘導されたＦＬ ＣＡ ＩＸに対応する５４／５８Ｋのさらに２つのバンドを示した（図５Ｂ）。ＡＳタンパク質から膜貫通ドメインおよび細胞内ドメインが完全に欠如しているため、本発明者らはまた、ＡＳ ＣＡ ＩＸ分子の少なくとも一部は、培地に放出されるはずであると推測した。この可能性を調べるため、細胞を、無血清培地中、酸素正常状態下および低酸素状態下で培養した。２４時間のインキュベーション後、培地の１／４を濃縮し、ＳＤＳ−ＰＡＧＥにより分析した。免疫ブロットにより、酸素正常状態下と低酸素状態下の双方で、培地中にＡＳ ＣＡ ＩＸの存在が示された（図５Ｂ）。これらを考え合わせると、これらのデータは、ほとんど細胞膜に限定されているＦＬ ＣＡ ＩＸとは対照的に、ＡＳは、細胞内ならびに細胞外空間に存在していることを示した。
</span>
&nbsp;&nbsp;Transfected HeLa-AS cells show on immunoblotting two bands of approximately 43/47 kDa corresponding to AS CA IX and two additional bands of 54/58 K corresponding to FL CA IX induced by hypoxia. (FIG. 5B). Because of the complete lack of transmembrane and intracellular domains from the AS protein, we also speculated that at least a portion of the AS CA IX molecule should be released into the medium. To investigate this possibility, cells were cultured in serum-free medium under normoxic and hypoxic conditions. After 24 hours of incubation, 1/4 of the medium was concentrated and analyzed by SDS-PAGE. Immunoblot showed the presence of AS CA IX in the medium both under normoxic and hypoxic conditions (FIG. 5B). Taken together, these data indicated that AS is present in the intracellular as well as extracellular space, as opposed to FL CA IX, which is mostly confined to the cell membrane.
</span>
      </p>
      <p num="0130" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  しかしながら、一部のＡＳ分子は、ＦＬ ＣＡ ＩＸと共にヘテロオリゴマー内に組み込まれる可能性が残っている。ＣＡ ＩＸの完全ドメインに正常に結合するが、ＡＳ変異体を認識できないモノクローナル抗体であるＶ／１０を用いて、この仮定を試験した（データは示していない）。ＦＬ分子との相互作用を介したＣＡ ＩＸオリゴマーの免疫沈降に、このＶ／１０  Ｍａｂを利用した。次いで、オリゴマーの成分（組み込まれた可能性のあるＡＳ分子を含め）を還元性ＰＡＧＥに溶解させ、ＦＬ型とＡＳ型の双方と反応するペルオキシダーゼ標識Ｍ７５抗体を用いる免疫ブロットにより視覚化した。非還元条件下、ＦＬタンパク質は、約１５３Ｋのオリゴマーを形成し、一方、ＡＳ ＣＡ ＩＸ変異体は、それができず、また、ＦＬ ＣＡ ＩＸタンパク質によって構築されたオリゴマー内に進入することもできなかった（図６；詳細は、材料と方法を参照）。
</span>
&nbsp;&nbsp;However, some AS molecules still have the potential to be incorporated into hetero-oligomers with FL CA IX. This hypothesis was tested with V / 10, a monoclonal antibody that binds normally to the complete domain of CA IX but does not recognize the AS variant (data not shown). This V / 10 Mab was used for immunoprecipitation of CA IX oligomers through interaction with FL molecules. The oligomeric components (including potentially incorporated AS molecules) were then dissolved in reducing PAGE and visualized by immunoblotting using peroxidase-labeled M75 antibody that reacts with both FL and AS forms. Under non-reducing conditions, the FL protein forms an oligomer of about 153K, while the AS CA IX variant cannot do it and cannot enter into the oligomer constructed by the FL CA IX protein. (FIG. 6; see Materials and Methods for details).
</span>
      </p>
      <p num="0131" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
実施例５<br class="style-scope patent-text">
ヒトＡＳ ＣＡ ＩＸの機能的特性<br class="style-scope patent-text">
  腫瘍細胞におけるＦＬ ＣＡ ＩＸの発現は、低酸素状態によって誘導される。低酸素状態はまた、ＣＡ ＩＸの触媒性能も活性化し、その結果、細胞外ｐＨの酸性化が増強される（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）。この酸性化能力は、ＣＡ ＩＸの触媒ＣＡドメインを欠くドミナントネガティブな変異体の過剰発現によって消滅する（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）。ＡＳタンパク質は、不完全なＣＡドメインしか含んでいないので、それが触媒的に活性であるかどうか、およびＦＬ ＣＡ ＩＸタンパク質によって媒介される酸性化を阻害する能力があるかどうかを分析することは特に重要であった。酵素活性の測定は、完全ＣＡドメイン［例えば、配列番号９］を含み、それによってＰＧドメインとＣＡドメインの双方［ａａ５２〜３９７（配列番号８３）］を含むＧＳＴ−ＰＧＣＡを形成するＦＬ ＣＡ ＩＸのＧＳＴ融合細胞外部分と比較して、切断ＣＡドメインを含む組換え細菌ＧＳＴ−ＡＳ融合タンパク質を用いて、ストップドフロー分光法により達成した。その結果、野生型ＣＡ ＩＸの触媒活性、Ｋ<sub class="style-scope patent-text">ｃａｔ</sub>（ＷＴ）＝３．８×１０<sup class="style-scope patent-text">５</sup>／秒は、スプライシング変異体において半分、Ｋ<sub class="style-scope patent-text">ｃａｔ</sub>（ＡＳ）＝１．９×１０<sup class="style-scope patent-text">５</sup>／秒に低下することが判明した。また、ＧＳＴ−ＡＳタンパク質は、炭酸脱水酵素のスルホンアミド阻害剤であるアセタゾールアミンに対して、かなり低い親和性：Ｋ<sub class="style-scope patent-text">ｉ</sub>  ＷＴ＝１４ｎＭ対Ｋ<sub class="style-scope patent-text">ｉ</sub>ＡＳ＝１１０ｎＭを示した。それらのデータにより、このスプライシングは、ＣＡ ＩＸの酵素活性と阻害剤に対するその親和性との双方を損なったことが示唆される。
</span>Example 5 <br class="style-scope patent-text"> Functional characteristics of human AS CA IX Expression of FL CA IX in tumor cells is induced by hypoxia. Hypoxia also activates the catalytic performance of CA IX, resulting in enhanced extracellular pH acidification (Svastova et al., 2004). This acidification ability is abolished by overexpression of a dominant negative mutant lacking the catalytic CA domain of CA IX (Svastova et al., 2004). Since the AS protein contains only incomplete CA domains, analyzing whether it is catalytically active and whether it is capable of inhibiting acidification mediated by the FL CA IX protein is Especially important. Enzyme activity measurements include the complete CA domain [eg, SEQ ID NO: 9], thereby the FL CA IX forming GST-PGCA containing both the PG domain and the CA domain [aa 52-397 (SEQ ID NO: 83)]. Achieved by stopped-flow spectroscopy using a recombinant bacterial GST-AS fusion protein containing a truncated CA domain compared to the GST-fused extracellular portion. As a result, the catalytic activity of wild type CA IX, K <sub class="style-scope patent-text">cat</sub> (WT) = 3.8 × 10 <sup class="style-scope patent-text">5</sup> / sec is reduced to half in the splicing mutant, and K <sub class="style-scope patent-text">cat</sub> (AS) = 1.9 × 10 <sup class="style-scope patent-text">5</sup> / sec. It has been found. The GST-AS protein also showed a rather low affinity for acetazolamine, a sulfonamide inhibitor of carbonic anhydrase: K <sub class="style-scope patent-text">i</sub> WT = 14 nM vs. K <sub class="style-scope patent-text">i</sub> AS = 110 nM. Their data suggest that this splicing impaired both CA IX enzymatic activity and its affinity for inhibitors.</span>
      </p>
      <p num="0132" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  また、本発明者らは、ＡＳ ＣＡ ＩＸが、低酸素条件下で、細胞外ｐＨを酸性化するＦＬ ＣＡ ＩＸの能力を調節できるかどうかを知ることを望んだ。その目的のために、本発明者らは、２％のＯ<sub class="style-scope patent-text">２</sub>（低酸素状態）および２１％のＯ<sub class="style-scope patent-text">２</sub>（酸素正常状態）において、４８時間インキュベートした形質移入ＨｅＬａ−ＡＳ細胞と偽形質移入対照とを分析した。低酸素インキュベーションは、酸素正常状態対応物に比較して、対照ならびにＡＳ形質移入ＨｅＬａ細胞において、予想された細胞外酸性化をもたらした（図７Ａ）。しかし、培地は、ＡＳ過剰発現細胞において、酸性化がおよそ０．２ｐＨ単位少なく、ＡＳが野生型のＣＡ ＩＸタンパク質の活性を阻害したことを示唆した。
</span>The inventors also wanted to know if AS CA IX can regulate the ability of FL CA IX to acidify extracellular pH under hypoxic conditions. To that end, the present inventors have 2% <sub class="style-scope patent-text">O 2</sub> (hypoxia) and 21% <sub class="style-scope patent-text">O 2</sub> in (normoxia), transfected HeLa-AS cells and mock transfected controls were incubated 48 hours And analyzed. Hypoxic incubation resulted in the expected extracellular acidification in control as well as AS transfected HeLa cells compared to normoxic counterparts (FIG. 7A). However, the medium was approximately 0.2 pH units less acidified in AS overexpressing cells, suggesting that AS inhibited the activity of wild type CA IX protein.</span>
      </p>
      <p num="0133" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＣＡ ＩＸの触媒部位は細胞外空間に曝露されるため、本発明者らは、ＡＳの細胞外画分の可能性のある役割を試験した。先に述べたように、ＣＡ ＩＸの活性は、その触媒部位が阻害剤によってアクセス可能である低酸素状態−活性化ＣＡ ＩＸにのみ結合するフルオレセイン標識ＣＡ阻害剤（ＦＩＴＣ−ＣＡ Ｉ）阻害剤を用いて間接的に示すことができる（スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年）。したがって、本発明者らは、低酸素処理した場合にＣＡ ＩＸ媒介の細胞外酸性化を示し、低酸素状態でＦＩＴＣ−ＣＡを蓄積するが、酸素正常状態においては蓄積しないＣＡ ＩＸ−形質移入ＭＤＣＫ細胞の確立されたモデルを用いた。ここで本発明者らは、ＡＳ分泌ＭＤＣＫ−ＣＡ ＩＸ細胞形質移入体からの培地の存在下および不在下で、ＭＤＣＫ−ＣＡ ＩＸ細胞におけるＦＩＴＣ−ＣＡ Ｉの蓄積を分析した。図７Ｂに示されるように、ＡＳ含有調整培地を混合した新鮮培地中でのＭＤＣＫ−ＣＡ ＩＸ細胞のインキュベーションにより、ＦＩＴＣ−ＣＡ ＩＸの蓄積が明らかに減少し、細胞外ＡＳが阻害剤の結合を減少させたという考えを裏付けていた。この実験を、１／２ならびに１／３のＡＳ含有調整培地によって繰り返した。獲得した画像を分析して、蛍光強度の差を特定した。その結果、ＡＳの細胞外画分は、ＦＩＴＣ−ＣＡ Ｉの蓄積をおよそ半分に減少させることが実証された（図７Ｃ）。
</span>
&nbsp;&nbsp;Since the catalytic site of CA IX is exposed to the extracellular space, we tested the possible role of the extracellular fraction of AS. As previously mentioned, the activity of CA IX is determined by the inhibition of a fluorescein-labeled CA inhibitor (FITC-CA I) inhibitor that binds only to hypoxia-activated CA IX whose catalytic site is accessible by the inhibitor. Can be used indirectly (Svastova et al., 2004). Thus, we show CA IX-mediated extracellular acidification when hypoxic treated and accumulate FITC-CA in hypoxic conditions but not in normoxic conditions. CA IX-transfected MDCK An established model of cells was used. Here we analyzed FITC-CA I accumulation in MDCK-CA IX cells in the presence and absence of media from AS secreted MDCK-CA IX cell transfectants. As shown in FIG. 7B, incubation of MDCK-CA IX cells in fresh medium mixed with AS-containing conditioned medium clearly reduced FITC-CA IX accumulation and extracellular AS caused inhibitor binding. It supported the idea that it was reduced. This experiment was repeated with 1/2 and 1/3 AS-containing conditioned media. The acquired images were analyzed to identify differences in fluorescence intensity. As a result, the extracellular fraction of AS was demonstrated to reduce FITC-CA I accumulation by approximately half (FIG. 7C).
</span>
      </p>
      <p num="0134" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＦＬ ＣＡ ＩＸの機能性に及ぼすＡＳ変異体の効果が、生物学的帰結を有し得るかどうかを調べるために、本発明者らは、偽形質移入対照と比較して、ＨｅＬａ−ＡＳ形質移入体の増殖パラメーターを分析した。酸素正常状態または低酸素状態に関係なく、接着培養における短期（７２時間）増殖に際して、これら２つの細胞型の間に有意な差は見られなかった（データは示していない）。したがって、本発明者らは、１４日間増殖させたＨｅＬａ細胞スフェロイドも作製し、ＨｅＬａ−ＡＳ細胞および対照ＨｅＬａ細胞それぞれから作出したスフェロイドの質量および形状を比較した。ＨｅＬａ−ＡＳスフェロイドはそれほどコンパクトでなく(less compact)、低酸素および酸性ｐＨを被る細胞を通常含む中央領域を欠いた（図７Ｄ）。これらＨｅＬａ−ＡＳスフェロイドの外見は、ｐＨを調節するＦＬ ＣＡ ＩＸの能力の低下を引き起こすＡＳの効果が、これらの微小環境ストレスを生き延びる細胞の能力に影響を及ぼし得ることを示唆した。
</span>
&nbsp;&nbsp;To investigate whether the effect of AS variants on FL CA IX functionality may have biological consequences, we compared HeLa-AS transfection compared to mock transfection controls. Body growth parameters were analyzed. There was no significant difference between these two cell types during short-term (72 hours) growth in adherent cultures regardless of normoxia or hypoxia (data not shown). Therefore, we also generated HeLa cell spheroids grown for 14 days and compared the mass and shape of spheroids produced from HeLa-AS cells and control HeLa cells, respectively. HeLa-AS spheroids were less compact and lacked a central region usually containing cells that suffered from hypoxia and acidic pH (FIG. 7D). The appearance of these HeLa-AS spheroids suggested that the effect of AS, which causes a decrease in the ability of FL CA IX to regulate pH, can affect the ability of cells to survive these microenvironmental stresses.
</span>
      </p>
      <p num="0135" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  これらをまとめると、我々の結果によって、ＡＳ ＣＡ ＩＸは、ＦＬ ＣＡ ＩＸと比較したときに、調節のされ方が異なっており、局在化が異常であり、機能が不能化されていることが示された。
</span>
&nbsp;&nbsp;In summary, our results indicate that AS CA IX is regulated differently when compared to FL CA IX, is abnormally localized, and is disabled. Indicated.
</span>
      </p>
      <p num="0136" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
考察<br class="style-scope patent-text">
  選択的スプライシングの脱制御は、特に癌においてよく認識された現象である（ベナブルス（Ｖｅｎａｂｌｅｓ）ら、２００６年）。ＣＤ４４、ＨＩＦ−α、ＶＥＧＦ、オステオポンチンなど、また他にも多くの、その産物が腫瘍の進行に因果的に関与している、選択的にスプライスされた遺伝子の例は多数ある（ワン（Ｗｏｎｇ）ら、２００３年、ゴチー（Ｇｏｔｈｉｅ）ら、２０００年、ロビンソン（Ｒｏｂｉｎｓｏｎ）ら、２００１年、フー（Ｈｅ）ら、２００６年）。ある場合、正常な組織では稀であるスプライス型が腫瘍においては一般的になり得、一方で、正常組織に存在する選択的スプライス型は、不変のままであり得る（ロイ（Ｒｏｙ）ら、２００５年）。
</span>Discussion Deregulation of alternative splicing is a well-recognized phenomenon, especially in cancer (Venables et al., 2006). There are many examples of alternatively spliced genes whose products are causally involved in tumor progression, such as CD44, HIF-α, VEGF, osteopontin, etc. (Wong) 2003, Gothie et al., 2000, Robinson et al., 2001, He et al., 2006). In some cases, splice types that are rare in normal tissue may become common in tumors, while alternative splice types present in normal tissue may remain unchanged (Roy et al., 2005). Year).</span>
      </p>
      <p num="0137" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本研究において同定されたヒトＣＡ ＩＸの選択的スプライシング変異体は、この範疇に分類できるが、完全長ＣＡ ＩＸの発現パターンはかなり特殊であるため、明快に結論づけることは難しい。ＦＬ ＣＡ ＩＸは、胃や小腸などのきわめてわずかな正常組織中に多量に存在するが、同時に、その選択的スプライシング変異体の発現は低レベルである。胃癌においては、ＦＬ ＣＡ ＩＸの発現は減少するが、ＡＳのレベルは正常な胃と同様である。他方、完全長ＣＡ ＩＸの発現は、正常な結腸および直腸において存在しないか、またはきわめて少なく（本研究において分析されていない他の正常組織においても）、対応する腫瘍においては有意に増加する（サーミオ（Ｓａａｒｎｉｏ）ら、１９８８年）。しかしながら、ＡＳ変異体は、正常な組織と結腸直腸癌の双方において、安定した発現レベルを示す。これらのデータにより、その発現は腫瘍の表現型に関連していないことが強く示唆される。さらには、そのレベルが密集培養で増殖させ低酸素状態に曝露された細胞において誘導されるＦＬ ＣＡ ＩＸとは対照的に、ＡＳ変異体は、基本的に低酸素状態および細胞密度には依存しない。
</span>
&nbsp;&nbsp;Alternative splicing variants of human CA IX identified in this study can be classified into this category, but the expression pattern of full-length CA IX is quite specific and difficult to conclude clearly. FL CA IX is abundant in very few normal tissues such as the stomach and small intestine, but at the same time its alternatively spliced variant expression is low. In gastric cancer, FL CA IX expression is decreased, but AS levels are similar to normal stomach. On the other hand, full-length CA IX expression is absent or very low in normal colon and rectum (even in other normal tissues not analyzed in this study) and significantly increased in the corresponding tumor (thermio (Saarnio et al., 1988). However, AS mutants show stable expression levels in both normal tissues and colorectal cancer. These data strongly suggest that its expression is not related to the tumor phenotype. Furthermore, in contrast to FL CA IX, whose levels are induced in cells grown in confluent cultures and exposed to hypoxia, AS variants are essentially independent of hypoxia and cell density. .
</span>
      </p>
      <p num="0138" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＳの比較的低いが構成的な発現は、可能性のある予後診断または予測の目的のために低酸素状態腫瘍のマーカーとしてＣＡ９転写を用いる臨床的研究にとってかなり重要である。正常および／または非低酸素状態組織におけるＦＬ ＣＡ９の不在下でＡＳが存在するために、スプライシングによって影響を受けない領域の検出を目的に設計されたプライマーまたはプローブは、ＣＡ９ ｍＲＮＡの２つの型を識別することができず、したがって、偽陽性の結果を与える可能性があり、低酸素状態に誘導されたＦＬ ＣＡ９の真の臨床値に影響を及ぼし得る。
</span>
&nbsp;&nbsp;The relatively low but constitutive expression of AS is of considerable importance for clinical studies using CA9 transcription as a marker for hypoxic tumors for potential prognostic or predictive purposes. Primers or probes designed to detect regions that are not affected by splicing due to the presence of AS in the absence of FL CA9 in normal and / or non-hypoxic tissues, have two types of CA9 mRNA. Cannot be identified and therefore may give false positive results and may affect the true clinical value of FL CA9 induced in hypoxia.
</span>
      </p>
      <p num="0139" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  注目すべきことに、ＦＬ転写体と比較したＡＳ ｍＲＮＡの５'ＰＡＣＥ分析により、同じ長さの産物が作出され、双方の変異体が同一のプロモーターから生じるという結論を裏付けている（データは示していない）。この事実は、転写装置(transcriptional apparatus)の、生理学的環境に依存するＣＡ９転写体のプロセシングにおけるスプライシング機構(splicing machinery)の成分との差動協力(differential cooperation)を示唆し得る。実際、ｈＴＥＲＴ、ＴｒｋＡおよびＸＢＰ１に関連するものなど、低酸素状態によって調節されるスプライシング事象がいくつかある（アンダーソン（Ａｎｄｅｒｓｏｎ）ら、２００６年、タコーネリ（Ｔａｃｏｎｅｌｌｉ）ら、２００４年、ロメロ−ラミレツ（Ｒｏｍｅｒｏ−Ｒａｍｉｒｅｚ）ら、２００４年）。ｈＴＥＲＴの場合、ＲＮＡポリメラーゼＩＩ、ＴＦＩＩＢ、ＨＩＦおよびコアクチベーターを含む転写複合体が、低酸素状態下でプロモーターに動員され、転写が進行する限り遺伝子に結合したままでいることが実証されている。これによって、酵素の活性形態に有利なスプライスパターンにおけるスイッチが誘起される（アンダーソン（Ａｎｄｅｒｓｏｎ）ら、２００６年）。ＣＡ９遺伝子の転写の間も同様な機序がはたらく可能性はかなり考え得ることである。
</span>
&nbsp;&nbsp;Of note, 5 'PACE analysis of AS mRNA compared to the FL transcript produced a product of the same length, supporting the conclusion that both variants originate from the same promoter (data shown) Not) This fact may suggest differential cooperation with components of the splicing machinery in the processing of CA9 transcripts that depend on the physiological environment of the transcriptional apparatus. In fact, there are several splicing events that are regulated by hypoxia, such as those associated with hTERT, TrkA and XBP1 (Anderson et al., 2006, Taconelli et al., 2004, Romero Ramirez (Romero). -Ramirez) et al., 2004). In the case of hTERT, a transcription complex containing RNA polymerase II, TFIIB, HIF and coactivator has been demonstrated to be recruited to the promoter under hypoxia and remain attached to the gene as long as transcription proceeds. . This induces a switch in a splice pattern that favors the active form of the enzyme (Anderson et al., 2006). It is quite possible that a similar mechanism works during transcription of the CA9 gene.
</span>
      </p>
      <p num="0140" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒトＣＡ９ ｍＲＮＡのＡＳ変異体は、エクソン８プラス９の欠失から生じ、膜貫通領域、細胞内テール、および触媒ドメインのＣ末端部分を含まない切断タンパク質に翻訳される。ＴＭおよびＩＣ領域の除去は明らかに、細胞内空間に優勢的に存在し、細胞外媒体にも放出されるこのＡＳ変異体の局在性の変更の原因となる。これは、内在性膜タンパク質(integral plasma membrane protein)であるＦＬ ＣＡ ＩＸタンパク質とは対照的である。触媒ドメインの部分的欠失に関連するそのような不適切な局在性は、タンパク質の機能性を危うくすると予想することができる。実際、ＧＳＴ−ＡＳは、完全な触媒ドメインを含む対応するＧＳＴ−ＰＧ＋ＣＡタンパク質の酵素活性の半分しか示さない。しかしながら、この知見を、ＣＡ ＩＸが低酸素状態下で重炭酸イオントランスポーターと相互作用し、細胞膜を横断するｐＨ調節に寄与する局所細胞の文脈（モーガン（Ｍｏｒｇａｎ）ら、２００７年、スバストバ（Ｓｖａｓｔｏｖａ）ら、２００４年、スウィータッチ（Ｓｗｉｅｔａｃｈ）ら、２００７年）に直接移し変えることはきわめて難しい。第１に、活性測定は、細胞下構造(subcellular structure)、タンパク質−タンパク質相互作用、イオン流、およびＣＡ ＩＸの触媒性能の調節に確かにある役割を果たしている微小環境の影響が無い設定下で、細菌において産生されたタンパク質を用いて実施した。第２に、種々の炭酸脱水酵素イソ酵素の触媒活性は、おおよそ２桁の大きさの範囲内で変動し、より高い活性イソ型は、中程度と考えられるイソ酵素よりも２０倍からほんの３倍までの活性の高さを示す（パストレコバ（Ｐａｓｔｏｒｅｋｏｖａ）ら、２００４年）。したがって、半分に減少した活性が、ＣＡ ＩＸの生理学的機能にとって十分であるかどうかを除外することはできない。いずれにせよ、ＡＳ変異体は細胞膜に適切に局在しておらず、ＣＡ ＩＸタンパク質の機能にとってきわめて重要な条件であるオリゴマーを形成することができないため、この疑問は恐らく重要ではない。
</span>
&nbsp;&nbsp;The AS variant of human CA9 mRNA results from a deletion of <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 <figure-callout id="9" label="plus" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">plus</a></figure-callout> 9, and is translated into a truncated protein that does not include the transmembrane region, intracellular tail, and C-terminal portion of the catalytic domain. Clearance of the TM and IC regions clearly causes a change in the localization of this AS variant that predominates in the intracellular space and is also released into the extracellular medium. This is in contrast to the FL CA IX protein, which is an integral plasma membrane protein. Such inappropriate localization associated with partial deletion of the catalytic domain can be expected to compromise protein functionality. Indeed, GST-AS shows only half of the enzymatic activity of the corresponding GST-PG + CA protein containing the complete catalytic domain. However, this finding suggests that CA IX interacts with bicarbonate ion transporters under hypoxia and contributes to pH regulation across the cell membrane (Morgan et al., 2007, Svastova. ) Et al., 2004, Sweeach et al., 2007). First, activity measurements are performed in a setting free from the influence of the microenvironment that certainly plays a role in the regulation of subcellular structure, protein-protein interactions, ion flow, and catalytic performance of CA IX. This was carried out using proteins produced in bacteria. Second, the catalytic activity of various carbonic anhydrase isoenzymes varies within a range of approximately two orders of magnitude, with higher active isoforms being 20 to 3 times less than the moderately considered isoenzyme. The activity is shown up to twice as high (Pasterekova et al., 2004). Therefore, it cannot be ruled out whether the reduced activity by half is sufficient for the physiological function of CA IX. In any case, this question is probably unimportant because AS mutants are not properly localized in the cell membrane and cannot form oligomers, a critical condition for CA IX protein function.
</span>
      </p>
      <p num="0141" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  しかしながら、ＡＳ型のＣＡ ＩＸを構成的に過剰発現する低酸素状態のＨｅＬａ−ＡＳ細胞の培養において見られる細胞外酸性化の減少により、ＡＳ型のＣＡ ＩＸは、内因性の低酸素状態誘導ＦＬタンパク質の機能を阻害することが明らかに示唆される。その機序は現在のところ明らかではないが、ＡＳ変異体で処理した低酸素状態のＭＤＣＫ−ＣＡ ＩＸ細胞におけるＣＡ阻害剤の蓄積減少に基づき、重炭酸イオン輸送メタボロン（metabolon）の細胞表面成分との相互作用に関して、ＡＳがＦＬ ＣＡ ＩＸと競合することを提案することができる。さらに、ＡＳの過剰発現が、対応する腫瘍内微小環境を有する腫瘍塊を模倣する３Ｄモデルとしてたびたび用いられるコンパクトなスフェロイド(compact spheroids)を形成するＨｅＬａ細胞の能力にかなりの影響を及ぼす。コア領域が、より酸性の微小環境により特徴づけられる固形腫瘍の低酸素領域と明らかな類似性を示すスフェロイドを横断する酸素分圧、ｐＨ、栄養物および代謝物の勾配が、多くの研究により十分に文書化されている（アルバレツ−ペレツ（Ａｌｖａｒｅｚ−Ｐｅｒｅｚ）ら、２００５年）。他に、ＦＬ ＣＡ ＩＸの細胞膜染色が、ＳｉＨａおよびＨｅＬａの子宮頚部癌細胞から生成した多細胞スフェロイドの最内部の細胞で有意に増加することが示されている（オリーブ（Ｏｌｉｖｅ）ら、２００１年、クラスチナ（Ｃｈｒａｓｔｉｎａ）ら、２００３年）。細胞が生き延びるために、低酸素ストレスおよび酸性微小環境の有害な影響に対する保護および／または適応の増大を必要としているまさにその領域にＦＬ ＣＡ ＩＸが存在することを、これらのデータは示している。ここでＦＬ ＣＡ ＩＸは、細胞内ｐＨの重炭酸媒介緩衝作用を介して作用する（スウィータッチ（Ｓｗｉｅｔａｃｈ）ら、２００７年）。このｐＨ調節を部分的に動揺させるＡＳ変異体は明らかに、スフェロイド内の酸性ｐＨに対する適応を許さず、スフェロイドのコアから最もストレスを受けた中心の細胞の除去をもたらす。この考えは、ＣＡ ＩＸの触媒活性が低酸素状態により調節されるという知見と一致し、ｐＨを調節するＣＡ ＩＸの能力は、低酸素腫瘍細胞の生き残りにとって重要であることを示唆している。後者の示唆はまた、ロバートソン（Ｒｏｂｅｒｔｓｏｎ）ら（２００４年）によるＲＮＡｉ実験によっても間接的に裏付けられている。
</span>
&nbsp;&nbsp;However, due to the reduced extracellular acidification seen in cultures of hypoxic HeLa-AS cells that constitutively overexpress AS-type CA IX, AS-type CA IX is endogenous hypoxia-induced FL. It is clearly suggested to inhibit protein function. The mechanism is not clear at present, but based on the decreased accumulation of CA inhibitors in hypoxic MDCK-CA IX cells treated with AS mutants, the cell surface components of bicarbonate ion transporting metabolon and It can be proposed that AS competes with FL CA IX for the interaction of. Furthermore, AS overexpression has a considerable impact on the ability of HeLa cells to form compact spheroids, often used as 3D models that mimic tumor masses with corresponding intratumoral microenvironments. Oxygen partial pressure, pH, nutrient and metabolite gradients across the spheroids where the core region clearly shows similarities to the hypoxic region of solid tumors characterized by a more acidic microenvironment are sufficient for many studies (Alvarez-Perez et al., 2005). In addition, FL CA IX cell membrane staining has been shown to be significantly increased in the innermost cells of multicellular spheroids generated from SiHa and HeLa cervical cancer cells (Olive et al., 2001). , Krastina et al., 2003). These data indicate that FL CA IX exists in that very area that requires protection and / or increased adaptation to the detrimental effects of hypoxic stress and the acidic microenvironment for cells to survive. Here, FL CA IX acts through a bicarbonate-mediated buffering action of intracellular pH (Sweeach et al., 2007). AS mutants that partially perturb this pH regulation clearly do not allow adaptation to the acidic pH within the spheroids, resulting in the removal of the most stressed central cells from the spheroid core. This notion is consistent with the finding that the catalytic activity of CA IX is regulated by hypoxia, suggesting that the ability of CA IX to regulate pH is important for the survival of hypoxic tumor cells. The latter suggestion is also indirectly supported by RNAi experiments by Robertson et al. (2004).
</span>
      </p>
      <p num="0142" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  天然に産生されたＡＳ変異体は低レベルで発現するが、ＦＬ ＣＡ ＩＸをほんの弱く誘導する生理学的環境および細胞型がある。例えば、機能的血液供給性血管から短距離に局在化した腫瘍細胞は、軽微な低酸素状態に曝露され、同等レベルのＦＬおよびＡＳを発現させて、ＣＡ ＩＸ活性のドミナントネガティブなダウンレギュレーションを可能にし得る。このような弱い低酸素状態の細胞は、おそらく苛酷なアシドーシスに曝露されず、したがって、このｐＨ制御機序の完全な実施から利益を得ない可能性がある。軽微な虚血を被っている正常組織にも同様な説明を適用することができる。この考えは、いくつかの腫瘍細胞株、高密度の酸素正常状態の細胞（細胞周辺の弱い低酸素状態に影響を受けた）およびいくつかの早期の低酸素状態の程度が低い腫瘍は、ただ低レベルのＦＬ ＣＡ ＩＸを発現するということを示す最近ならびに以前のデータによって裏付けられている。結論として本発明者らは、ＡＳ変異体が、双方のタンパク質が同時発現される環境下で、ＦＬ ＣＡ ＩＸのモジュレーターとして働くことを提案する。可能な予後診断または予測を目的とした、低酸素腫瘍のマーカーとしてのＣＡ９転写に基づいた臨床的研究のために、選択的スプライシング変異体の低いが構成的な発現はかなり重要である。正常および／または非低酸素状態組織におけるＦＬ ＣＡ９の不在下でＡＳが存在するために、スプライシングによって影響を受けない領域の検出を目的に設計されたプライマーまたはプローブは、ＣＡ９ ｍＲＮＡの２つの型を識別することができず、したがって、偽陽性の結果を与える可能性があり、低酸素状態に誘導されたＦＬ ＣＡ９の真の臨床値に影響を及ぼし得る。実際これは、今までに公開されたいくつかの研究［例えば、マッキーナン（ＭｃＫｉｅｒｎａｎ）ら、Ｃａｎｃｅｒ．８６（３）：４９２〜４９７頁（１９９９年）；スパン（Ｓｐａｎ）ら、Ｂｒ  Ｊ  Ｃａｎｃｅｒ．８９（２）：２７１〜２７６頁（２００３年）；シミ（Ｓｉｍｉ）ら、Ｌｕｎｇ  Ｃａｎｃｅｒ．５２（１）：５９〜６６頁（２００６年）；グライナー（Ｇｒｅｉｎｅｒ）ら、Ｂｌｏｏｄ．１０８（１３）：４１０９〜４１１７頁（２００６年）］において、生じ得る。この理由から、マイクロアレイチップおよびＲＴ−ＰＣＲのための正しいプライマーおよびプローブの設計は注意して行なう必要があり、ＡＳ型のＭＮ／ＣＡ ＩＸを考慮に入れる必要がある。
</span>
&nbsp;&nbsp;Although naturally produced AS variants are expressed at low levels, there are physiological environments and cell types that induce FL CA IX only weakly. For example, tumor cells localized at a short distance from a functional blood supply vessel are exposed to mild hypoxia and express equivalent levels of FL and AS, resulting in a dominant negative down-regulation of CA IX activity. Can be possible. Such weakly hypoxic cells are probably not exposed to severe acidosis and may therefore not benefit from the full implementation of this pH control mechanism. Similar explanations can be applied to normal tissues suffering from slight ischemia. The idea is that some tumor cell lines, dense normoxic cells (affected by weak hypoxia around the cell) and some early-stage hypoxic tumors are just Supported by recent as well as previous data showing that it expresses low levels of FL CA IX. In conclusion, we propose that AS mutants act as modulators of FL CA IX in an environment where both proteins are co-expressed. For clinical studies based on CA9 transcription as a marker of hypoxic tumors for the purpose of possible prognosis or prediction, low but constitutive expression of alternative splicing variants is of considerable importance. Primers or probes designed to detect regions that are not affected by splicing due to the presence of AS in the absence of FL CA9 in normal and / or non-hypoxic tissues, have two types of CA9 mRNA. Cannot be identified and therefore may give false positive results and may affect the true clinical value of FL CA9 induced in hypoxia. In fact, this is due to several studies published so far [eg McKiernan et al., Cancer. 86 (3): 492-497 (1999); Span et al., Br J Cancer. 89 (2): 271-276 (2003); Simi et al., Lung Cancer. 52 (1): 59-66 (2006); Greiner et al., Blood. 108 (13): 4109-4117 (2006)]. For this reason, the correct primer and probe design for microarray chips and RT-PCR must be done with care and AS type MN / CA IX must be taken into account.
</span>
      </p>
      <p num="0143" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
ブダペスト条約の寄託<br class="style-scope patent-text">
  下記に掲げた物質は、アメリカン・タイプ・カルチャー・コレクション（ＡＴＣＣ）（米国２０１１０−２２０９バージニア州マナッサスUniversity Blvd.，10810所在）に寄託された。この寄託は、the Budapest Treaty on the International Recognition of Deposited Microorganisms for the Purpose of Patent Procedure and Regulations（ブダペスト条約）にしたがって行なわれた。生存可能な培養物の維持は、寄託日から３０年間保証される。ハイブリドーマおよびプラスミドは、ブダペスト条約の下、ＡＴＣＣにより入手でき、当該出願から特許が付与された際に、寄託されたハイブリドーマおよびプラスミドの公的に非制限的利用を保証する出願者とＡＴＣＣ間の同意に従う。寄託された株が利用可能であることは、任意の政府当局のもとでその特許法に従って付与された権利に違反して、本発明を実施することの許可として解釈すべきではない。
</span>Deposit of the Budapest Treaty The substances listed below have been deposited with the American Type Culture Collection (ATCC) (University Blvd., 10810, Manassas, Virginia, USA). The deposit was made in accordance with the Budapest Treaty on the International Recognition of Deposited Microorganisms for the Purpose of Patent Procedure and Regulations. Maintenance of viable cultures is guaranteed for 30 years from the date of deposit. Hybridomas and plasmids are available from the ATCC under the Budapest Treaty, and the agreement between the applicant and the ATCC guarantees the public, unrestricted use of the deposited hybridomas and plasmids when patented from that application. Follow. The availability of deposited stock should not be construed as a permit to practice the invention in violation of the rights granted under any patent authority under its patent law.</span>
      </p>
      <p num="0144" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000010" he="37" wi="119" file="0005866328.tif" img-format="tif" img-content="drawing" width="476" height="148" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000011" he="44" wi="118" file="0005866328.tif" img-format="tif" img-content="drawing" width="472" height="176" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div>
  同様に、Ｖ／１０モノクローナル抗体を産生するハイブリドーマ細胞株Ｖ／１０−ＶＵは、ブダペスト条約の下、ヘント大学（Universiteit Gent）（ベルギー国ヘントＢ−９０００，K. L. Ledeganckstraat 35所在）のthe Laboratorium voor Moleculaire Biologie-Plasmidencollectie（ＬＭＢＰ）にある、ベルギーの微生物保存機関（the Belgian Coordinated Collections of Microorganisms）（ＢＣＣＭ）［ＢＣＣＭ／ＬＭＢＰ］の国際寄託当局（the International Depository Authority）（ＩＤＡ）に、２００３年２月１９日に登録番号６００９ＣＢとして寄託された。
 <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000010" he="37" wi="119" file="0005866328.tif" img-format="tif" img-content="drawing" width="476" height="148" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png" class="style-scope patent-text"><img id="000011" he="44" wi="118" file="0005866328.tif" img-format="tif" img-content="drawing" width="472" height="176" alt="Figure 0005866328" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/87/13/f31eb071f250b3/0005866328-9.png"></a></div> Similarly, the hybridoma cell line V / 10-VU producing the V / 10 monoclonal antibody is the Laboratorium voor Moleculaire of Universiteit Gent (Gent B-9000, KL Ledeganckstraat 35, Belgium) under the Budapest Treaty. February 19th, 2003 to the International Depository Authority (IDA) of the Belgian Coordinated Collections of Microorganisms (BCCM) [BCCM / LMBP] in Biologie-Plasmidencollectie (LMBP) Deposited as registration number 6009CB on the day.
      <p class="style-scope patent-text"></p>
      <p num="0145" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本発明の前述の実施形態の記載は、例示および説明目的のために提供された。それらは、逐一的ではなく、または開示された正確な形態に本発明を限定する意図はなく、多くの修飾および変更が、上記の教示に鑑みて可能であることは明らかである。本発明の原理およびその実際の適用を説明し、それによって当業者が考慮される特定の使用に適するように種々の実施形態で、および種々の変更によって本発明を利用することができるように、これらの実施形態が選択され記載されている。
</span>
&nbsp;&nbsp;The descriptions of the foregoing embodiments of the invention have been provided for purposes of illustration and description. They are not intended to be exhaustive or intended to limit the invention to the precise form disclosed, and it will be apparent that many modifications and variations are possible in light of the above teachings. In order to explain the principles of the invention and its practical application, so that the invention can be utilized in various embodiments and with various modifications to suit the particular use considered by those skilled in the art. These embodiments have been selected and described.
</span>
      </p>
      <p num="0146" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書に引用された全ての参考文献は、参照として本明細書に援用されている。
</span>
&nbsp;&nbsp;All references cited herein are hereby incorporated by reference.
</span>
      </p>
      <p num="0147" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <u class="style-scope patent-text">他の実施態様</u> <br class="style-scope patent-text">
１．完全長［ＦＬ］および選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡの発現、あるいは、ＡＳおよびＦＬのＭＮ／ＣＡ ＩＸの発現の差異を識別する工程を有してなる、哺乳動物における異常なＭＮ／ＣＡ ＩＸの発現に関連する前新生物疾患／新生物疾患の診断および／または予後診断方法。
</span> <u class="style-scope patent-text">Other Embodiments</u> Abnormalities in mammals comprising identifying differential expression of full-length [FL] and alternatively spliced [AS] MN / CA9 mRNA or MN / CA IX of AS and FL A method for diagnosis and / or prognosis of preneoplastic / neoplastic disease associated with the expression of active MN / CA IX.</span>
      </p>
      <p num="0148" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２．１種類以上のプローブおよび／またはプライマーを使用して、ＦＬおよび／またはＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現を検出、または検出および定量化する実施態様１に記載の方法。
</span>
2. The method of <figure-callout id="1" label="embodiment" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 1, wherein more than one type of probe and / or primer is used to detect or detect and quantify FL and / or AS MN / CA9 mRNA expression.
</span>
      </p>
      <p num="0149" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３．（ａ）選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］のＭＮ／ＣＡ９ ｍＲＮＡを検出するためのプローブおよび／またはプライマー；<br class="style-scope patent-text">
  （ｂ）ＦＬのＭＮ／ＣＡ９ ｍＲＮＡは検出せず、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡを検出するためのプローブおよび／またはプライマー；および／または<br class="style-scope patent-text">
  （ｃ）ＦＬおよびＡＳのＭＮ／ＣＡ９ ｍＲＮＡの双方を検出するためのプローブおよび／またはプライマー<br class="style-scope patent-text">
の使用を含んでなる実施態様２に記載の方法。
</span>3. (A) probes and / or primers for detecting full-length [FL] MN / CA9 mRNA without detecting alternatively spliced [AS] MN / CA9 mRNA; <br class="style-scope patent-text"> (B) Probes and / or primers for detecting AS MN / CA9 mRNA without detecting FL MN / CA9 mRNA; and / or (c) Detecting both FL and AS MN / <figure-callout id="3" label="CA9 mRNA Embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">CA9 mRNA Embodiment</a></figure-callout> 3. The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, comprising the use of probes and / or primers for</span>
      </p>
      <p num="0150" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４．前記哺乳動物がヒトであり、前記１種類以上のプローブおよび／またはプライマーが、配列番号９７〜１０１および、配列番号９７〜１０１と少なくとも８０％相同である核酸配列からなる群から選択される実施態様２に記載の方法。
</span>
4). Embodiment wherein the mammal is a human and the one or more probes and / or primers are selected from the group consisting of SEQ ID NOs: 97-101 and nucleic acid sequences that are at least 80% homologous to SEQ ID NOs: 97-101. 2. The method according to 2.
</span>
      </p>
      <p num="0151" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５．核酸増幅方法の使用を含んでなる実施態様２に記載の方法。
</span>
5. <figure-callout id="3" label="Embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Embodiment</a></figure-callout> 3. The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, comprising the use of a nucleic acid amplification method.
</span>
      </p>
      <p num="0152" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
６．前記核酸増幅方法が、ＰＣＲ、ＲＴ−ＰＣＲ、リアルタイムＰＣＲまたは定量的リアルタイムＲＴ−ＰＣＲの使用を含んでなる実施態様５に記載の方法。
</span>
6). <figure-callout id="6" label="Embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Embodiment</a></figure-callout> 6. The method of <figure-callout id="5" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 5, wherein the nucleic acid amplification method comprises the use of PCR, RT-PCR, real-time PCR or quantitative real-time RT-PCR.
</span>
      </p>
      <p num="0153" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
７．選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡに結合するプローブ、および／またはＦＬのＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡに結合するプローブを含む、マイクロアレイチップの使用を含んでなる実施態様２に記載の方法。
</span>
7). Probes that bind to alternatively spliced [AS] MN / CA9 mRNA but not to full-length [FL] MN / CA9 mRNA, and / or do not bind to FL MN / CA9 mRNA, but The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, comprising the use of a microarray chip comprising a probe that binds to MN / CA9 mRNA.
</span>
      </p>
      <p num="0154" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
８．ＦＬ：ＡＳのＭＮ／ＣＡ９ ｍＲＮＡの比を決定する工程をさらに有してなる実施態様２に記載の方法。
</span>
8). The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, further comprising the step of determining the ratio of FL: AS MN / CA9 mRNA.
</span>
      </p>
      <p num="0155" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
９．前記ＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現が、正常なＭＮ／ＣＡ９遺伝子発現を示し、前記ＦＬのＭＮ／ＣＡ９ ｍＲＮＡ発現が、異常なＭＮ／ＣＡ９遺伝子発現を示す実施態様２に記載の方法。
</span>
9. 3. The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, wherein the AS MN / CA9 mRNA expression indicates normal MN / CA9 gene expression and the FL MN / CA9 mRNA expression indicates abnormal MN / CA9 gene expression.
</span>
      </p>
      <p num="0156" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１０．前記ＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現が、酸素正常状態のＭＮ／ＣＡ９遺伝子発現を示し、前記ＦＬのＭＮ／ＣＡ９ ｍＲＮＡ発現が、低酸素状態のＭＮ／ＣＡ９遺伝子発現を示す実施態様２に記載の方法。
</span>
10. The method of <figure-callout id="2" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 2, wherein the AS MN / CA9 mRNA expression indicates normoxic MN / CA9 gene expression, and the FL MN / CA9 mRNA expression indicates hypoxic MN / CA9 gene expression. .
</span>
      </p>
      <p num="0157" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１１．１種類以上の抗体を使用して、前新生物／新生物組織におけるＦＬおよびＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現の差異を識別する工程を有してなる実施態様１に記載の方法。
</span>
11. The method of <figure-callout id="1" label="embodiment" filenames="0005866328-12.png,0005866328-24.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 1, comprising identifying differences in FL and AS MN / CA9 mRNA expression in pre-neoplastic / neoplastic tissue using one or more antibodies.
</span>
      </p>
      <p num="0158" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１２．前記組織においてＡＳのＭＮ／ＣＡ ＩＸを検出、または検出および定量化する工程を有してなる実施態様１１に記載の方法。
</span>
12 12. The method of <figure-callout id="11" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 11, comprising detecting or detecting and quantifying AS MN / CA IX in the tissue.
</span>
      </p>
      <p num="0159" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１３．前記組織においてＦＬのＭＮ／ＣＡ ＩＸレベルのＡＳのＭＮ／ＣＡ ＩＸレベルに対する比を決定する工程をさらに有してなる実施態様１２に記載の方法。
</span>
13. 13. The method of <figure-callout id="12" label="embodiment" filenames="0005866328-35.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 12, further comprising determining a ratio of FL MN / CA IX level to AS MN / CA IX level in the tissue.
</span>
      </p>
      <p num="0160" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１４．前記比が、前記組織における低酸素状態の存在または程度を示す実施態様１３に記載の方法。
</span>
14 Embodiment 14. The method of <figure-callout id="13" label="embodiment" filenames="0005866328-35.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 13, wherein the ratio indicates the presence or extent of hypoxia in the tissue.
</span>
      </p>
      <p num="0161" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１５．脊椎動物の組織においてＦＬのＭＮ／ＣＡ ＩＸおよびＡＳのＭＮ／ＣＡ ＩＸを検出、または検出および定量化する工程であって、<br class="style-scope patent-text">
（ａ）前記脊椎動物の組織サンプルを、少なくとも２種の抗体、少なくとも２種の抗原結合性抗体断片、または抗体および抗原結合性抗体断片の混合物に同時にまたは連続的に接触させる工程であって、<br class="style-scope patent-text">
  ここで、少なくとも１種の抗体／抗体断片は、ＦＬのＭＮ／ＣＡ ＩＸタンパク質には特異的に結合するが、ＡＳのＭＮ／ＣＡ ＩＸタンパク質には結合せず、<br class="style-scope patent-text">
  少なくとも１種の他の抗体／抗体断片は、ＦＬのＭＮ／ＣＡ ＩＸとＡＳのＭＮ／ＣＡ ＩＸの双方に特異的に結合する、<br class="style-scope patent-text">
ことを特徴とする工程と、<br class="style-scope patent-text">
（ｂ）前記サンプルにおいて前記抗体／抗体断片の結合を検出および定量化する工程と、<br class="style-scope patent-text">
（ｃ）前記特異的に結合する抗体／抗体断片の結合を比較して、ＦＬのＭＮ／ＣＡ ＩＸとＡＳのＭＮ／ＣＡ ＩＸの相対的レベルを決定する工程と、<br class="style-scope patent-text">
を有してなる実施態様１１に記載の方法。
</span>15. Detecting or detecting and quantifying FL MN / CA IX and AS MN / CA IX in vertebrate tissue comprising: <br class="style-scope patent-text"> (A) contacting the vertebrate tissue sample simultaneously or sequentially with at least two antibodies, at least two antigen-binding antibody fragments, or a mixture of antibodies and antigen-binding antibody fragments, <br class="style-scope patent-text"> Here, at least one antibody / antibody fragment specifically binds to FL MN / CA IX protein, but does not bind to AS MN / CA IX protein, <br class="style-scope patent-text"> At least one other antibody / antibody fragment specifically binds to both MN / CA IX of FL and MN / CA IX of AS, <br class="style-scope patent-text"> A process characterized by: <br class="style-scope patent-text"> (B) detecting and quantifying the antibody / antibody fragment binding in the sample; <br class="style-scope patent-text"> (C) comparing the binding of said specifically binding antibody / antibody fragment to determine the relative levels of FL MN / CA IX and AS MN / CA IX; <br class="style-scope patent-text"> <figure-callout id="12" label="Embodiment" filenames="0005866328-35.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Embodiment</a></figure-callout> 12. The method of <figure-callout id="11" label="embodiment" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 11 comprising:</span>
      </p>
      <p num="0162" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１６．前記抗体／抗体断片、または、ＦＬのＭＮ／ＣＡ ＩＸに特異的に結合するが、ＡＳのＭＮ／ＣＡ ＩＸには結合しない抗体／抗体断片が、ＭＮ／ＣＡ ＩＸの炭酸脱水酵素（ＣＡ）ドメインに特異的であり、<br class="style-scope patent-text">
  前記抗体／抗体断片、または、ＦＬのＭＮ／ＣＡ ＩＸとＡＳのＭＮ／ＣＡ ＩＸの双方に特異的に結合する抗体／抗体断片が、ＭＮ／ＣＡ ＩＸのプロテオグリカン様（ＰＧ）ドメインに特異的である、<br class="style-scope patent-text">
実施態様１５に記載の方法。
</span>16. The antibody / antibody fragment or the antibody / antibody fragment that specifically binds to MN / CA IX of FL but not to MN / CA IX of AS is a carbonic anhydrase (CA) domain of MN / CA IX Specific to <br class="style-scope patent-text"> The antibody / antibody fragment or an antibody / antibody fragment that specifically binds to both MN / CA IX of FL and AS / MN / CA IX of FL is specific to the proteoglycan-like (PG) domain of MN / CA IX. is there, <br class="style-scope patent-text"> Embodiment 16. The method according to embodiment 15.</span>
      </p>
      <p num="0163" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１７．前記ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な前記抗体が、登録番号ＬＭＢＰ６００９ＣＢとして、ベルギー国ヘント所在のＢＣＣＭ（商標）／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体であり、<br class="style-scope patent-text">
  前記ＭＮ／ＣＡ ＩＸのＰＧドメインに特異的な前記抗体が、ＡＴＣＣ指定番号ＨＢ１１１２８として、アメリカン・タイプ・カルチャー・コレクション（ＡＴＣＣ）に寄託されたハイブリドーマＶＵ−Ｍ７５により産生されるＭ７５モノクローナル抗体である、<br class="style-scope patent-text">
実施態様１６に記載の方法。
</span>17. The antibody specific for the CA domain of the MN / CA IX is V / 10 monoclonal produced by the hybridoma VU-V / 10 deposited at BCCM ™ / LMBP, Ghent, Belgium, under the accession number LMBP6009CB. An antibody, <br class="style-scope patent-text"> The antibody specific for the PG domain of the MN / CA IX is an M75 monoclonal antibody produced by the hybridoma VU-M75 deposited with the American Type Culture Collection (ATCC) as ATCC designation number HB11128. <br class="style-scope patent-text"> Embodiment 17. The method according to embodiment 16.</span>
      </p>
      <p num="0164" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１８．脊椎動物における異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患の診断および／または予後診断方法であって、<br class="style-scope patent-text">
  脊椎動物の組織において選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸタンパク質は検出せず、完全長［ＦＬ］ＭＮ／ＣＡ ＩＸタンパク質を検出、または検出および定量化する工程であって、<br class="style-scope patent-text">
  （ａ）前記脊椎動物の組織サンプルを、抗体または抗体断片と接触させる工程であって、前記抗体または抗体断片が、ＡＳのＭＮ／ＣＡ ＩＸには結合しないが、ＦＬのＭＮ／ＣＡ ＩＸには特異的に結合することを特徴とする工程と、<br class="style-scope patent-text">
  （ｂ）前記サンプルにおける前記抗体／抗体断片の結合を検出および定量化する工程と、<br class="style-scope patent-text">
を有してなる方法。
</span>18. A method for diagnosing and / or prognosing preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression in vertebrates comprising: <br class="style-scope patent-text"> Detecting or detecting and quantifying full-length [FL] MN / CA IX protein without detecting alternatively spliced [AS] MN / CA IX protein in vertebrate tissue, <br class="style-scope patent-text"> (A) contacting the vertebrate tissue sample with an antibody or antibody fragment, wherein the antibody or antibody fragment does not bind to AS MN / CA IX, but to FL MN / CA IX; A step characterized by binding specifically; <br class="style-scope patent-text"> (B) detecting and quantifying the antibody / antibody fragment binding in the sample; <br class="style-scope patent-text"> A method comprising:</span>
      </p>
      <p num="0165" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
１９．前記抗体または抗体断片が、ＭＮ／ＣＡ ＩＸの炭酸脱水酵素（ＣＡ）ドメインに特異的である実施態様１８に記載の方法。
</span>
19. 19. The method of embodiment 18, wherein the antibody or antibody fragment is specific for the carbonic anhydrase (CA) domain of MN / CA IX.
</span>
      </p>
      <p num="0166" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２０．前記ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な前記抗体が、登録番号ＬＭＢＰ６００９ＣＢとして、ベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体である実施態様１９に記載の方法。
</span>
20. The V / 10 monoclonal antibody produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP in Ghent, Belgium, under the registration number LMBP6009CB, the antibody specific for the CA domain of the MN / CA IX Embodiment 20. The method of embodiment 19, wherein
</span>
      </p>
      <p num="0167" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２１．哺乳動物における異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物／新生物疾患の診断および／または予後診断方法であって、<br class="style-scope patent-text">
  哺乳動物の前新生物／新生物サンプルにおける選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡを検出、または検出および定量化する工程を有してなり、前記サンプルからのｍＲＮＡを、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡには結合しないが、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡに特異的に結合するプライマーまたはプローブに接触させる工程を有してなることを特徴とする方法。
</span>21. A method for diagnosing and / or prognosing a pre-neoplasm / neoplastic disease associated with abnormal MN / CA IX expression in a mammal, comprising: <br class="style-scope patent-text"> It does not detect alternatively spliced [AS] MN / CA9 mRNA in mammalian preneoplastic / neoplastic samples, and has the process of detecting or detecting and quantifying full-length [FL] MN / CA9 mRNA. And the step of contacting the mRNA from the sample with a primer or probe that does not bind to the MN / CA9 mRNA of AS but specifically binds to the MN / CA9 mRNA of FL. And how to.</span>
      </p>
      <p num="0168" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２２．哺乳動物における選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡ発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡ発現とを識別するために使用されるプローブまたはプライマー。
</span>
22. Probes or primers used to distinguish between alternatively spliced [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in mammals.
</span>
      </p>
      <p num="0169" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２３．前記哺乳動物がヒトであり、<br class="style-scope patent-text">
  前記プローブまたはプライマーが、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡは検出せず、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用され、<br class="style-scope patent-text">
  前記プローブまたはプライマーが、ＭＮ／ＣＡ９遺伝子のエクソン７および１０のスプライスジャンクションに結合する核酸を含む、<br class="style-scope patent-text">
実施態様２２に記載のプローブまたはプライマー。
</span>23. The mammal is a human; <br class="style-scope patent-text"> The probe or primer is used to detect AS MN / CA9 mRNA, not FL MN / CA9 mRNA; <br class="style-scope patent-text"> The probe or primer comprises a nucleic acid that binds to a splice junction of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 10 of the MN / CA9 gene; <br class="style-scope patent-text"> Embodiment 23. A probe or primer according to embodiment 22.</span>
      </p>
      <p num="0170" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２４．前記プローブまたはプライマーが、配列番号１０１の配列、または配列番号１０１と少なくとも８０％相同な配列を有する実施態様２３に記載のプローブまたはプライマー。
</span>
24. 24. The probe or primer of embodiment 23, wherein the probe or primer has the sequence of SEQ ID NO: 101, or a sequence that is at least 80% homologous to SEQ ID NO: 101.
</span>
      </p>
      <p num="0171" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２５．実施態様２２に記載のプローブまたはプライマーを発現するベクター。
</span>
25. A vector that expresses a probe or primer according to embodiment 22.
</span>
      </p>
      <p num="0172" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２６．実施態様２５に記載のベクターを含む宿主細胞。
</span>
26. A host cell comprising the vector of embodiment 25.
</span>
      </p>
      <p num="0173" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２７．前記哺乳動物がヒトであり、<br class="style-scope patent-text">
  前記プローブまたはプライマーが、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡは検出せず、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用され、<br class="style-scope patent-text">
  前記プローブまたはプライマーが、ヒトＭＮ／ＣＡ９遺伝子のエクソン８またはエクソン９に結合するか、またはヒトＭＮ／ＣＡ９遺伝子のエクソン７および８のスプライスジャンクション、エクソン８および９のスプライスジャンクション、またはエクソン９および１０のスプライスジャンクションに結合する核酸を含む、<br class="style-scope patent-text">
実施態様２２に記載のプローブまたはプライマー。
</span>27. The mammal is a human; <br class="style-scope patent-text"> The probe or primer is used to detect FL MN / CA9 mRNA, not AS MN / CA9 mRNA; <br class="style-scope patent-text"> The probe or primer binds to <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 or <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 of the human MN / CA9 gene, or <figure-callout id="7" label="exon" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout></a></figure-callout> 7 and 8 splice junction, <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout></a></figure-callout> 8 and 9 splice junction of human MN / CA9 gene, or <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 and 10 A nucleic acid that binds to a splice junction of <br class="style-scope patent-text"> Embodiment 23. A probe or primer according to embodiment 22.</span>
      </p>
      <p num="0174" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２８．前記プローブまたはプライマーが、配列番号１００の配列、または配列番号１００と少なくとも８０％相同な配列を有する実施態様２７に記載のプローブまたはプライマー。
</span>
28. 28. The probe or primer of embodiment 27, wherein the probe or primer has the sequence of SEQ ID NO: 100, or a sequence that is at least 80% homologous to SEQ ID NO: 100.
</span>
      </p>
      <p num="0175" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２９．実施態様２２に記載のプローブを１種類以上含むマイクロアレイチップ。
</span>
29. A microarray chip comprising one or more types of probes according to embodiment 22.
</span>
      </p>
      <p num="0176" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３０．哺乳動物における選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡと完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡとの発現を識別するために使用される一対のプローブおよび／またはプライマー。
</span>
30. A pair of probes and / or primers used to discriminate between alternatively spliced [AS] MN / CA9 mRNA and full-length [FL] MN / CA9 mRNA expression in mammals.
</span>
      </p>
      <p num="0177" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３１．完全長［ＦＬ］のヒトＭＮ／ＣＡ９ ｍＲＮＡは検出せず、選択的にスプライスされた［ＡＳ］ヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される実施態様３０に記載の一対のプローブおよび／またはプライマー。
</span>
31. 31. A pair of probes according to embodiment 30 used to detect alternatively spliced [AS] human MN / CA9 mRNA, and not full-length [FL] human MN / CA9 mRNA and / or Primer.
</span>
      </p>
      <p num="0178" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３２．配列番号９９および１０１、または配列番号９９および１０１と少なくとも８０％相同な核酸配列からなる実施態様３１に記載の一対のプローブまたはプライマー。
</span>
32. 32. A pair of probes or primers according to embodiment 31, consisting of SEQ ID NO: 99 and 101, or a nucleic acid sequence that is at least 80% homologous to SEQ ID NO: 99 and 101.
</span>
      </p>
      <p num="0179" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３３．選択的にスプライスされた［ＡＳ］ヒトＭＮ／ＣＡ９ ｍＲＮＡは検出せず、完全長［ＦＬ］ヒトＭＮ／ＣＡ９ ｍＲＮＡを検出するために使用される実施態様３０に記載の一対のプローブおよび／またはプライマー。
</span>
33. 31. A pair of probes and / or primers according to embodiment 30, used for detecting full-length [FL] human MN / CA9 mRNA, without detecting alternatively spliced [AS] human MN / CA9 mRNA. .
</span>
      </p>
      <p num="0180" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３４．配列番号９９および１００、または配列番号９９および１００と少なくとも８０％相同な核酸配列からなる実施態様３３に記載の一対のプローブまたはプライマー。
</span>
34. 34. A pair of probes or primers according to embodiment 33 consisting of SEQ ID NO: 99 and 100, or a nucleic acid sequence that is at least 80% homologous to SEQ ID NO: 99 and 100.
</span>
      </p>
      <p num="0181" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３５．配列番号９７および９８、または配列番号９７および９８と少なくとも８０％相同な核酸配列からなるＡＳのヒトＭＮ／ＣＡ９ ｍＲＮＡおよびＦＬのヒトＭＮ／ＣＡ９ ｍＲＮＡの双方を検出するために使用され、<br class="style-scope patent-text">
  前記ＡＳのｍＲＮＡおよび前記ＦＬのｍＲＮＡが、その長さにより識別される、<br class="style-scope patent-text">
実施態様３０に記載の一対のプローブおよび／またはプライマー。
</span>35. Used to detect both AS human MN / CA9 mRNA and FL human MN / CA9 mRNA consisting of nucleic acid sequences at least 80% homologous to SEQ ID NOs: 97 and 98, or SEQ ID NOs: 97 and 98; <br class="style-scope patent-text"> The AS mRNA and the FL mRNA are distinguished by their lengths, <br class="style-scope patent-text"> A pair of probes and / or primers according to embodiment 30.</span>
      </p>
      <p num="0182" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３６．哺乳動物の選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸをコードする単離された核酸であって、前記ＡＳのＭＮ／ＣＡ ＩＸが、約４３〜約４８０００の分子量を有することを特徴とする単離された核酸。
</span>
36. An isolated nucleic acid encoding a alternatively spliced [AS] MN / CA IX of a mammal, wherein the AS MN / CA IX has a molecular weight of about 43 to about 48,000. An isolated nucleic acid.
</span>
      </p>
      <p num="0183" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３７．実施態様３６に記載の単離された核酸配列を発現するベクター。
</span>
37. A vector expressing the isolated nucleic acid sequence of embodiment 36.
</span>
      </p>
      <p num="0184" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３８．実施態様３７に記載のベクターを含む宿主細胞。
</span>
38. A host cell comprising the vector of embodiment 37.
</span>
      </p>
      <p num="0185" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３９．ＭＮ／ＣＡ９のエクソン８およびエクソン９に相当するヌクレオチドを欠失させることを特徴とし、ここで前記ＡＳのＭＮ／ＣＡ ＩＸがヒトである実施態様３６に記載の単離された核酸。
</span>
39. 37. The isolated nucleic acid of embodiment 36, characterized in that nucleotides corresponding to <figure-callout id="8" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 8 and <figure-callout id="9" label="exon" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exon</a></figure-callout> 9 of MN / CA9 are deleted, wherein said AS MN / CA IX is human.
</span>
      </p>
      <p num="0186" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４０．配列番号１０８、または配列番号１０８と少なくとも８０％相同である単離された核酸を有し、ここで前記ＡＳのＭＮ／ＣＡ ＩＸがヒトである実施態様３６に記載の単離された核酸。
</span>
40. 38. The isolated nucleic acid of embodiment 36, having SEQ ID NO: 108, or an isolated nucleic acid that is at least 80% homologous to SEQ ID NO: 108, wherein the MN / CA IX of the AS is human.
</span>
      </p>
      <p num="0187" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４１．配列番号１０８、または実施態様４０に記載の単離された核酸によりコードされたＡＳ型のＭＮ／ＣＡ ＩＸであって、前記ＡＳ型のＭＮ／ＣＡ ＩＸが、ＡＴＣＣ番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクションに寄託されたハイブリドーマＶＵ−Ｍ７５から分泌されるＭ７５モノクローナル抗体により特異的に結合されるが、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体によっては結合されないことを特徴とするＡＳ型のＭＮ／ＣＡ ＩＸ。
</span>
41. AS type MN / CA IX encoded by the isolated nucleic acid of SEQ ID NO: 108 or embodiment 40, wherein said AS type MN / CA IX is an American type culture as ATCC No. HB11128 Hybridoma VU-V / 10, which is specifically bound by the M75 monoclonal antibody secreted from the hybridoma VU-M75 deposited in the collection but deposited at “BCCM” / LMBP in Ghent, Belgium under the registration number LMBP6009CB AS type MN / CA IX, characterized in that it is not bound by the V / 10 monoclonal antibody produced by
</span>
      </p>
      <p num="0188" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４２．ＭＮ／ＣＡ ＩＸのＰＧドメインに特異的な抗体により特異的に結合されるが、ＭＮ／ＣＡ ＩＸのＣＡドメインに特異的な抗体によっては結合されないことをさらに特徴とする実施態様３６に記載の単離された核酸によりコードされたＡＳ型のＭＮ／ＣＡ ＩＸ。
</span>
42. 37. The singleton according to embodiment 36, further characterized by being specifically bound by an antibody specific for the PG domain of MN / CA IX but not by an antibody specific for the CA domain of MN / CA IX. AS-type MN / CA IX encoded by released nucleic acids.
</span>
      </p>
      <p num="0189" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４３．実施態様４２に記載されたＡＳ型のＭＮ／ＣＡ ＩＸであって、ＡＴＣＣ番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクションに寄託されたハイブリドーマＶＵ−Ｍ７５から分泌されるＭ７５モノクローナル抗体により特異的に結合されるが、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体によっては結合されないことをさらに特徴とするＡＳ型のＭＮ／ＣＡ ＩＸ。
</span>
43. AS type MN / CA IX as described in embodiment 42, which is specifically bound by the M75 monoclonal antibody secreted from the hybridoma VU-M75 deposited with the American Type Culture Collection as ATCC No. HB11128. AS type MN further characterized in that it is not bound by the V / 10 monoclonal antibody produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP located in Ghent, Belgium under the registration number LMBP6009CB / CA IX.
</span>
      </p>
      <p num="0190" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４４．実施態様３６に記載のＡＳのＭＮ／ＣＡ ＩＸに特異的に結合するが、ＦＬのＭＮ／ＣＡ ＩＸには特異的に結合しないことを特徴とする抗体または抗原結合性抗体断片。
</span>
44. An antibody or antigen-binding antibody fragment characterized in that it specifically binds to the MN / CA IX of AS, but not specifically to the MN / CA IX of FL according to embodiment 36.
</span>
      </p>
      <p num="0191" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４５．実施態様３６に記載のＡＳのＭＮ／ＣＡ ＩＸに特異的に結合するが、可溶性のＭＮ／ＣＡ ＩＸ（ｓ−ＣＡ ＩＸ）には特異的に結合しないことを特徴とする抗体または抗原結合性抗体断片。
</span>
45. An antibody or an antigen-binding antibody that specifically binds to MN / CA IX of AS according to embodiment 36, but does not specifically bind to soluble MN / CA IX (s-CA IX) fragment.
</span>
      </p>
      <p num="0192" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４６．哺乳動物における前新生物疾患／新生物疾患を治療する方法であって、前記疾患が、ＭＮ／ＣＡ ＩＸの異常発現に関連し、完全長［ＦＬ］ＭＮ／ＣＡ ＩＸのレベルと比較して選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを増加させる薬剤を含む組成物を治療に有効な量で前記哺乳動物に投与する工程を有してなる方法。
</span>
46. A method of treating a preneoplastic / neoplastic disease in a mammal, wherein the disease is associated with aberrant expression of MN / CA IX and selected relative to the level of full-length [FL] MN / CA IX Administering to said mammal a therapeutically effective amount of a composition comprising an agent that increases the level of optionally spliced [AS] MN / CA IX.
</span>
      </p>
      <p num="0193" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４７．前記ＡＳのＭＮ／ＣＡ ＩＸの相対的レベルの増加により、前記ＦＬのＭＮ／ＣＡ ＩＸの炭酸脱水酵素の活性が阻害される実施態様４６に記載の方法。
</span>
47. 47. The method of embodiment 46, wherein an increase in the relative level of the AS MN / CA IX inhibits the activity of the FL MN / CA IX carbonic anhydrase.
</span>
      </p>
      <p num="0194" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４８．前記薬剤が、生理学的に許容できる担体中のＡＳのＭＮ／ＣＡ ＩＸ自体、ＡＳのＭＮ／ＣＡ９ ｍＲＮＡ発現ベクター、ＦＬのＭＮ／ＣＡ ＩＸの発現を遮断するがＡＳのＭＮ／ＣＡ ＩＸの発現は遮断しないアンチセンスオリゴヌクレオチド、前記アンチセンスオリゴヌクレオチドを発現するベクター、ＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡ、または前記ＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡを発現するベクターである実施態様４６に記載の方法。
</span>
48. The agent blocks AS MN / CA IX itself, AS MN / CA9 mRNA expression vector, FL MN / CA IX expression in a physiologically acceptable carrier, but AS MN / CA IX expression is An antisense oligonucleotide that does not block, a vector that expresses the antisense oligonucleotide, a siRNA specific to the FL MN / CA9 isoform, or a vector that expresses a siRNA specific to the FL MN / CA9 isoform 47. The method of embodiment 46, wherein
</span>
      </p>
      <p num="0195" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
４９．前記ＦＬのＭＮ／ＣＡ９のイソ型に特異的なｓｉＲＮＡが、ＭＮ／ＣＡ９ ｍＲＮＡのエクソン７と８、エクソン８と９、またはエクソン９と１０のスプライスジャンクションを標的とする実施態様４８に記載の方法。
</span>
49. 49. The method of <figure-callout id="48" label="embodiment" filenames="0005866328-35.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">embodiment</a></figure-callout> 48, wherein the siRNA specific for the FL MN / CA9 isoform targets a splice junction of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8, <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, or <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10 of MN / CA9 mRNA. .
</span>
      </p>
      <p num="0196" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５０．前記薬剤が、ＡＳおよび／またはＦＬのＭＮ／ＣＡ９の前ｍＲＮＡスプライシングを調節するアンチセンスオリゴヌクレオチドである実施態様４６に記載の方法。
</span>
50. 47. The method of embodiment 46, wherein the agent is an antisense oligonucleotide that modulates AS and / or FL MN / CA9 pre-mRNA splicing.
</span>
      </p>
      <p num="0197" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５１．完全長［ＦＬ］ＭＮ／ＣＡ ＩＸのレベルと比較して選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを増加させるオリゴヌクレオチドであって、異常なＭＮ／ＣＡ ＩＸ発現に関連する前新生物疾患／新生物疾患の治療に使用されることを特徴とするオリゴヌクレオチド。
</span>
51. An oligonucleotide that increases the level of [AS] MN / CA IX selectively spliced compared to the level of full-length [FL] MN / CA IX, prior to being associated with aberrant MN / CA IX expression Oligonucleotide characterized by being used for the treatment of neoplastic / neoplastic diseases.
</span>
      </p>
      <p num="0198" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５２．ＡＳのＭＮ／ＣＡ９の前ｍＲＮＡには相補的ではないが、ＦＬのＭＮ／ＣＡ９の前ｍＲＮＡに相補的なアンチセンスオリゴヌクレオチドである実施態様５１に記載のオリゴヌクレオチド。
</span>
52. 52. The oligonucleotide according to embodiment 51, which is an antisense oligonucleotide that is not complementary to the AS MN / CA9 pre-mRNA but is complementary to the FL MN / CA9 pre-mRNA.
</span>
      </p>
      <p num="0199" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５３．ＡＳのＭＮ／ＣＡ９ ｍＲＮＡには相補的ではないが、ＦＬのＭＮ／ＣＡ９ ｍＲＮＡには相補的な、ｓｉＲＮＡである実施態様５１に記載のオリゴヌクレオチド。
</span>
53. 52. The oligonucleotide according to embodiment 51, which is an siRNA that is not complementary to the AS MN / CA9 mRNA, but is complementary to the FL MN / CA9 mRNA.
</span>
      </p>
      <p num="0200" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５４．ＦＬのＭＮ／ＣＡ９ ｍＲＮＡのエクソン７と８、エクソン８と９、またはエクソン９と１０のスプライスジャンクションに相補的である実施態様５３に記載のオリゴヌクレオチド。
</span>
54. 54. The oligonucleotide of embodiment 53, which is complementary to a splice junction of <figure-callout id="7" label="exons" filenames="0005866328-12.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 7 and 8, <figure-callout id="8" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 8 and 9, or <figure-callout id="9" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="10" label="exons" filenames="0005866328-12.png,0005866328-19.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">exons</a></figure-callout></a></figure-callout> 9 and 10 of the MN / CA9 mRNA of FL.
</span>
      </p>
      <p num="0201" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
５５．ＡＳのＭＮ／ＣＡ ＩＸを発現する細胞を、前記細胞における前記ＡＳのＭＮ／ＣＡ ＩＸのレベルを調節すると思われる薬剤に接触させる工程と、<br class="style-scope patent-text">
  前記ＡＳのＭＮ／ＣＡ ＩＸのレベルの変化を検出および定量化する工程と、<br class="style-scope patent-text">
を有してなる、選択的にスプライスされた［ＡＳ］ＭＮ／ＣＡ ＩＸのレベルを調節する能力のある薬剤をインビトロにおいて同定する方法。
</span>55. Contacting a cell expressing AS MN / CA IX with an agent suspected of modulating the level of AS MN / CA IX in said cell; <br class="style-scope patent-text"> Detecting and quantifying a change in the level of MN / CA IX in the AS; <br class="style-scope patent-text"> A method for identifying in vitro an agent capable of modulating the level of alternatively spliced [AS] MN / CA IX comprising:</span>
      </p>
    </embodiments-example>
  </description-of-embodiments>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(10)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Japanese</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM93358991" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒト患者における選択的にスプライスされた切断［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡの発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡの発現とを識別するために使用される少なくとも２１塩基長を有するプローブまたはプライマーであって、ＦＬ  ＭＮ／ＣＡ９ ｍＲＮＡを検出しないでＡＳ  ＭＮ／ＣＡ９ ｍＲＮＡを検出するのに使用され、<u class="style-scope patent-text">ヒト</u>ＭＮ／ＣＡ９遺伝子のエクソン７および１０のスプライスジャンクションに結合する核酸を含み、<br class="style-scope patent-text">
  <u class="style-scope patent-text">前記ＡＳ ＭＮ／ＣＡ９ ｍＲＮＡは、配列番号１０８の核酸配列に相補的な配列または配列番号１０８の配列と少なくとも９０％同一である核酸配列に相補的な配列を有し、かつヒトＭＮ／ＣＡ９遺伝子のエクソン８および９を含まない</u>ことを特徴とするプローブまたはプライマー。
</span>With a probe or primer having a length of at least 21 bases used to distinguish between alternatively spliced cleavage [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in human patients A nucleic acid that is used to detect AS MN / CA9 mRNA without detecting FL MN / CA9 mRNA and binds to the splice junctions of exons 7 and 10 of the <u class="style-scope patent-text">human</u> MN / CA9 gene; <br class="style-scope patent-text"> <u class="style-scope patent-text">Said AS MN / CA9 mRNA has a sequence complementary to the nucleic acid sequence of SEQ ID NO: 108 or a sequence complementary to a nucleic acid sequence which is at least 90% identical to the sequence of SEQ ID NO: 108, and of the human MN / CA9 gene</u> A probe or primer characterized in <u class="style-scope patent-text">that</u> it <u class="style-scope patent-text">does not contain exons 8 and 9</u> .</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒト患者における選択的にスプライスされた切断［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡの発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡの発現とを識別するために使用される少なくとも２１塩基長を有するプローブまたはプライマーであって、ＡＳ  ＭＮ／ＣＡ９ ｍＲＮＡは検出しないでＦＬ  ＭＮ／ＣＡ９ ｍＲＮＡを検出するのに使用され、ヒトＭＮ／ＣＡ９遺伝子のエクソン８またはエクソン９に結合するか、またはヒトＭＮ／ＣＡ９遺伝子のエクソン７および８のスプライスジャンクション、エクソン８および９のスプライスジャンクション、またはエクソン９および１０のスプライスジャンクションに結合する核酸を含み、<br class="style-scope patent-text">
  <u class="style-scope patent-text">前記ＡＳ ＭＮ／ＣＡ９ ｍＲＮＡは、配列番号１０８の核酸配列に相補的な配列または配列番号１０８の配列と少なくとも９０％同一である核酸配列に相補的な配列を有し、かつヒトＭＮ／ＣＡ９遺伝子のエクソン８および９を含まない</u>ことを特徴とするプローブまたはプライマー。
</span>With a probe or primer having a length of at least 21 bases used to distinguish between alternatively spliced cleavage [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in human patients And is used to detect FL MN / CA9 mRNA without detecting AS MN / CA9 mRNA and binds to exon 8 or exon 9 of the human MN / CA9 gene or exon 7 of the human MN / CA9 gene And a nucleic acid that binds to the splice junction of exons 8 and 9, or the splice junction of exons 9 and 10. <br class="style-scope patent-text"> <u class="style-scope patent-text">Said AS MN / CA9 mRNA has a sequence complementary to the nucleic acid sequence of SEQ ID NO: 108 or a sequence complementary to a nucleic acid sequence which is at least 90% identical to the sequence of SEQ ID NO: 108, and of the human MN / CA9 gene</u> A probe or primer characterized in <u class="style-scope patent-text">that</u> it <u class="style-scope patent-text">does not contain exons 8 and 9</u> .</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  請求項１記載のプローブを１以上含むマイクロアレイチップ。
</span>
&nbsp;&nbsp;A microarray chip comprising one or more probes according to claim 1.
</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒト患者における選択的にスプライスされた切断［ＡＳ］ＭＮ／ＣＡ９ ｍＲＮＡの発現と完全長［ＦＬ］ＭＮ／ＣＡ９ ｍＲＮＡの発現とを識別するために使用される一対の少なくとも２１塩基長を有するプローブおよび／またはプライマーであって、ＦＬ  ＭＮ／ＣＡ９ ｍＲＮＡを検出しないでＡＳ  ＭＮ／ＣＡ９ ｍＲＮＡを検出するのに使用され、<u class="style-scope patent-text">ヒト</u>ＭＮ／ＣＡ９遺伝子のエクソン７および１０のスプライスジャンクションに結合する核酸を含み、<br class="style-scope patent-text">
  <u class="style-scope patent-text">前記ＡＳ ＭＮ／ＣＡ９ ｍＲＮＡは、配列番号１０８の核酸配列に相補的な配列または配列番号１０８の配列と少なくとも９０％同一である核酸配列に相補的な配列を有し、かつヒトＭＮ／ＣＡ９遺伝子のエクソン８および９を含まない</u>ことを特徴とする一対のプローブおよび／またはプライマー。
</span>A pair of probes having a length of at least 21 bases used to distinguish between alternatively spliced truncated [AS] MN / CA9 mRNA expression and full-length [FL] MN / CA9 mRNA expression in a human patient; And / or a primer, which is used to detect AS MN / CA9 mRNA without detecting FL MN / CA9 mRNA and comprises a nucleic acid that binds to the splice junctions of exons 7 and 10 of the <u class="style-scope patent-text">human</u> MN / CA9 gene; <br class="style-scope patent-text"> <u class="style-scope patent-text">Said AS MN / CA9 mRNA has a sequence complementary to the nucleic acid sequence of SEQ ID NO: 108 or a sequence complementary to a nucleic acid sequence which is at least 90% identical to the sequence of SEQ ID NO: 108, and of the human MN / CA9 gene</u> A pair of probes and / or primers characterized in that they <u class="style-scope patent-text">do not contain exons 8 and 9</u> .</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ヒトにおける選択的にスプライスされた切断［ＡＳ］ＭＮ／ＣＡ ＩＸをコードする単離核酸であって、前記ＡＳ  ＭＮ／ＣＡ ＩＸが、４３〜４８ｋＤａの分子量を有し、<u class="style-scope patent-text">該核酸は、配列番号１０８の核酸配列または配列番号１０８の配列と少なくとも９０％同一である核酸配列を有し、かつヒトＭＮ／ＣＡ９遺伝子のエクソン８および９に相当するヌクレオチドを含まず、</u>前記ＡＳ  ＭＮ／ＣＡ ＩＸが、２％以下のｐＯ<sub class="style-scope patent-text">２</sub>の低酸素状態下におけるＦＬ  ＭＮ／ＣＡ ＩＸ発現細胞による細胞外酸性化を阻害し得ることを特徴とする単離核酸。
</span>An isolated nucleic acid encoding alternatively spliced cleavage [AS] MN / CA IX in humans, said AS MN / CA IX having a molecular weight of 43-48 kDa, said <u class="style-scope patent-text">nucleic acid comprising SEQ ID NO: 108 Or comprising no nucleotides corresponding to exons 8 and 9 of the human MN / CA9 gene,</u> wherein the AS MN / CA IX is 2 An isolated nucleic acid characterized by being capable of inhibiting extracellular acidification by FL MN / CA IX-expressing cells under a hypoxic state of pO <sub class="style-scope patent-text">2</sub> or less of%.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
 配列番号１０８の配列を有することを特徴とする、請求項<u class="style-scope patent-text">５</u>記載の単離核酸。
</span>6. The isolated nucleic acid according to claim <u class="style-scope patent-text">5</u> , having the sequence of SEQ ID NO: 108.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  請求項<u class="style-scope patent-text">５</u>記載の単離核酸を発現するベクター。
</span>A vector for expressing the isolated nucleic acid according to claim <u class="style-scope patent-text">5</u> .</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  請求項<u class="style-scope patent-text">７</u>記載のベクターを含む宿主細胞。
</span>A host cell comprising the vector of claim <u class="style-scope patent-text">7</u> .</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  配列番号１０８の配列または請求項<u class="style-scope patent-text">５</u>記載の単離核酸によりコードされ、ＡＴＣＣ番号ＨＢ１１１２８としてアメリカン・タイプ・カルチャー・コレクションに寄託されたハイブリドーマＶＵ−Ｍ７５から分泌されるＭ７５モノクローナル抗体により特異的に結合されるが、登録番号ＬＭＢＰ６００９ＣＢとしてベルギー国ヘント所在の「ＢＣＣＭ」／ＬＭＢＰに寄託されたハイブリドーマＶＵ−Ｖ／１０により産生されるＶ／１０モノクローナル抗体によっては結合されないことを特徴とする、ＡＳ型のＭＮ／ＣＡ ＩＸ。
</span>Specifically bound by the M75 monoclonal antibody encoded by the sequence SEQ ID NO: 108 or the isolated nucleic acid of claim <u class="style-scope patent-text">5</u> and secreted from the hybridoma VU-M75 deposited at the American Type Culture Collection as ATCC No. HB11128 AS type MN, characterized in that it is not bound by the V / 10 monoclonal antibody produced by the hybridoma VU-V / 10 deposited at “BCCM” / LMBP located in Ghent, Belgium under the registration number LMBP6009CB / CA IX.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  配列番号１０８の配列によりコードされることを特徴とする、請求項<u class="style-scope patent-text">９</u>記載のＡＳ型のＭＮ／ＣＡ ＩＸ。
</span>The AS-type MN / CA IX according to claim <u class="style-scope patent-text">9</u> , which is encoded by the sequence of SEQ ID NO: 108.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (16)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6093548A/en"><a id="link" href="#" class="style-scope state-modifier">US6093548A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2000-07-25</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">Detection and quantitation of MN-specific antibodies. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6027887A/en"><a id="link" href="#" class="style-scope state-modifier">US6027887A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2000-02-22</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Solvak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6069242A/en"><a id="link" href="#" class="style-scope state-modifier">US6069242A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2000-05-30</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5989838A/en"><a id="link" href="#" class="style-scope state-modifier">US5989838A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-11-23</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">Immunological methods of detecting MN proteins and MN polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5387676A/en"><a id="link" href="#" class="style-scope state-modifier">US5387676A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1995-02-07</span>
                    <span class="td style-scope patent-result">Ciba Corning Diagnostics Corp.</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6297041B1/en"><a id="link" href="#" class="style-scope state-modifier">US6297041B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2001-10-02</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5981711A/en"><a id="link" href="#" class="style-scope state-modifier">US5981711A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-11-09</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN-specific antibodies and hybridomas 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5972353A/en"><a id="link" href="#" class="style-scope state-modifier">US5972353A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-10-26</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN proteins, polypeptides, fusion proteins and fusion polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6297051B1/en"><a id="link" href="#" class="style-scope state-modifier">US6297051B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-01-24</span>
                    <span class="td style-scope patent-result">2001-10-02</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6204370B1/en"><a id="link" href="#" class="style-scope state-modifier">US6204370B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">2001-03-20</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">MN gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5955075A/en"><a id="link" href="#" class="style-scope state-modifier">US5955075A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-09-21</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">Method of inhibiting tumor growth using antibodies to MN protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2192678C/en"><a id="link" href="#" class="style-scope state-modifier">CA2192678C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-06-15</span>
                    <span class="td style-scope patent-result">2010-12-14</span>
                    <span class="td style-scope patent-result">Jan Zavada</span>
                    <span class="td style-scope patent-result">Mn gene and protein 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6087098A/en"><a id="link" href="#" class="style-scope state-modifier">US6087098A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-04-15</span>
                    <span class="td style-scope patent-result">2000-07-11</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6204887B1/en"><a id="link" href="#" class="style-scope state-modifier">US6204887B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-11</span>
                    <span class="td style-scope patent-result">2001-03-20</span>
                    <span class="td style-scope patent-result">Hitachi America, Ltd.</span>
                    <span class="td style-scope patent-result">Methods and apparatus for decoding and displaying multiple images using a common processor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060084123A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060084123A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-13</span>
                    <span class="td style-scope patent-result">2006-04-20</span>
                    <span class="td style-scope patent-result">Harris Adrian L</span>
                    <span class="td style-scope patent-result">MN and hypoxia 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2006056766A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2006056766A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-24</span>
                    <span class="td style-scope patent-result">2006-06-01</span>
                    <span class="td style-scope patent-result">St George's Enterprises Limited</span>
                    <span class="td style-scope patent-result">Diagnosis of prostate cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9150927B2/en"><a id="link" href="#" class="style-scope state-modifier">US9150927B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-10-12</span>
                    <span class="td style-scope patent-result">2015-10-06</span>
                    <span class="td style-scope patent-result">Medimmune, Llc</span>
                    <span class="td style-scope patent-result">Quantification of IR-A and IR-B for tumor classification 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10487153B2/en"><a id="link" href="#" class="style-scope state-modifier">US10487153B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-10</span>
                    <span class="td style-scope patent-result">2019-11-26</span>
                    <span class="td style-scope patent-result">National Research Council Of Canada</span>
                    <span class="td style-scope patent-result">Carbonic anhydrase IX-specific antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN110862457B/en"><a id="link" href="#" class="style-scope state-modifier">CN110862457B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-05</span>
                    <span class="td style-scope patent-result">2021-09-24</span>
                    <span class="td style-scope patent-result">中国人民解放军陆军特色医学中心</span>
                    <span class="td style-scope patent-result">Camel source nano antibody capable of being specifically combined with carbonic anhydrase IX and application thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4488351B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4488351B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-06-23</span>
                    <span class="td style-scope patent-result">
  Soluble carbonic anhydrase IX (s-CAIX), assay to detect s-CAIX, co-expression of CAIX and HER-2 / neu / c-erbB-2, CAIX specific monoclonal for non-immunodominant epitopes antibody
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/7320309197710483382"><a id="link" href="#" class="style-scope state-modifier">Cubas et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009</span>
                    <span class="td style-scope patent-result">Trop2: a possible therapeutic target for late stage epithelial carcinomas</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7521195B1/en"><a id="link" href="#" class="style-scope state-modifier">US7521195B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-04-21</span>
                    <span class="td style-scope patent-result">Lung disease targets and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DK2081586T3/en"><a id="link" href="#" class="style-scope state-modifier">DK2081586T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-14</span>
                    <span class="td style-scope patent-result">
  RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014017491A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014017491A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-01-30</span>
                    <span class="td style-scope patent-result">Fusion gene of cep55 gene and ret gene 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20060095114A/en"><a id="link" href="#" class="style-scope state-modifier">KR20060095114A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-08-31</span>
                    <span class="td style-scope patent-result">A therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2011064704A/en"><a id="link" href="#" class="style-scope state-modifier">JP2011064704A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-03-31</span>
                    <span class="td style-scope patent-result">Mn/caix and cancer prognosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5866328B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5866328B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-02-17</span>
                    <span class="td style-scope patent-result">
  MN / CA9 splice variant
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7781414B2/en"><a id="link" href="#" class="style-scope state-modifier">US7781414B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-24</span>
                    <span class="td style-scope patent-result">Targets for tumor growth inhibition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO328884B1/en"><a id="link" href="#" class="style-scope state-modifier">NO328884B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-06-07</span>
                    <span class="td style-scope patent-result">
  Polypeptide and its use and peptide complex, and method for identifying an organic or inorganic molecule.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2006501153A/en"><a id="link" href="#" class="style-scope state-modifier">JP2006501153A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-01-12</span>
                    <span class="td style-scope patent-result">
  Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2004519209A/en"><a id="link" href="#" class="style-scope state-modifier">JP2004519209A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-02</span>
                    <span class="td style-scope patent-result">
  Human RRP sequence and method of use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2420867C/en"><a id="link" href="#" class="style-scope state-modifier">CA2420867C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-05</span>
                    <span class="td style-scope patent-result">Methods for enhancing the efficacy of cancer therapy 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070155689A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070155689A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-07-05</span>
                    <span class="td style-scope patent-result">Methods of regulating growth and death of cancer cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3674325A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3674325A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-07-01</span>
                    <span class="td style-scope patent-result">Fusion protein of dctn1 protein with ret protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2007203291B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2007203291B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-09</span>
                    <span class="td style-scope patent-result">Methods for enhancing the efficacy of cancer therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20030031998A/en"><a id="link" href="#" class="style-scope state-modifier">KR20030031998A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-04-23</span>
                    <span class="td style-scope patent-result">Methods for enhancing the efficacy of cancer therapy 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014034798A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014034798A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-03-06</span>
                    <span class="td style-scope patent-result">Method for detection of cancer, diagnostic drug and diagnostic kit for cancer, and pharmaceutical composition for treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007111275A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2007111275A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-10-04</span>
                    <span class="td style-scope patent-result">Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060211008A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060211008A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-09-21</span>
                    <span class="td style-scope patent-result">Beta-parvin expression for use in diagnostic methods for assessment of breast cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101741826B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101741826B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-05-31</span>
                    <span class="td style-scope patent-result">Agents for inhibiting movement of ANO1 to plasma membrane for cancer therapy and method for screening the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20050037963A1/en"><a id="link" href="#" class="style-scope state-modifier">US20050037963A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-17</span>
                    <span class="td style-scope patent-result">Methods of regulating focal adhesion kinase and its associated cellular functions by fak family-interacting protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPWO2005021739A1/en"><a id="link" href="#" class="style-scope state-modifier">JPWO2005021739A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-10-26</span>
                    <span class="td style-scope patent-result">
  Antibody against Nox1 polypeptide, cancer diagnostic method using Nox1 gene, and screening method for cancer growth inhibitory substance
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/1586278345606860861"><a id="link" href="#" class="style-scope state-modifier">Stanford</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012</span>
                    <span class="td style-scope patent-result">Regulation of Fos related antigen-1 (Fra-1) accumulation in human bladder cancer</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20110281803A1/en"><a id="link" href="#" class="style-scope state-modifier">US20110281803A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-17</span>
                    <span class="td style-scope patent-result">Sulfatase enzymes 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            
            <h3 id="parentApplications" class="scroll-target style-scope patent-result">
              Parent Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Relation</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5479099B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2009532452A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-10-12</span>
                    <span class="td nowrap style-scope patent-result">2007-10-12</span>
                    <span class="td nowrap style-scope patent-result">
                        Division<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">
  MN / CA9 splice variant
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US85139806P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-10-12</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US60/851,398<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-10-12</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-02-12</span>
                    <span class="td nowrap style-scope patent-result">A131</span>
                    <span class="td nowrap style-scope patent-result">Notification of reasons for refusal</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A131</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20150210</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-05-11</span>
                    <span class="td nowrap style-scope patent-result">A601</span>
                    <span class="td nowrap style-scope patent-result">Written request for extension of time</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A601</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20150511</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-06-05</span>
                    <span class="td nowrap style-scope patent-result">A601</span>
                    <span class="td nowrap style-scope patent-result">Written request for extension of time</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A601</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20150605</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-07-10</span>
                    <span class="td nowrap style-scope patent-result">A601</span>
                    <span class="td nowrap style-scope patent-result">Written request for extension of time</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A601</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20150710</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-08-10</span>
                    <span class="td nowrap style-scope patent-result">A521</span>
                    <span class="td nowrap style-scope patent-result">Written amendment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A523</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20150810</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-11-18</span>
                    <span class="td nowrap style-scope patent-result">TRDD</span>
                    <span class="td nowrap style-scope patent-result">Decision of grant or rejection written</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-12-02</span>
                    <span class="td nowrap style-scope patent-result">A01</span>
                    <span class="td nowrap style-scope patent-result">Written decision to grant a patent or to grant a registration (utility model)</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A01</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20151201</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2016-01-07</span>
                    <span class="td nowrap style-scope patent-result">A61</span>
                    <span class="td nowrap style-scope patent-result">First payment of annual fees (during grant procedure)</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A61</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20160104</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2016-01-08</span>
                    <span class="td nowrap style-scope patent-result">R150</span>
                    <span class="td nowrap style-scope patent-result">Certificate of patent or registration of utility model</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Ref document number</strong>: 5866328</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Country of ref document</strong>: JP</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: R150</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-01-08</span>
                    <span class="td nowrap style-scope patent-result">LAPS</span>
                    <span class="td nowrap style-scope patent-result">Cancellation because of no payment of annual fees</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.354219622" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.354219622" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=592362584" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>